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RhoA Ras homolog gene family, member A  
RIP Regulated intramembrane proteolysis 
ROI Reactive oxygen intermediates 
ROS Reactive oxygen Species 
SAA Serum amyloid A 
SAPK Stress activated protein kinase 
SDS Sodium dodecyl sulfate 
SE Standard Error 
Sf Spodoptera friguperda 
SFK Src family of kinases 
SMC Smooth muscle cells 
SNP Single nucleotide polymorphism 
SPR Surface plasmon resonance 
sRAGE Soluble receptor for advanced glycation end-products 
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Abbreviation Full name 
STAT Signal transducer and activator of transcription 
TBARS Thiobarbituric acid reactive substances 
TBE Tris-borate EDTA buffer 
TCA Trichloroacetic acid 
TL Toll-like receptor 
TMB 3,5,3’,5’ - tetramethylbenzidine 
TNFα Tumour necrosis factor - alpha 
TTR Transthyretin 
V domain Variable domain 
VCAM Vascular cell adhesion molecule 
VMD Visual molecular dynamics 
WASP Wiskott-aldrich syndrome protein  
WAVE Wasp family verproline-homologous protein 
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ABSTRACT 
The receptor for advanced glycation end products (RAGE) is a human cell surface 
receptor that defies simple structural and functional classification.  Since its discovery in 
1992, a diverse repertoire of RAGE ligands have been identified that progress a myriad 
of pathophysiological outcomes and disease states. 
The promiscuity of this pluripotent pattern receptor has been identified through a 
number of studies investigating the different molecular characteristics of RAGE and their 
relationship with its many ligands.  Interestingly, there has been a mix and match 
approach to the source of RAGE used in these studies over the last 20 years, employing 
both endogenous and recombinant forms expressed in insect and prokaryotic hosts. 
Verification as to whether these recombinant forms are analogous to their endogenous 
counterparts has been done sporadically and using a variety of different methodologies 
and isoforms of the receptor. 
Here we set about to evaluate prokaryotic and insect expression systems for the 
production of three extracellular domain constructs of soluble RAGE (sRAGE).  
Additionally, this project aimed to produce a number of RAGE ligands using a common 
expression vector and host, with the intention of simplifying the production of a 
catalogue of molecules for use in studying the RAGE-ligand paradigm. 
This study found that the use of expression vectors for the stable production of RAGE in 
insect cells that utilise modern recombinant technologies such as single-step 
topoisomerase cloning (TOPO®) enabled the production of constructs in a matter of 
days.  Transfection of Lepidoptera cell lines was simple with high survival rates following 
optimisation of a lipid transfection methodology.  The Tn5 insect cell line was found to 
produce soluble RAGE (VC1C2) at levels 7-fold greater than the Sf9 insect cell line 
traditionally used for RAGE baculoviral expression.  Heterogeneity of glycosylation of 
RAGE was observed in both Sf9 and Sf21 cell lines, with the Tn5 cell line producing 
homogeneously glycosylated forms of the receptor.  Optimisation of culturing conditions 
for the Tn5 cell line increased the yield of soluble RAGE by about 20%, however, the  
quantity of protein produced per litre of culture were well short of the mg/L range 
normally produced by baculoviral systems, or required for structural studies. 
Bacterial expression of RAGE has traditionally utilised strains such as BL21 (DE3) and 
more recently, Origami™ strains.  This study utilised five bacterial strains optimised for 
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protein expression that included BL21 (DE3), Origami™ B, Rosetta-gami™ B, T7 Shuffle® 
B and T7 Shuffle® K12.  It was found that heterologous gene features impacted on the 
ability of Origami™ B strains to translate RAGE mRNA.  Indeed, optimisation of the 
canonical human RAGE gene led to a 4-fold improvement in the levels of expression in 
Origami™ B.  Additionally, the correct formation of disulphide bonds was found to be a 
rate limiting step.  T7 Shuffle® K12 engineered to express the disulphide bond isomerase 
C (DsbC) foldase in the cytosolic compartment expressed recombinant soluble RAGE at 
levels nearly 4-fold higher than Origami™ B.  Collectively, this study found that the 
optimisation of the native sequence, and an enhancement in disulphide bond formation 
improved yields 27, 10 and 14-fold respectively for RAGE V, VC1 and VC1C2 in comparison 
to the use of the canonical RAGE sequence in Origami strains in this study and as 
previously reported in the literature.  Importantly, with the exception of the isolated V-
domain,  mg/L yields of both VC1 and VC1C2 RAGE were obtained using the T7 Shuffle® 
K12 cells, making this cell line most suitable for future functional and structural studies.  
Moreover, this cell line also expressed S100A6, S100B, S100P and two HMGB1 
constructs with similar mg/L yields. 
The isolated V-domain of RAGE was very poorly expressed (g/L) in all bacterial and 
eukaryotic hosts tested in this study.  This was strongly correlated with the successive 
removal of the two C-type lectin domains of RAGE.  Indeed, in bacterial hosts, the VC1 
and V domains were expressed at levels 4 to 12-fold and 40 to 100-fold lower, 
respectively than VC1C2 sRAGE.  The predicted minimum free energy structure of mRNA 
encoding the V domain suggests a tendency to form matched stem loop structures in 
the absence of the C1 domain.  Interestingly, the V domain demonstrated a tendency to 
clone into the TOPO vector in the reverse orientation 93% of the time, suggesting that 
the 5’ end was obscured or unavailable for ligation.  Additionally, there was no increase 
in aggregation of recombinant RAGE with the removal of the C-type domains.  In this 
study, it is speculated that the declining levels of expression with the removal of the C-
type domains is due to the formation of mRNA structures that impede translation.   
Each of the three RAGE constructs and the various S100 and HMGB1 ligands were 
purified following optimisation of their expression.   Because every protein is different, 
different technologies and purification strategies were investigated for each type of 
protein with careful consideration given to the intended use of each protein.   The 
objective in each case was to minimise the number of steps needed to achieve an 
appropriate level of purity whilst considering the speed, cost and versatility of each 
 Page xxii 
 
method. The RAGE proteins were purified utilising a hexa-histidine tag attached to its C-
terminus and the known affinity of RAGE for heparin.  Full length HMGB1 was purified 
based on its remarkable solubility under acidic conditions and with the aid of a 
molecular sieve polishing step.  Truncated HMGB1 was purified by utilising a GST tag 
attached to its C-terminus and an on-column cleavage protocol.  Each of the S100 
proteins were purified by phenyl Sepharose® chromatography, utilising the intrinsic 
calcium binding characteristics of S100s that leads to the exposure of a hydrophobic 
cleft able to bind the phenyl side chains.  Given the oligomeric propensity of many of the 
ligands and the likely multivalent nature of their interactions with RAGE, a molecular 
sieve step immediately prior to the use of any of the proteins expressed and purified in 
this study is strongly recommended to ensure they are aggregate free prior to 
commencing functional and structural studies. 
The RAGE and HMGB1 proteins expressed and purified in this study had circular 
dichroism spectra consistent with other published studies and, in general, in accordance 
with their known secondary structures.  Moreover, the functionality of each of the 
proteins expressed and purified was demonstrated in several assay formats. A novel 
plate-based assay was developed that was simple to use and did not require expensive 
equipment or enzyme-conjugated forms of RAGE.  This assay demonstrated that there 
was no discernible difference in the strength of binding between Tn5 insect and T7 
Shuffle® K12 expressed soluble RAGE with a number of its ligands.  Although the 
complex mammalian glycosylation of RAGE has been shown to affect its ability to bind 
HMGB1 2-fold, no such difference was observed between insect expressed RAGE 
containing simple N-linked glycans and bacterial expressed RAGE with no glycans.  As 
such, this study concluded that the post translational modifications offered by insect cell 
systems, such as glycosylation, do not provide a compelling justification for the use of 
insect over prokaryotic hosts.   These observations using a novel plate-based binding 
assay developed in this study were also confirmed for several ligands by surface 
plasmon resonance studies.   
In conclusion, this study reports the development of a common vector and host capable 
of the cytosolic expression of soluble RAGE at levels 13-fold higher than those previously 
reported.  This same host and vector also yielded milligram quantities of the RAGE 
ligands HMGB1, truncated HMGB1, S100B, S100P and S100A6.  The development of a 
novel plate based binding assay demonstrated that recombinant RAGE expressed in 
both insect cells Tn5 and T7 Shuffle® K12 E. coli is synonymous in function, with 
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estimates of affinity correlating closely with those determined by surface plasmon 
resonance.  Applications of the proteins produced using this common ‘toolbox’ 
methodology is already revealing significant insights into HMGB1 oligomerisation and its 
binding and activation of RAGE.   
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1.1 Discovery of the Receptor for Advanced Glycation End Products 
During the 1980’s and early 90’s, considerable effort went towards identifying cell 
surface molecules believed to bind protein-aldose adducts commonly known as 
advanced glycation end products (AGEs).  It was thought that AGE molecules initiated or 
progressed a number of pathologies associated with diabetes and aging through binding 
a cell surface receptor (Vlassara, 1990; Takata et al., 1989).  In 1992, two polypeptides 
were identified in bovine endothelial cell and lung extract that demonstrated specific 
AGE binding (Neeper et al., 1992). These were named receptor for advanced glycation 
end product (RAGE), and lactoferrin-like polypeptide (LF-L) (Neeper et al., 1992; Schmidt 
et al., 1992). 
RAGE has since been classified as a member of the immunoglobulin super family and 
implicated in a variety of pathologies such as diabetes, amyloidoses, tumour metastasis 
and inflammation (Matrone et al., 2014; Schmidt and Stern, 2000; Singh et al., 2014; Lee 
and Park, 2013).  It is a multi-ligand receptor that binds a variety of seemingly unrelated 
ligands including HMGB1, calgranulins, AGE’s and β-sheet fibrils characteristic of 
amyloids (Lee and Park, 2013; Donato, 2007; Manigrasso et al., 2014). 
 
1.2 Expression and Structure of the Receptor for Advanced Glycation End Products 
1.2.1 Genetic characterisation and expression of RAGE 
RAGE is highly conserved across a number of mammalian species with greater than 80% 
sequence identity observed between the human, mouse, canine, sheep and bovine 
forms of the gene (Neeper et al., 1992). 
The human gene for RAGE is located on chromosome 6p21.3, near the junction of the 
major histocompatibility complex (MHC) classes II and III locus. Gene ontology 
assessment identifies numerous roles for RAGE including protein binding, trans 
membranous cell signalling and inflammatory responses (Sugaya et al., 1994).  This 
region of chromosome 6 is a highly polymorphic, gene-rich region.  A broad array of cell 
surface receptors and adhesion molecules, consistent with the many roles of RAGE, are 
located within this region (Figure 1) (Neeper et al., 1992).  This locus has been 
associated with the etiology of numerous chronic diseases such as diabetes and auto-
immune responses (Traherne, 2008).  The location of RAGE within this locus may explain 
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some of these associations between this region and pathologies such as diabetic 
complications, excessive inflammatory responses, and innate immunity. 
 
 
Figure 1.  Chromosomal organisation of RAGE and contiguous MHC class genes in 
Homo sapiens. 
The RAGE gene consists of a relatively small 5’-promoter region containing binding sites 
for nuclear factor-к B (NF-кB) and Sp1 (Yan et al., 1994). The 11 coding regions (~1300 
bp) are interlaced with 10 introns, and a 3’-untranslated region (Yan et al., 1994; Hudson 
et al., 2008).  Conserved domain analysis of the RAGE sequence identifies a number of 
regions correlating with various immunoglobulin-type domains found in cell adhesion 
molecules such as neuronal cell adhesion molecule (NCAM), CD2, CD4 and CD8. 
Early studies into RAGE frequently identified polypeptides ranging in size from 30-50 kDa 
(Neeper et al., 1992; Schmidt, Vianna et al., 1992; Brett et al., 1993).  These isoforms 
were attributed to possible proteolytic cleavage of RAGE from the cell surface, alternate 
splicing of the gene or post-translational modification (Neeper et al., 1992; Schmidt et 
al., 1992; Schmidt et al., 2001).  Regulated intramembrane proteolysis (RIP) results in 
soluble forms of type 1 trans membranous receptors such as NOTCH and LRP (Kopan 
and Ilagan 2004; Galichet et al., 2008).  Similarly, RAGE expressed in HEK293 cells 
undergoes RIP mediated by ADAM (a disintegrin and metalloprotease ) 
metalloproteases and γ-secretase to produce soluble RAGE (sRAGE) (Galichet et al., 
2008).  The administration of sRAGE to animal models of tumorigenesis and 
atherosclerosis, dramatically curtails progression of these diseases by acting as a ligand 
decoy (Hofmann et al., 1999; Taguchi et al., 2000).  Whether RAGE-RIP occurs in vivo to 
produce biologically significant levels of sRAGE has not been fully explored.  
Development of a method to quantify this particular proteolytic form of RAGE in plasma 
would provide an excellent means of clarifying this observation. 
A large body of research on RAGE alternate splice variants supports this as the 
predominant mechanism by which receptor isoforms occur (Park et al., 2004; Hudson et 
al., 2008; Kalea et al., 2009).  Alternative splicing is a key mechanism in expanding the 
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repertoire and activity of biologically significant molecules, with an estimated 35% of all 
genes predicted to result in alternatively spliced variants (Hanke et al., 1999).  To date, 
23 mRNA RAGE isoforms in mouse and human tissues have been identified and 
described in accordance with the human gene nomenclature (HGNC) (Hudson et al., 
2008; Kalea et al., 2009; Sterenczak et al., 2009).  These variants are generally 
considered to be grouped according to whether they are N-terminally or C-terminally 
truncated/modified forms of RAGE. 
N-terminus RAGE isoforms are those where introns 1-5 undergo alteration such as 
occurs in RAGE_v5.  In normal lung and aortic smooth muscle cells, RAGE_v5 accounts 
for approximately 5% of total RAGE mRNA and is distinguished by the presence of two 
juxtaposed in-frame intron 4 inserts (Hudson et al., 2008). This modification results in an 
additional 17 residues in the V domain, however, the impact of this on ligand binding 
has not been evaluated.  Two RAGE mRNA transcripts have been identified in which the 
majority of the ectodomain is deleted or modified: N-truncated RAGE (RAGE_v2) and 
RAGE_v13 (Hudson et al., 2008).  These forms exhibit no affinity for AGE’s and do not 
initiate signal transduction in response to ligand binding (Yonekura et al., 2003; Ding and 
Keller, 2005). 
One of the first C-terminal splice variants of RAGE identified was an endogenous 
secretory isoform, hRAGEsec (human secretory RAGE) (Malherbe et al., 1999).  This is 
now classified as RAGE_v16 and contains alterations in introns 2/3 and 7/8 respectively 
(Malherbe et al., 1999; Hudson et al., 2008). These frame-shift modifications result in a 
loss of the hydrophobic transmembrane spanning domain, allowing this variant to be 
secreted (Malherbe et al., 1999).  Yonekura et al. (2003) identified a secretory isoform 
(esRAGE), now classified as RAGE_v1.  This variant is characterised by the inclusion of 
intron 9 in place of the exon encoding the transmembrane domain (Yonekura et al., 
2003; Hudson et al., 2008).  Similar studies identified additional secretory isoforms 
known as sRAGE 1/2/3 expressed in microvascular and pericyte cell types (Schlueter et 
al., 2003; Hudson et al., 2008). Of these, sRAGE3 is now considered to be RAGE_v1, with 
sRAGE1 and sRAGE3 termed RAGE_v14 and RAGE_v15 respectively (Schlueter et al., 
2003; Hudson et al., 2008).  
This complex array of 23 alternate splice RAGE transcripts does not directly translate 
into a milieu of RAGE proteins. A large number described by Hudson et al., are predicted 
to be directed to the nonsense-mediated mRNA decay (NMD) pathway (Hudson et al., 
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2008). Recent in vitro expression studies confirm most of the NMD predictions, 
supporting the likelihood that RAGE_v1 is the predominant human secretory RAGE 
isoform (Hudson et al., 2008).   
Deregulation of RAGE_v1 expression correlates with progression of a number of disease 
states including type I and II diabetes, Alzheimer’s diseases, atherosclerosis, rheumatoid 
arthritis, renal disease, numerous cancers and inflammation (Tesarova et al., 2007; 
Hudson et al., 2008; Nakamura et al., 2008; Romero et al., 2008; Chen et al., 2009).  
Expression of RAGE_v2 is also thought to reduce RAGE signal transduction by displacing 
full-length receptor from cell membranes (Yonekura et al., 2003).  There is an increasing 
body of evidence correlating sRAGE plasma and tissue levels with a number of chronic 
diseases (Basta, 2008; Maillard-Lefebvre et al., 2009; Ramasamy et al., 2009).  However, 
much of the work to date has quantified total sRAGE rather than individual RAGE 
isoforms.  Before sRAGE plasma levels can be used as biomarkers of disease, 
development of a system that discriminates between the numerous soluble RAGE forms 
must be developed. Characterisation of the regulatory mechanisms controlling 
expression of these RAGE isoforms also offers a novel therapeutic opportunity.  By 
controlling expression of RAGE isoforms that antagonise canonical RAGE, a new means 
of tackling chronic disease may be realised.  
The MHC class III region and its highly variable nature correlates with the occurrence of 
gene polymorphisms within this locus (Traherne, 2008).  To date, some 30 
polymorphisms in the various gene elements of RAGE have been identified and occur in 
both coding and non-coding regions (Hudson et al., 1998; Hudson et al., 2001; Kankova 
et al., 2001; Jang et al., 2007). Of significance is the common Gly82Ser polymorphism 
located within the V-binding domain, and three mutations within the 5’ regulatory 
region that include -429 T/C, -374 T/A and a 63 bp deletion (Hudson et al., 2001; Hudson 
et al., 2008; Kalea et al., 2009).   
The Gly82Ser polymorphism falls within the V domain, increasing binding affinity with a 
number of S100 and AGE ligands (Hofmann et al., 2002; Osawa et al., 2007). Not only 
does this SNP cause local structural changes, but also partially destabilises the entire 
RAGE structure (Xie et al., 2008). This polymorphism correlates with disease progression 
in diabetes, and certain cancers (Kim et al., 2009; Kalea et al., 2009b; Jang et al., 2007; 
Hofmann et al., 2002; Tesarova et al., 2007). This is likely due to increased pro-
inflammatory responses and reduced levels of circulating sRAGE observed in 
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Gly82Ser/Gly82Ser RAGE homozygotes (Hofmann et al., 2002).  Hereditary rheumatoid 
arthritis is known to correlate with the human leukocyte antigen HLA-DR4 (Pall et al., 
2008).  The RAGE Gly82Ser SNP is reported to occur in disequilibrium with HLA-DR4 in a 
human case control study of rheumatoid arthritis patients, linking this polymorphism to 
the progression of this disease (Hofmann et al., 2002).   
The precise structural explanation of how the Gly82Ser influences RAGE activation has 
not yet been determined, however it is postulated to involve disruption of receptor 
oligomerisation (Xie et al., 2008).  This polymorphism is the most prevalent of all RAGE 
gene mutation.  It occurs in approximately 5% of study cohorts compared to 1% for all 
other RAGE gene alterations (Kalea et al., 2009b). 
Alterations within the upstream promoter region of the RAGE locus increase 
transcription through interference with a negative gene regulatory element (Hudson et 
al., 2001; Li and Schmidt, 1997).  There have been a number of studies looking at the 
correlation between retinopathies and the -429 T/C and -374 T/A SNPs. Although the 
study cohorts were small in size, a statistically significant association between the 
development of retinopathy and the -429 T/C polymorphism was found (Hudson et al., 
2001; Ramprasad et al., 2007).  This is somewhat surprising, as the -374 T/A SNP results 
in significantly increased gene transcription and subsequent RAGE expression (Hudson et 
al., 2001).  The -374 T/A SNP is, however, strongly associated with protection against 
vasculopathies. Studies in both diabetic and non-diabetic populations show -374 T/A 
homozygotes have decreased occurrence of cardiac and neurovasculopathies, as well as 
nephropathies (Falcone et al., 2008; Maruyama et al., 2007; Pettersson-Fernholm et al., 
2003; Falcone et al., 2005).  Identifying correlations between RAGE SNPs and chronic 
disease is critical in identifying and managing those at risk.  
The role and distribution of RAGE in homeostatic and disease states was first 
investigated by Brett et al. (1993) who quantified mRNA and antigenic RAGE levels in 
bovine organs (Brett et al., 1993).  RAGE is present on the surface of numerous cell types 
including macrophages, monocytes, endothelial cells, and is abundant in whole lung 
tissue (Schmidt et al., 1992; Brett et al., 1993).   Although RAGE is intimately involved in 
a number of physiological pathways and responses, RAGE -/- mice have been produced 
with normal macroscopic  tissue organisation and histopathology (Chavakis et al., 2003).  
RAGE expression is now known to be extremely complex. Factors such as homeostatic 
state, pathophysiology, cell type, developmental stage and genetic predispositions all 
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affect types and levels of RAGE expression.  Briefly, RAGE is present in the central 
nervous system during pre-natal development where it is involved in neuronal extension 
and migration (Huttunen et al., 1999; Huttunen et al., 2000; Chou et al., 2004). Under 
homeostatic conditions, it is detectable in micro and macrovascular endothelium, 
smooth muscle cells and mesangial cells (Brett et al., 1993; Chou et al., 2004; Fiuza et 
al., 2003; Warboys et al., 2009; Sterenczak et al., 2009).  Numerous organs constitutively 
express RAGE, with lung and the central nervous system expressing the highest levels of 
canonical RAGE (Brett et al., 1993; Chou et al., 2004; Fiuza et al., 2003; Warboys et al., 
2009; Sterenczak et al., 2009).  Needless to say, the predominant form of RAGE 
expressed within the body is membrane bound. Full length RAGE accounts for some 80% 
of RAGE mRNA in whole lung homogenate, followed by RAGE_v1 (7%) and RAGE_v5 
(4%) (Hudson et al., 2008a).  These levels change based on tissue source, the presence of 
single or multiple polymorphisms, and other multigenetic factors (Brett et al., 1993; 
Tesarova et al., 2007; Kalea et al., 2009b; Hudson et al., 2008a). 
The genetic character and regulation of RAGE expression is extremely complex. 
Elucidating the relationships between gene polymorphisms, RAGE isoform production 
and disease states is a challenging task.  Efforts to understand these mechanisms will, 
however, provide exciting therapeutic opportunities to influence the progression of 
those diseases currently associated with the activation and regulatory dysfunction of 
RAGE. 
1.2.2 Proteomic structure of RAGE 
The full length RAGE transcript is translated into a single chain, type I trans membranous 
receptor of approximately 50 kDa. This 404 amino acid peptide consists of several 
structural elements including a 22 amino acid N-terminal signal peptide, an Ig V-type 
domain, two juxtaposed C-type domains, a hydrophobic trans membranous region 
followed by a negatively charged, highly acidic cytosolic tail (Figure 2). 
As with most multi-ligand receptors, RAGE defies simple structural and functional 
classification, with NMR based information only recently becoming available.  It is 
generally accepted, however, that RAGE is a pattern recognition receptor based on its 
multi-domain structure and ability to recognise multiple, unrelated ligands (Xie et al., 
2008; Chavakis et al., 2003). 
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Figure 2.  Structural representation of RAGE domains.  Full length RAGE consists of an 
N-terminus Ig-V type domain, two IgG C-type domains separated by a predicted mobile 
loop, a trans-membranous region and short cytosolic C-terminal tail. 
 
1.2.3 V-type ligand binding domain 
Variable Type Ig domains (V domain) are found in a number of cell surface proteins 
including alternately spliced isoforms of neural cell adhesion molecules (NCAM 140), 
vascular cell adhesion molecule (VCAM) and CD20 (Neeper et al., 1992; Schmidt et al., 
1996).  Until recently, the variable domain of RAGE was believed to mediate all ligand 
binding. A number of RAGE elements are believed to facilitate these interactions, 
including anionic carbohydrates, a hydrophobic pocket, and an N-terminus cationic 
patch (Kislinger et al., 1999; Yan et al., 1996; Hofmann et al., 1999; Leclerc et al., 2007).  
Two confirmed asparagine glycosylation sequons (Asn81 and Asn25) are located within 
the RAGE V domain (Figure 2.) (Srikrishna et al., 2002; Neeper et al., 1992).  Removal of 
these glycans reduces RAGE-HMGB1 binding affinity two-fold, while increasing 
glycoaldehyde-AGE binding three fold (Srikrishna et al., 2002; Osawa et al., 2007).  The 
anionic nature of these glycans almost certainly plays a role in either localising cationic 
ligands to proximal V domain binding site/s or reducing the rate of association of like-
charge ligands.  Whether this is their principal role is yet to be determined, as glycans 
serve a multitude of functions such as protection of proteolytic sensitive sites and 
stabilization of protein secondary/tertiary structures. 
Point mutation and antibody blockade studies of the RAGE V domain identify it as the 
primary ligand binding region for HMGB1, AGEs, S100B and β-amyloid (Kislinger et al., 
1999; Taguchi et al., 2000; Yan et al., 1996). The nature and number of these binding 
sites, however, remains unclear.  Matsumoto et al. (2008) produced an NMR solution 
N-terminus C-terminus 
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structure of the RAGE V domain (Figure 3) (Matsumoto et al., 2008).  This structure 
closely resembles other immunoglobulin variable domains with two β-sheet structures 
composed of seven β-strands, 6 loops and a single, short α-helix.  A disulphide bridge 
between residues Cys38 and Cys99 links the β-sheets, stabilising the tertiary structure in 
a β-sandwich like conformation (Matsumoto et al., 2008).  Of particular interest is a 
positively charged area forming a cationic patch around loops 2 and 6 (Figure 3) 
(Matsumoto et al., 2008).  Charge is known to play a significant role in RAGE binding to 
certain ligands such as HMGB1 and various AGE molecules. However, difficulty 
dissociating certain RAGE-AGE complexes with 1 M NaCl solutions suggests additional 
interactions are involved (Xie et al., 2008; Matsumoto et al., 2008).  
A hydrophobic cleft with an estimated solvent accessible surface of -300 Å2 is located in 
close proximity to this cationic centre and located laterally to the disulphide linkage 
(Matsumoto et al., 2008).  Loop 3 of the variable domain is unique to RAGE when 
compared to canonical Ig variable domain structures.  The flexible nature of this loop 
may enable it to act as a gate to the hydrophobic pocket (Matsumoto et al., 2008).  This 
hydrophobic element of RAGE may explain the high-affinity interactions previously 
observed for glycaldehyde-AGE structures and various monomeric and fibrillary 
amyloids. The positively charged region and hydrophobic pocket are, interestingly, 
closely associated with the Asn81 glycosylation site in loop 4. It is possible that this N-
linked glycan interacts with charged ligands to either recruit or retard their interaction 
with these elements of the V domain. Further studies are required to verify these 
observations. 
Currently, a number of mechanisms by which ligand binds to the RAGE V domain have 
been proposed:  ionic interaction with a cationic patch on the V domain; interaction with 
a hydrophobic pocket possibly gated by loop 3; and receptor oligomerisation that causes 
conformational changes influencing ligand accessibility (Xue et al., 2014).  Indeed, 
oligomerisation of RAGE has been shown to increase estimates of affinity by nearly 50-
fold (Xue et al., 2011; Xue et al., 2014; Xie et al., 2008; Valencia et al., 2004). There is, 
however, evidence that some ligands directly bind RAGE at sites associated with the C-
type domains of the receptor, and that C1 is involved in the binding of certain ligands in 
concert with the V domain (Dattilo et al., 2007; Leclerc et al., 2007).  
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Figure 3.  The NMR solution structure of the variable domain of RAGE. (a) The 
secondary structures in cartoon representation showing two beta sheets coloured in 
yellow and orange, with the 6 principle loops labelled and alpha helices coloured blue as 
predicted by VMD. (b) Electrostatic surface profile, as predicted using Accelrys modelling 
suite, of the domain showing a strong cationic area at the top of the molecule. (c) A 
hydrophobic cleft coloured gold formed by loops 4, 3 and 2.  (PDB Structure: 2E5E.pdb). 
20° 
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1.2.4 C-type lectin domains  
C-type lectin domains are found predominantly, but not exclusively, in a wide range of 
vertebrate immunoglobulin and adhesion molecules such as eosinophil major basic 
protein and CD22.  The function of these animal lectin domains in RAGE biology is poorly 
understood.  They are, however, generally associated with membrane proteins involved 
in glycoprotein endocytosis and inflammation (Drickamer, 1998). 
The role of these domains in RAGE was recently investigated, focusing on the binding of 
S100 molecules (Dattilo et al., 2007).  This study found that the C-domains fulfil separate 
and important roles. The N-terminus C1 domain stabilises the V domain structure, while 
C2 is a structurally discrete domain with significant rotational freedom provided by a C1-
C2 interdomain loop (Figure 2.) (Dattilo et al., 2007; Xie et al., 2008).  It is possible that 
the C1 domain is more important for initial correct folding of the V domain tertiary 
structures rather than functional requirements such as ligand binding. NMR studies, 
however, suggest that the C1 domain is a crucial element that reduces the plasticity of 
the V domain mobile loops. In the absence of C1, the V domain demonstrates 
conformational heterogeneity and significantly weaker affinity for S100B and AGEs 
(Dattilo et al., 2007; Xie et al., 2008).  As the structural studies performed by Matsumoto 
et al. (2008), utilised a V domain-only construct, this structure may not represent an 
accurate representation of this domain compared to canonical RAGE.  Further NMR or 
modelling studies utilising a VC1 form of RAGE would provide additional insights into 
ligand binding and receptor-receptor interactions. 
Surface plasmon resonance studies demonstrate that a discrete RAGE C2 domain 
construct binds S100A6 (Leclerc et al., 2007). It is proposed that S100B and S100A6 
exhibit different cellular outcomes by interacting with separate domains, following the 
one domain - one ligand paradigm.  Xie et al. (2007) similarly report that hexameric 
S100A12 binds to a C1C2 RAGE construct independent of the V domain through two 
symmetric hydrophobic patches available in the presence of Ca2+ (Xie et al., 2007).   
Although there is evidence that C2 is structurally independent of VC1, it is not confirmed 
that C2 or C1C2 constructs used in these studies are comparable to their equivalent 
domains in eukaryotic VC1C2 RAGE.  Evaluation of S100A6 and S100A12 binding to 
eukaryotic V, VC1 and VC1C2 eukaryotic RAGE constructs may help to clarify this 
observation.  Additionally, the concentration of Ca2+ and Zn2+ in these assays should be 
carefully considered as calgranulins undergo conformational changes and 
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oligomerisation in the presence of these divalent cations (Boom et al., 2004; Donato, 
2007).  Homology modelling of the VC1 and C2 domains suggests that the constant 
domains are connected by a mobile loop comprising 12 residues from Ala223 to Glu236  
(Dattilo et al., 2007).  Whether the flexible nature of this loop is involved in allosteric 
signal transduction following ligand binding by the VC1 structure is unknown.   
A number of immunoglobulin superfamily receptors are known to form homodimers 
(Srikrishna et al., 2002).  Recent studies using S100B suggest that RAGE similarly 
undergoes oligomerisation following ligand binding (Dattilo et al., 2007).  Matsumoto et 
al. (2008) observed sRAGE oligomerisation using NMR, while titrating BSA-AGE into a 
sRAGE solution (Matsumoto et al., 2008). These findings support the hypothesis that in 
the presence of certain ligands, RAGE forms homophilic receptor superstructures 
(Matsumoto et al., 2008).  RAGE was originally thought to form a heterodimer with a 
lactoferrin-like molecule based on native PAGE electrophoretic studies showing RAGE in 
association with a 35 kDa structure (Schmidt et al., 1992).  More recently, RAGE purified 
from mouse lung was found to migrate as part of a 200 kDa complex under non-
denaturing conditions (Hanford et al., 2004). Thus, it is generally thought that RAGE 
forms homodimer/oligomers, however, there is conflicting evidence as to whether RAGE 
exists in a native oligomerised form, or requires ligand binding to initiate RAGE-RAGE 
associations (Abel et al., 1995; Leclerc et al., 2007; Ostendorp et al., 2007; Xie et al., 
2007; Matsumoto et al., 2008; Xie et al., 2008).  The stoichiometry of oligomerisation is 
uncertain, with reports of dimeric, trimeric and tetrameric RAGE quarternary structures 
in various contexts (Xie et al., 2007; Xie et al., 2008; Dattilo et al., 2007; Schmidt et al., 
1994).  Of particular interest is a report that the C1 domain plays a key role in 
oligomerisation of sRAGE expressed in a bacterial recombinant protein system (Xie et 
al., 2007). The role of the interdomain angle between C1–C2 mediated by the mobile 
loop has been proposed as one possible factor influencing RAGE oligomerisation and 
associated signal transduction (Dattilo et al., 2007; Xie et al., 2007). Indeed, recently 
Sitkiewicz et al (2013) demonstrated the involvement of this loop in the formation of 
dimer-tetramers of RAGE which is now considered its constitutive form (Xie et al., 2008; 
Koch et al., 2010).   
Clearly, the Ig C-domains of RAGE are not lay bystanders in the activity of this 
pluripotent receptor.  Their roles in directly binding various calgranulins independent of 
the V domain, stabilisation of the V domain secondary and tertiary structures, as well as 
RAGE oligomerisation are significant issues requiring further investigation.  Do multiple 
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ligands bind RAGE simultaneously, modifying signal transduction or inhibiting receptor 
oligomerisation? Do full ectodomain constructs behave differently to the C1C2  and C2 
RAGE constructs used in structural studies to date?  What is the RAGE-RAGE 
stoichiometry before and after ligation?  These fundamental questions about the 
structure of RAGE all require significant investigation. 
1.2.5 Intracellular C-terminal signalling domain 
RAGE is a non-canonical type I transmembrane receptor as it lacks a tyrosine kinase or 
similar intracellular signalling motif.  The RAGE intracellular domain is highly conserved 
across species including human, bovine, rat and mouse (Ishihara et al., 2003). It is 
described as consisting of a proximal 17 residue basic region, a central 17 residue 
glutamic acid region, and a poorly conserved 6 residue C-terminus (Ishihara et al., 2003). 
The highly acidic, 40 amino acid cytosolic tail (CT) contains more than 30% glutamatic 
acid residues and assumes a disordered structure (Dattilo et al., 2007).  NMR and 
circular dichroism studies suggest few persistent secondary or tertiary structures within 
the CT domain (Dattilo et al., 2007). Despite these unusual features, this domain is 
requisite for RAGE-ligand mediated intracellular signalling (Hudson et al., 2008b; 
Huttunen et al., 1999; Hassid et al., 2009; Sakaguchi et al., 2003). 
Although the CT domain is unusual in structure, two intracellular binding targets have 
been identified: extracellular signal-regulated protein kinase-1 and -2 (ERK 1/2),   and 
Diaphanous-1 (Dia1) (Ishihara et al., 2003; Hudson et al., 2008b).  The RAGE basic amino 
acid region of the cytoplasmic tail is consistent with a D-domain and directly binds ERK 
1/2 (Ishihara et al., 2003).  D-domains are essential in mediating the efficient 
phosphorylation of MAP kinases (Tanoue and Nishida, 2002). The phosphorylation state 
of the RAGE CT domain does not, however, influence ERK binding, with other members 
of the MAPK family such as JNK or p38 demonstrating no affinity for this structure 
(Ishihara et al., 2003). This observation suggests that RAGE is not a substrate for ERK, 
but a specific intracellular anchor that localizes this kinase to the extracellular 
membrane (Ishihara et al., 2003). Whether RAGE activation of the ERK signalling 
pathway is cell, ligand or sub-cellular compartmentally regulated, is yet to be well 
defined. 
More recently, Hudson et al. (2008) identified Diaphanous-1 as a key molecule that 
directly interacts with RAGE to mediate cellular outcomes (Hudson et al., 2008b). 
Diaphanous-1 is a member of the formin family of Rho GTPase binding proteins 
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principally involved in actin/cytoskeletal reorganisation (Tominaga et al., 2000; Chardin, 
2003).  Immunofluorescence and yeast two-hybrid studies confirm that Dia1 co-localises 
with RAGE at the extracellular membrane and directly interacts with the CT domain 
(Hudson et al., 2008b).  Specifically, RAGE binds to the proline-rich formin homology 
domain (FH1) as opposed to the Rho binding domain of Dia1 (Hudson et al., 2008b). The 
interaction of RAGE with Dia1 leads to activation of the Rac/cdc42 pathway involved in 
cell motility, cytokinesis, membrane protrusion and extension (Yamana et al., 2006).  
This is in concert with previous observations associating RAGE-ligand binding with 
neurite outgrowth and macrophage/lymphocyte migration (Huttunen et al., 1999; Chen 
et al., 2004). 
Recently, a number of questions as to the role of receptor oligomerisation and the CT 
domain have emerged.  Does the CT domain undergo re-organisation following 
oligomerisation? Does this allow other intracellular molecules to interact with the 
cytosolic domain of RAGE?  How does the pleiotropic nature of RAGE manifest through 
this small 40 amino acid structure? 
1.2.6 Lactoferrin-like polypeptide structural association with RAGE 
Early research to identify AGE binding proteins led to the discovery of RAGE, along with 
a 35 kDa Lactoferrin-like polypeptide (LF-L) (Schmidt et al., 1992; Neeper et al., 1992).  It 
was hypothesised that LF-L interacted with RAGE on endothelial and monocyte cell 
surfaces in a non-covalent, time dependent and reversible manner (Schmidt et al., 1994; 
Schmidt et al., 1992).  Competitive binding studies of bound and free RAGE against LF-L 
demonstrated specific binding of LF-L to immobilised RAGE, however, the stoichiometry 
of association was indeterminate (Schmidt et al., 1994).  Schmidt et al., observed that 
when individual components of the LFL-RAGE complex were targeted with IgG 
antibodies, ligand binding of the entire complex was inhibited (Schmidt et al., 1994).  
The RAGE–LF-L complex, although non-covalently stabilised, withstood exposure to very 
high salt (2 M) and pH (pH 3), with an affinity estimate (KD) of 100 pM (Schmidt et al., 
1994; Brownlee, 1995). Immunoelectron microscopy studies similarly located LF-L and 
RAGE in close proximity to each other, with cross-linking producing a single 70 kDa band 
immune-reactive for both molecules (Schmidt et al., 1992).  A Blockade study of the 
individual LFL-RAGE components and erythrocyte surface AGEs reported that these two 
AGE receptors bind differing species of AGE structures (Wautier et al., 1994).  This 
observation has not, to date, been confirmed. 
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At the time of these observations, little was known about RAGE structure.  New 
evidence, however, has revealed that RAGE is capable of forming oligomeric quarternary 
structures.  It is possible that the LF-L-RAGE complex is a heterophilic RAGE dimer; 
however, significant investigation is required to test this hypothesis.  
 
1.3 RAGE Ligands 
A number of RAGE extracellular ligands have been identified including advanced 
glycation end-products, HMGB1, calgranulins and various amyloids.  A few unusual RAGE 
ligands have also been reported, including the integrin Mac-1, advanced oxidation 
protein products (AOPP), and hyaluronic acid aggregates (Orlova et al., 2007; Neumann 
et al., 1999; Guo et al., 2008).  This review focuses on the four primary families of 
molecules known to bind and activate RAGE. 
1.3.1 Advanced glycation end-products (AGE) 
Advanced glycation end products are a heterogeneous class of irreversibly cross-linked 
adducts resulting from the non-enzymatic modification of amino acids by aldose sugars 
(Figure 4) (Brett et al., 1993; Gerrard, 2002).  This class of RAGE ligand has been strongly 
linked to the etiology of diabetic complications and aging, in particular its involvement in 
the progression of vasculopathies throughout the body (Chong et al., 2006; Leclerc et 
al., 2009; Salahuddin et al., 2014).  These characteristically yellow/brown, pigmented 
fluorescent adducts are also prevalent in commonly consumed foods such as 
commercially prepared breakfast cereals, olive oil, butter and various broiled and fried 
meats (Goldberg et al., 2004; Esposito et al., 1989).  Whether ingested exogenous 
sources of AGEs contribute to the development or progression of AGE related 
pathologies is yet to be clearly demonstrated. 
AGE formation begins with an initial condensation reaction between the free amine 
group in lysine or arginine, and a carbonyl group associated with reducing sugars such as 
glucose, ribose, lactose or the glyoxalase system metabolite methylglyoxal (Gerrard, 
2002; Westwood et al., 1994). This reaction was first described in 1912 by Louis-Camille 
Maillard after he observed gentle heating of sugar and amino acids in water produced a 
yellow brown colour (Gerrard, 2002; Maillard, 1912).  Although the chemistry of this 
reaction was unknown to Maillard, the implication that two common components of 
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food goods form a biologically active adduct has now been considered extensively in 
metabolic disorders such as diabetes. 
Early stages of protein glycation by this process are reversible from the initial formation 
of Schiff base products, through to the intermediate Amadori product which has a 
physiological half-life of 6-8 months (Gerrard, 2002).  These intermediate Maillard 
products undergo further irreversible modification leading to AGE production.  In some 
cases, the Maillard reaction causes protein cross-linking, particularly in proteins with a 
long half-life such as collagen and lens α-crystallins (Monnier et al., 1999; Nagaraj and 
Sady, 1996).  These structural changes contribute significantly to numerous pathologies 
such as diabetic complications. Because of this, certain AGEs such as glycated 
haemoglobin (HbA1c), N
ε-Carboxymethyl-lysine (CML), pentosidine and collagen bound 
furosine are utilised as indicators of diabetes progression (Monnier et al., 1999; Ikeda et 
al., 1996).   
For many years, it has been known that an inverse relationship exists between 
mammalian longevity and collagen glycation (Kohn, 1982). The distribution of AGEs 
throughout various tissues appears to correlate strongly with the protein species located 
in the various organs, protein turn-over and the expression of AGE receptors at these 
sites (Westwood et al., 1994).  The accumulating of AGEs is also often described as a 
function of protein half-life and sugar availability (Gerrard, 2002; Brownlee et al., 1988; 
Sell and Monnier, 1989).  During homeostasis, intravascular AGEs levels are partially 
controlled by vascular endothelial endocytosis/transcytosis (Esposito et al., 1989).  
The ability of various biological sugars to participate in the Maillard reaction varies 
greatly. Glucose is the least reactive of the aldohexoses, because of its role as a principle 
energy carrier in biological systems (Schmidt et al., 2001; Gerrard, 2002). Sugars such as 
ribose and fructose have reducing power that can lead to highly reactive AGE structures 
(Gerrard, 2002; Valencia et al., 2004). 
AGEs bind a wide array of cell surface receptors other than RAGE, including lactoferrin, 
scavenger receptor types I and II, oligosaccharyl transferase (OST-48), 80K-H 
phosphoprotein, galectin-3 and CD36 (Li et al., 1996; Vlassara et al., 1995; el Khoury et 
al., 1994).  The extreme diversity in biological AGE structures makes their in vivo 
characterisation difficult.  Numerous radio ligand studies have, however, produced KD 
estimates ranging from µM to nM for the binding of common physiological AGEs with 
RAGE (Xie et al., 2008; Kislinger et al., 1999; Valencia et al., 2004).    
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Figure 4.  General example of the formation of biologically significant advanced 
glycation end-products (Schmidt et al., 2001). 
Heterogeneity of AGE binding was first demonstrated by competitive binding assays 
involving radiolabelled methylglyoxal modified BSA (MS-AGE) and BSA-AGE (Westwood 
et al., 1994).  This study reported that radiolabelled AGE ligand is displaced by cold 
ligand of the same type, but not completely by alternate cold ligand (Westwood et al., 
1994).  This is possibly explained by the innate ability of MS-AGE to form protein cross-
linkages, in this case with BSA-AGE (Gerrard, 2002; Frye et al., 1998).  Cross-link 
formation and polymerisation of AGEs is known to contribute significantly to the robust 
nature of these macromolecules, reducing their solubility, increasing heat denaturation 
times and increasing protease resistance in vivo (Vlassara et al., 1992; Sell and Monnier, 
1989).   
The biological activity of AGEs is facilitated through four general mechanisms: 
intracellular signalling pathway activation following receptor-ligand binding; the 
structural modification of biological structures via the Maillard reaction; base 
modification at apurinic/apyrimidinic sites in DNA causing genomic disruption; and the 
oxidative effect of AGE molecules on nearby contiguous structures (Brownlee, 1995; 
Sakurai et al., 1990; Xie et al., 2008; Mullokandov et al., 1994; Bao et al., 2014).   
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The implication of AGE accumulation in vivo includes increased endothelial cell 
permeability, monocyte chemotaxis, expression of cytokine and growth factors, diabetes 
related renal failure, and nitric oxide dependent vasodilation (Esposito et al., 1989; 
Kirstein et al., 1990; Vlassara et al., 1992; Bucala et al., 1991; Mallipattu and Uribarri, 
2014; Merhi et al., 2014) .  Much debate exists as to whether AGEs are a specific RAGE 
ligand or accidental protagonist.  This consideration is, however, moot in the shadow of 
the severe biological outcomes of AGE accumulation.  A greater understanding of the 
kinetics of interaction between AGEs and RAGE will assist in understanding how this 
interplay promotes chronic disease.  
1.3.2 Amyloids 
The term amyloid was first used in 1854 by Virchow to describe an anomalous brain 
structure, corpora amylacea, which resembled botanical cellulose-like structures  
referred to at the time as amyloid (Virchow R, 1854).  Today, amyloids are characterised 
as fibrillary structures often composed of amyloid light chain (AL) or amyloid associated 
(AA) protein with cross-linked β-structures, an affinity for Congo red, and green 
birefringence (Westermark et al., 2005).  A number of in vivo amyloid fibril precursors 
have been identified and associated with local and systemic pathologies generally 
termed amyloidoses (Figure 5.) (Westermark et al., 2005). Endogenous Aβ is a 39-43 
amino acid peptide that makes up the majority of extracellular fibrillary aggregates 
commonly known as amyloid plaques (Balleza-Tapia and Pena, 2009).  Aβ exists as a 
monomer, insoluble (AβF) and soluble (AβO) oligomeric fibrillary structures, and 
aggregate (AβA) forms (Sturchler et al., 2008). 
RAGE directly interacts with amyloid fibrillary structures (Yan et al., 1996; Yu and Ye, 
2014; Origlia et al., 2014).  The first study showing this found that synthetic amyloid β-
peptide (1-40) (Aβ1-40), bound RAGE with nanomolar affinity in both brain endothelium 
and cortical neurons (Yan et al., 1996).  This interaction is inhibited in a dose-dependent 
manner by anti-RAGE IgG or excess sRAGE in both in-vivo and in-vitro cell binding assays 
(Yan et al., 1996). The ability of various synthetic Aβ ligands to bind RAGE is now known 
to involve residues 25-35 of the peptide, with scrambled Aβ25-35 having no binding 
activity (Yan et al., 1996).  These 4-5 kDa peptides are produced by the sequential 
activity of β- and γ- secretase on transmembrane protein amyloid precursor protein 
(APP) (Selkoe, 2001; Kimberly et al., 2003).  Particular mutations in the gene of APP as 
well as the presenilins (PS1 and PS2) involved in APP processing, correlate strongly with 
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familial Alzheimer’s disease (Hardy, 1997). These mutations result in the expression of 
amyloidogenic peptides, namely Aβ1-42, that cause progressive cognitive impairment 
(Hardy, 1997; Balleza-Tapia and Pena, 2009). 
 
 
Figure 5. Human precursors for amyloid fibril structures and their associated 
syndromes (Westermark et al., 2005). 
Whether these β-sheet fibrils bind common or discrete V domain binding sites to that of 
BSA-AGE’s and HMGB1 ligands, was investigated in competitive I125-Aβ1-40 binding 
assays.  Each of these ligands reversibly blocked I125-Aβ1-40 interaction with RAGE in a 
dose-dependent manner, supporting the hypothesis of overlapping or contiguous 
binding sites (Yan et al., 1996).  The conclusion that Aβ exclusively binds the V domain of 
RAGE was further strengthened by atomic force microscopy and modelling studies 
(Chaney et al., 2005). 
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The observation that monomeric and fibrillary forms of amyloid β-peptide bind RAGE 
with differing affinities prompted the question whether the receptor recognised a 
sequence motif or a tertiary/quarternary structural motif involving β-sheet structures 
(Yan et al., 2000; Qosa et al., 2014).  To answer this, RAGE binding studies were 
performed utilizing non-amyloidogenic erabutoxin B - an all β-sheet protein, non-cross-
linked β fibril collagen and elastin molecules as ligands.  These structures did not interact 
with the receptor, suggesting that RAGE recognises cross-linked β-structured amyloids 
only, with the exception of monomeric Aβ-peptide (Yan et al., 2000).  The necessity for 
these quarternary amyloid structures in RAGE binding was further confirmed by the 
observation that SAA 1 (forming amyloidogenic fibrils) and not SAA 2 (does not form 
fibrillary structures) binds and initiates cellular stress through RAGE (Malle et al., 2009).  
Recently, the oligomeric state of Aβ was shown to influence RAGE binding (Sturchler et 
al., 2008). This study reported that Aβ aggregates specifically interact with the C1 
domain, while monomeric and oligomeric Aβ bind the V domain (Sturchler et al., 2008).  
Currently, a number of fibrillary RAGE binding molecules have been identified. Serum 
amyloid A, transthyretin amyloid fibrils (TTR), as well as protein/protein fragments such 
as amyloid β-peptide, amylin and prion-derived peptides promote cellular dysfunction 
through RAGE (Yan et al., 2000).   
A common factor in RAGE activation by amyloids is oxidative stress through reactive 
oxygen species (ROS) production and subsequent IκB-α degradation.  This event leads to 
the activation and nuclear translocation of NF-κB by intracellular signalling pathways 
(Yan et al., 2000).  Through this transcription factor, oxidative stress and other signalling 
pathways, amyloid-RAGE promotes cellular dysfunction and ultimately neuronal 
apoptosis (Malle et al., 2009; Chong et al., 2006).  Inversely, under homeostatic 
conditions, RAGE facilitates the clearance of amyloid via lysosomal compartment 
degradation (Chaney et al., 2005).  
Although RAGE mediated signal transduction is a significant pathway promoting Aβ 
outcomes, the promiscuous nature of amyloids suggest it is not the only avenue of 
action (Balleza-Tapia and Pena, 2009).  A multitude of Aβ cell surface binding sites other 
than RAGE have been identified.  These include alpha-5 β-1 integrin, N-methyl D-
aspartate receptor (NMDA-R), nicotinic receptors, formyl-peptide receptor-like-1 
(FPRL1) and certain adhesion and tyrosine kinase receptors (Kalea et al., 2009a; 
Ramprasad et al., 2007; Falcone et al., 2005; Balleza-Tapia and Pena, 2009).  Recently, 
RAGE has been identified as having a role in the transportation of Aβ from the blood 
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stream into the central nervous system, further confirming it as a key player in the 
progression of neurodegenerative conditions (Andras et al., 2012). 
The mechanistic elements of RAGE-amyloid ligation remain largely unknown.  The 
consequences of this interaction are, however, well documented and include 
progressing rheumatoid arthritis, neoplasia, systemic amyloidosis, and Alzheimer’s 
disease (Yan et al., 2000; Yan et al., 1996; Malle et al., 2009; Chen et al., 2007).   
1.3.3 Calgranulins 
Calgranulins are known as S100 proteins due to their solubility in 100% saturated 
ammonium sulfate (Donato, 2001; Moore, 1965).  This heterogeneous family of 21 Ca2+ 
modulated proteins is exclusively expressed by vertebrates in both intracellular and 
extracellular spaces (Donato, 2007).  Calgranulins are characterised by a highly 
conserved EF-hand tertiary structure composed of two α-helices flanking a Ca2+ binding 
loop that collectively form a helix-loop-helix motif.  The first loop in the amino-terminus 
EF hand structure is long and disordered in comparison to the second carboxyl-terminus 
EF hand loop which is canonical in arrangement (Donato, 1986; Donato, 2007). These 
differences result in low and high Ca2+ binding affinities respectively (Donato, 1986; 
Donato, 2007).  Although the calcium binding regions are highly conserved within the 
S100 family, the hinge region joining the two EF hands is  highly variable (Santamaria-
Kisiel et al., 2006; Yanez et al., 2012).  
S100 proteins are an acidic, low molecular weight species often within the range of 9–14 
kDa. The human genes encoding 13 members of this family are found in a cluster on 
chromosome 1 (Donato, 2001; Schafer et al., 1995).  The majority of in vivo S100 
proteins exist as non-covalently bound homophilic oligomers with the exception of 
S100G which is monomeric (Donato, 2001; Skelton et al., 1994).  Extracellular 
heterodimers of S100A12/S100B, S100A8/S100A9 and S100B/S100A6 are common, with 
the A8/A9 dimer being the preferred intracellular form for S100A8 and S100A9 (Hunter 
and Chazin, 1998; Donato, 2001; Leclerc et al., 2009).  Monomers stack in an anti-
parallel orientation to each other to form non-covalent structures that upon binding of 
Ca2+, Zn2+ or Cu2+, undergo significant conformational change to expose a hydrophobic 
cleft (Santamaria-Kisiel et al., 2006; Boom et al., 2004).  This hydrophobic region is one 
mechanism by which oligomeric S100 quarternary structures affect intracellular target 
molecules (Leclerc et al., 2009). It is, however, postulated that other unidentified 
aspects of calgranulin structure are also involved (Donato, 2007). 
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S100 molecules are implicated in a broad array of physiological processes that include 
cell proliferation, differentiation and cytoskeletal organisation, membrane trafficking, 
protein phosphorylation, gene expression and metabolism (Leclerc et al., 2007; 
Hofmann et al., 1999; Leclerc et al., 2009). Calgranulins are expressed in a cell specific 
manner (Leclerc et al., 2009).  Whether this explains why certain S100 proteins are 
associated with diseases affecting particular tissues, or that various calgranulins have 
unique and specific biological targets from each other, requires considerable 
clarification. 
Based upon the high degree of structural homology within the functional Ca2+ binding 
domain of this family, it is not unreasonable to suggest that S100s may bind a number of 
common targets. Based on this hypothesis, it was thought likely that a number of 
calgranulins bind RAGE based on initial observations that S100B and S100A12 are RAGE 
ligands (Chavakis et al., 2003; Bianchi et al., 2007; Yang et al., 2007).  Subsequent studies 
have shown that S100A1, A4, A6, A7, A8/A9 dimers, A11, A13 and S100P potentially 
promote physiological outcomes, in part, through RAGE (Donato, 2007; Leclerc et al., 
2009; Tothova and Gibadulinova, 2013; Chen et al., 2014b). 
S100B is the most studied of the calgranulins, predominantly expressed in brain tissue 
by astrocytes at levels greater than any other cell type (Santamaria-Kisiel et al., 2006; 
Donato, 2001).  Of all the S100 family, S100B is the only member with an encoding gene 
located on chromosome 21 (Donato, 2001).  The prevalence of S100B in down-syndrome 
(chromosome 21 trisomy), and a number of neurodegenerative disorders has promoted 
the hypotheses that S100B-RAGE plays either a neuro-protective role or contributes to 
neurological pathogenesis.  It is known that outcomes of S100B/RAGE interaction are 
ligand and RAGE concentration dependent.    The duality of S100B activity being both 
neurotrophic and degenerative is apparent at concentrations above 500nM, which 
promotes neuronal apoptosis (Donato, 2001; Donato, 2007).  Low concentrations of 
both RAGE and S100B inhibit neuronal apoptosis by up-regulating Bcl-2 through the Ras-
MEK (MAP-k)-ERK 1/2 pathway (Donato, 2001; Van Eldik and Wainwright, 2003).  
Exposure of neurons to low-levels of S100B is similarly prophylactic.  Subsequent 
exposure of these cells to high concentrations of S100B or β-amyloid greatly reduces 
toxicity, likely due to pre-activation of Bcl-2 (Huttunen et al., 2000).  The principle effect 
of persistent high S100B levels on neuronal cells is the over-production of RAGE, and an 
exaggerated inflammatory response facilitated by ROS, phosphoinositide 3-kinase 
(PI3K), and NF-κB activation mediated by RAGE (Schafer et al., 1995).  The dependency 
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of S100B on RAGE signal transduction is evident in neurons expressing cytosolic tail 
deleted RAGE (RAGE∆cyto).  These cells show no apparent toxicity to high levels of 
S100B, while low levels do not trigger normal homeostatic outcomes such as neurite 
outgrowth (Huttunen et al., 2000).  Collectively, these findings support roles for S100B-
RAGE mediated cellular outcomes in the development of central nervous tissue and 
early response to brain injury.  Extended and excessive accumulation of S100B, like 
other RAGE ligands, tends to lead to cellular dysfunction through an exaggerated 
inflammatory response and ROS production (Hunter and Chazin, 1998; Huttunen et al., 
2000; Schafer et al., 1995; Hofmann et al., 1999; Xie et al., 2013; Adami et al., 2004). 
The specific cellular outcomes of calgranulins, and the involvement of RAGE in the 
transduction of intracellular signals is extremely complex.  In brief, S100A4 has been 
clearly shown to progress tumour metastasis and articular pathophysiology as seen in 
the tumour-like behaviour of rheumatoid arthritis synovium (Shaw et al., 2003; Helfman 
et al., 2005; Senolt et al., 2006).  S100A6 similarly plays a role in tumour development 
through direct ligation with the tetramerization domain (residues 325-355) of p53, and 
neuronal apoptosis in a RAGE dependent manner (Leclerc et al., 2007; van Dieck et al., 
2009; Gross et al., 2014).  S100A8 and A9 are often referred to as neutrophil cytosolic 
proteins due to their prevalence in neutrophils, monocytes/macrophages, activated glial 
cells and their roll in leukocyte adhesion and migration (McCormick et al., 2005; Donato, 
2007; Ibrahim et al., 2013). Like S100B, S100A8 and A9 are secreted from leukocytes at 
sites of inflammation in response to proinflammatory stimuli (such as endotoxin), 
through a positive feedback mechanism involving RAGE and heparan sulphate 
proteoglycans (Donato, 2007; Ibrahim et al., 2013).  These calgranulins are, therefore, 
often associated with chronic inflammatory disorders such as diabetes and tumour 
metastasis, making them accurate blood-born markers of ongoing inflammation (Foell et 
al., 2007).  S100A8/A9 heterodimers promote a number of physiological changes in 
homeostasis that generally increase vascular permeability, platelet aggregation and the 
recruitment of leukocytes (Roth et al., 2003; Leclerc et al., 2009). NF-κB activation 
similarly follows S100A8/A9 up regulation, resulting in gene transcription of pro-
inflammatory cytokines and cell adhesion receptors such as VCAM (Roth et al., 2003; 
Donato, 2007; Xu et al., 2012).  S100A12 is predominantly expressed in granulocytes and 
keratinocytes, exerting physiological outcomes such as leukocyte activation and 
infiltration at sites of inflammation (Roth et al., 2003; Donato, 2007).  RAGE mediates 
S100A12 activity through NF-κB activation, particular in monocytes and endothelium 
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following exposure to TNF-α and endotoxin (van Zoelen et al., 2011; Wittkowski et al., 
2007).  These stimuli promote S100A12 expression as seen in synovial fluid of 
rheumatoid arthritis patients (Chen et al., 2009b). As with S100A8/A9 proteins, RAGE is 
unlikely the sole receptor mediating S100A12 biological outcomes, with S100A12 
activating mast cells not expressing RAGE (Yang et al., 2007). 
The S100 family of molecules represents an extremely complex array of molecules with 
autocrine and paracrine effects on neurons, microglia, astrocytes, monocytes, 
endothelial cells, vascular smooth muscle cells and numerous tumour cells (Donato, 
2007; Bianchi et al., 2007; Ponath et al., 2007; Reeves et al., 1994; Xie et al., 2013; 
Leclerc et al., 2009).  RAGE is clearly a mediator in a number of these cell types for some, 
but not all calgranulins. This role is central in a number of pathologies involving pro-
inflammatory responses, and represents a novel opportunity for intervention in a 
number of diseases.  A greater understanding of the nature of interaction between 
RAGE and calgranulins is, however, required to realise this ambition. 
1.3.4 High-mobility group box chromosomal protein 1 
High-Mobility Group - 1 Box Proteins (HMGB1) are a family of essential, multi-functional, 
non-histone proteins that bind to DNA in a sequence independent manner (Bianchi et 
al., 2007).  Within the HMG set of molecules are sub-groups defined by common 
functional motifs: HMG-1/2 (HMG box), HMG-14/17 (nucleosome binding domain) and 
HMG-I/Y (AT-hook) (Hassid et al., 2009).  Despite these distinguishing characteristics, all 
members of the HMG family possess an overarching ability to modify the conformation 
of DNA, enhancing the efficiency of gene transcription and chromatin plasticity (Hassid 
et al., 2009).  The ability of these molecules to interact with DNA is mediated by two 
homologous HMG box domains made up of α-helical secondary structures (Read et al., 
1993).  The original name, amphoterin, reflects the dipolar contiguous arrangement of a 
basic 185 amino acid domain with a 30 residue anionic region (Hsin et al., 2010). 
The role of this family of proteins first identified in the 1970’s, was believed to be limited 
to intra-nuclear functions including gene transcription, replication, repair, and 
nucleosome stabilization (Kokkola et al., 2005; Fiuza et al., 2003).  Recently, however, a 
number of extracellular roles have been identified for HMGB1.  These involve pro-
inflammatory responses, central nervous system development, mediation of 
endotoxicity and modulation of haemostasis and thrombosis (Kokkola et al., 2005; Fiuza 
et al., 2003; Huttunen et al., 2002; Tanoue and Nishida, 2002; Hassid et al., 2009).  
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It is known that B16 melanoma, neuroblastoma and immune cells such as monocytes 
secrete HMGB1 in response to early pro-inflammatory signals including 
lipopolysaccharide (LPS), TNF-α and interleukin 1 (IL-1) (Kay et al., 2009; Hsin et al., 
2010).  Normal cytokine secretion occurs through classical endoplasmic reticulum-Golgi 
exocytosis, in which protein trafficking is determined by a leader sequence (Yamana et 
al., 2006).  Despite functional similarities to cytokines, HMGB1 is exuded into the 
extracellular milieu by a non-classical, Ca2+ -regulated secretory lysosome pathway 
(Gardella et al., 2002).  This process requires a stimulatory element such as LPS, phorbol 
myristoyl acetate (PMA), TNF-α or IL-1, activation of protein kinase C (PKC), and the 
bioactive lipid lysophosphatidylcholine (LPC) (Gardella et al., 2002; Wang et al., 1999; 
Hsin et al., 2010).  In the presence of these stimuli, nuclear HMGB1 molecules relocalise 
to cytoplasmic organelles such as the endolysosomal compartment before undergoing 
vesicle-facilitated exocytosis (Gardella et al., 2002).  Although the majority of circulating 
HMGB1 relies on this ordered secretory pathway, a small proportion is released from 
necrotic cells (Kokkola et al., 2005; Stephenson et al., 2010). As with a number of pro-
inflammatory molecules, HMGB1 imparts a positive influence at nontoxic levels, 
recruiting macrophages to sites of injury and promoting monocyte tissue infiltration and 
senescence (Valencia et al., 2004; Stephenson et al., 2010).   
Elevated levels of circulating HMGB1 are a late-stage marker of endotoxicity, 
immediately followed by increased TNF-α and IL-1 expression (Wang et al., 1999).  
Inhibitors of both TNF-α and IL-1 have little impact on endotoxicity survival in mice 
(Wang et al., 1999). Double negative mice for these cytokines, however, demonstrate 
significant increases in endotoxemic tolerance (Wang et al., 1999).  This clinical paradox 
is explained by the observation that rapid release of TNF-α and IL-1 promotes late-stage 
secretion of HMGB1 and associated symptoms of endotoxicity (Wang et al., 1999).  This 
is supported by the observation that injection of recombinant HMGB1 into double 
negative TNF-α and IL-1 mice induces endotoxemia with 60% mortality (Wang et al., 
1999).   
The pluripotent outcomes of HMGB1 are known to be, in part, mediated by the ligation 
of HMGB1 with RAGE (Hori et al., 1995; Huttunen et al., 2002; Huttunen et al., 2000; 
Taguchi et al., 2000; Xie et al., 2013; Ibrahim et al., 2013).  The ability of HMGB1 to bind 
RAGE in a saturable, dose-dependent manner was first reported in 1995, with an 
estimated KD of approximately 6-10 nM (Hori et al., 1995).  Since this time,  a number of 
groups have reported estimates of binding that range from KD ≈ 90-700 nM (Liu et al., 
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2009; Ling et al., 2011).  The region of HMGB1 interacting with RAGE is refined to amino 
acids 150-183 that constitute part of a COOH-terminal motif (Huttunen et al., 2002; Hsin 
et al., 2010).  Interestingly, this region of HMGB1 shares sequence similarity with 
residues 3-39 of S100A12 that constitute the calgranulin EF-hand motif (Huttunen et al., 
2002).  In endothelial cells, RAGE activation by HMGB1 results in a cell adhesion 
phenotype characterised by increased expression of intercellular (ICAM) and vascular 
cell adhesion molecules (VCAM), and activation of β1 and β2 integrins (Patel et al., 2010; 
Fiuza et al., 2003). Prolonged activation in both endothelia and monocytes results in the 
secretion of interleukin-8 (IL-8), monocyte chemo attractant protein-1 (MCP-1), TNF-α 
secretion, RAGE up-regulation and the production of fibrinolysis modulators (Fiuza et al., 
2003; Ibrahim et al., 2013; Xie et al., 2013).  Activation of these pro-inflammatory 
elements clearly defines HMGB1 as an agonist of diseases exacerbated by chronic 
inflammation.  
Co-localization of RAGE with HMGB1 in developing rat brain, suggests a homeostatic 
role for RAGE distinct from chronic disease (Huttunen et al., 2000).  Tissue surveys 
confirmed the expression of RAGE during mammalian development, in particular in the 
central nervous system (Hori et al., 1995; Brett et al., 1993).  HMGB1 coated culture 
flasks promote neurite outgrowth of cultured rat cortical neurons, with the presence of 
sRAGE or anti-RAGE antibodies reversibly inhibiting neuronal development (Huttunen et 
al., 1999; Hori et al., 1995).  Cell motility is also in part, influenced by RAGE-HMGB1. A 
study utilising neuroblastoma cells transfected with a cytosolic domain deleted RAGE 
(DN-RAGE) construct observed a complete loss of cell migration, otherwise apparent 
with wild type RAGE (Huttunen and Rauvala, 2004).  This observation clearly supports a 
role for HMGB1-RAGE in cytoskeletal reorganisation affecting cellular outgrowth, 
cytokinesis and cellular differentiation.  
RAGE is clearly involved in mediating HMGB1 physiological outcomes.  However, a 
number of alternative cell surface receptors exist for HMG proteins, including syndecan-
1, toll-like receptors (TL2 and TL4), receptor-type tyrosine phosphatise β/ζ, and 
sulfoglucuronyl carbohydrates on some cell surface adhesion molecules (Salmivirta et 
al., 1992; Chou et al., 2004; Park et al., 2004b).  It is clear that activation of RAGE by 
HMGB1 in neuronal, tumour, endothelial and leukocyte cells, ultimately leads to the 
activation of transcription factors NF-κB, Sp1 and cAMP response element binding 
(CREB) (Huttunen et al., 1999; Taguchi et al., 2000; Fiuza et al., 2003; Rauvala and 
Rouhiainen, 2007; Urbonaviciute et al., 2008).   
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The interplay between HMGB1 and RAGE is a significant and complex factor in both 
disease and health. The myriad of intracellular signalling pathways by which HMGB1-
RAGE facilitates these physiological opposites, still requires significant investigation. 
 
1.4 RAGE Intracellular Signalling Pathways 
Intracellular signalling is one of the most complex areas of molecular biology 
investigation.  The intrinsic cross-talk, redundancy, subtle mechanisms of 
regulation/activation and rate of molecular action persistently hamper efforts to 
understand the inner world of cells. 
RAGE is known to mediate multiple, parallel signalling cascades through its cytosolic 
domain (Hofmann et al., 1999; Taguchi et al., 2000).  These cascades have roles in both 
homeostasis and a number of chronic disease states. RAGE signalling pathways are 
complex and influenced by cell type, ligand, receptor isoform and oligomeric state, 
pathophysiology, multigenetic factors and developmental maturity (Kalea et al., 2009b; 
Ramasamy et al., 2009; Yan et al., 2009; Ishihara et al., 2003).  They can, however be 
described in relation to three general cellular outcomes: actin/myosin cytoskeletal 
regulation, pro-inflammatory outcomes, and regulation of gene expression. 
1.4.1 Cytoskeletal regulation 
Regulation of cellular cytoskeletal elements including actin microfilaments, microtubules 
and myosin motor proteins facilitate cytokinesis, cell adhesion, extension, and motility 
(Cho and Klemke, 2000; Huttunen et al., 2000; Huttunen and Rauvala, 2004).  Cancer cell 
lines such as N18 neuroblastoma, C6 glioma and glioblastoma are increasingly invasive 
when RAGE is activated by ligand (Taguchi et al., 2000; Huttunen et al., 2002; Yamana et 
al., 2006; Bassi et al., 2008).  Similarly, homeostatic cells such as neuronal, endothelial 
and smooth muscle cells exhibit cytoskeletal reorganisation events such as neurite 
outgrowth, cell spreading and regulated cell adhesion following the interaction of AGE, 
S100 and HMGB1 with RAGE (Huttunen et al., 1999; Higashi et al., 1997; Christiansen et 
al., 2009; Leclerc et al., 2007; Rauvala and Rouhiainen, 2010). Inflammatory immune 
cells such as dendritic cells, monocytes, macrophages, neutrophils and leukocytes all 
undergo chemotaxis, homing and adhesion to foci of inflammation in response to RAGE-
ligand binding (Kokkola et al., 2005; Orlova et al., 2007; Rouleau et al., 2003).  
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Common to these studies is the observation that inhibiting RAGE-ligand association, cell 
division cycle 42 (cdc42) or Ras-related C3 botulinum toxin substrate-1 (Rac1) 
antagonises actomyosin mediated cell behaviours (Huttunen et al., 1999; Hori et al., 
1995; Taguchi et al., 2000; Bianchi et al., 2007; Hudson et al., 2008b; Ramasamy et al., 
2009).  Collectively, these observations support the conclusion that RAGE activates Rac1 
and Cdc42 members of the Rho family of small GTPase molecules classically involved in 
cell adhesion, motility and migration (Figure 6) (Huveneers and Danen, 2009).  RhoA 
directly regulates stress fibres and filamentous actin (f-actin) contraction essential for 
cell adhesion and spreading (DeMali and Burridge, 2003).  Cdc42 and Rac1 generally 
promote membrane extension and filamentous actin growth.  Appropriately, RhoA and 
Rac1 inhibit each other when active, allowing only one to be functional in the presence 
of the other.  Cdc42 and Rac1 are both required for motility through the recruitment of 
wiskott-aldrich syndrome protein (WASP) and WASP family verproline-homologous 
protein (WAVE) respectively (Huveneers and Danen, 2009).  In combination, these 
proteins recruit actin related protein 2/3 (Arp 2/3) that facilitates actin growth (DeMali 
and Burridge, 2003).   
Integrins in collaboration with Src-family kinases, oversee the activity of Rho-GTPases 
through regulation of guanine-exchange factors (GEFs) and GTPase-activating proteins 
(GAPs).  GEF and GAP are essential in controlling the active conformation of Rho-
GTPases by acting as GTP exchange factors (Marignani and Carpenter, 2001).  Integrin 
control of Rac1 and cdc42 was observed in HMGB1-RAGE dependent neutrophil 
recruitment involving the β2 integrin Mac-1 (Orlova et al., 2007).  In this study, HMGB1 
induced motility in neutrophils and adhesion in leukocytes in a RAGE dependent manner 
(Orlova et al., 2007).  Crosstalk between growth factor/cell adhesion and integrin/Rho-
GTPase signalling pathways facilitates cell-cell adhesion and spreading through Rac1 
(Wildenberg et al., 2006).  This may explain how RAGE-HMGB1 stimulates migration in 
one cell type and an adhesion phenotype in another.  If the cell, such as endothelia, 
express high levels of epidermal growth factor receptor (EGFR) or inter-cellular 
adhesion, cross-talk with the integrin-Rac1 pathway will promote cell spreading and 
adhesion (Wildenberg et al., 2006; Huveneers and Danen, 2009).  Ligation of integrins 
such as Mac-1, promotes Src phosphorylation and activation of unengaged EGFR 
(Huveneers and Danen, 2009).  EGFR consequently recruits PI3K which mediates 
activation of Vav2-Rac1-PAK, reducing Arp2/3 levels and promoting cell 
adhesion/spreading (Figure 6) (Huveneers and Danen, 2009).   
 Page 29 
 
PI3K is involved in RAGE-AGE induced cell adhesion (Toure et al., 2008).  Inhibition of 
PI3K following RAGE activation retards cell adhesion and restores cell motility (Toure et 
al., 2008).  In the absence of growth and adhesion cell surface molecules, migration 
occurs in response to the classic Cdc42-Rac1-Arp2/3 pathway.  Src-family of kinases 
(SFK) and caveolin-1 play a role in S100B-RAGE smooth muscle cell initiated cell motility 
(Reddy et al., 2006).  It has been reported that inhibition of SFK, RAGE or caveolin-1 in 
smooth muscle cells (SMCs), suppresses cell motility (Reddy et al., 2006).  Directional 
cell migration requires cell polarisation.  This manifests in sub-cellular 
compartmentalisation of Rho-GTPases whereby the rear of the cell contracts towards 
the migrating front of the cell in unison with extension of lamellipodia at the front of the 
cell in the direction of migration.  Contraction is controlled by RhoA, while extension and 
cell direction is controlled by Cdc42-Rac1.  Activation of Rho GTPases is influenced by 
SFK-mediated phosphorylation of GAF and GEF intermediates (Huveneers and Danen, 
2009).  The blockade of SFK in SMC could, therefore, retard cell migration by inhibiting 
either contraction, extension or both.  Caveolin-1 is essential for endosomal recycling 
and sorting of SFKs and integrins (Huveneers and Danen, 2009).  Disruption of this 
process through caveolin-1 inhibition, ultimately derails RhoA/Cdc42-Rac1 directional 
chemotaxis in SMC through a loss of SFK activity (Huveneers and Danen, 2009).   
Diaphanous-1 is an effector of RhoA activity and was recently identified as a RAGE 
intracellular ligand (Hudson et al., 2008b).  In response to RhoA activation, Dia1 
activates Cdc42 at the front of migrating cells along with other intermediates, to 
promote actin extension and Rac1 activation (Hudson et al., 2008b; Huveneers and 
Danen, 2009). Interestingly, Hudson et al., observed Rac1 activation following Dia-1 
recruitment by RAGE in C6 glioma cells (Hudson et al., 2008b).  It may be that RAGE-Dia-
1 usurps RhoA-Dia1 regulation of Cdc42/Rac1 and encourages cell motility.   
ERK 1 and 2 bind to the RAGE cytosolic domain (Ishihara et al., 2003).  It is not known 
how these members of the MAP kinase family influence cell motility or adhesion.  
However, ERK in concert with paxillin and myosin light chain kinase (MLCK), increase 
Rac1-GTP and cdc42-GTP levels at the front of migrating cells, inevitably promoting taxis 
(Huveneers and Danen, 2009).  Alternatively, cytosolic ERK may be activated by Rac-PAK-
MEK to promote cell adhesion and spreading (Figure 6).  Clarification of the role that ERK 
plays in cytoskeletal regulation, as discrete from cell survival, is therefore needed.  
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Interestingly, the HMGB1 receptor syndecan 4, interacts with PKC to facilitate the 
formation of a Ras-GAP-Rho-GAP complex that inhibits RhoA activation (Huveneers and 
Danen, 2009).  Bianchi et al. (2007) reported Ras activation following RAGE-S100B 
ligation, accompanied by membrane extension (Bianchi et al., 2007). Whether syndecan 
activation by HMGB1 accounts for the observations of Bianchi et al. (2007), or are a 
result of RAGE activity, still requires further investigation to define the reported role of 
Ras. 
Together, these various complex pathways hypothetically demonstrate how ERK1/2, 
integrins, Ras, Rac1, cdc42, RhoA and Dia-1 may interact to promote cell adhesion, 
membrane extension and chemotaxis.  Significant experimentation is required to 
delineate direct outcomes of RAGE activation from those mediated by cross-talk with 
growth factors and adhesion molecule intracellular cascades. 
1.4.1 Pro-inflammatory signalling and gene expression 
One of the most significant outcomes of RAGE ligation in disease is the activation of pro-
inflammatory signalling pathways and regulation of gene expression. RAGE mediated 
inflammatory outcomes depend on ligand, cell type, RAGE isoforms, existing 
pathophysiology, and multigenetic factors. 
The first intracellular signalling molecules shown to directly interact with RAGE were 
extracellular regulated kinases 1 and 2 (ERK 1/2) (Ishihara et al., 2003).  ERK is activated 
in a number of scenarios primarily involving cell proliferation and apoptosis.  It is 
suggested that ERK promotes these antipodal roles through sub-cellular localization 
(Mebratu and Tesfaigzi, 2009).  RAGE activation and subsequent ERK binding is 
associated with cell death and tumour progression in neuronal and C6 glial cell lines 
(Chong et al., 2006; Taguchi et al., 2000).  RAGE localization of ERK to the cytosolic 
compartment encourages  
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activation of death-associated protein kinase 1 (DAPK-1), a proapoptotic protein, and 
the formation of tropomyosin-1, which is essential in stress fibre formation (Xie et al., 
2013; Houle et al., 2007; Mebratu and Tesfaigzi, 2009).  In these scenarios, ERK is 
commonly activated by oxidative stress.  Interestingly, RAGE activation is associated 
with phospholipase C-mediated activation of Ca2+-dependent PKC, leading to NADPH 
oxidase production of reactive oxygen species (ROS) (Warboys et al., 2009; Xie et al., 
2013; Guo et al., 2008).  Increased PKC-NADPH-ERK activity is associated with cell death 
and altered gene expression following exposure to RAGE ligands such as AGES (Chong et 
al., 2006; Nitti et al., 2007; Ding et al., 2007; Wautier et al., 2001).  Additionally, 
PI3K/MEK1/2 induces ERK1/2 activation and nitric oxide production in mouse microglia 
cells following AGE-RAGE binding (Dukic-Stefanovic et al., 2003). These sources of 
reactive oxygen intermediates (ROI) and localisation of ERK to the cytosolic 
compartment support the hypothesis that RAGE may mediate apoptosis through RAGE 
bound, ROI activated ERK1/2.   
Interestingly, Aβ1-42 oligomer-RAGE engagement in rat brain leads to ERK 1/2-caspase-3 
dependent proteolytic cleavage of Tau (Chong et al., 2006).  Inhibition of ERK 
significantly reduces Aβ toxicity in rats, confirming an association between 
neurodegenerative pathology and RAGE-ERK signalling (Chong et al., 2006; Balleza-Tapia 
and Pena, 2009). Currently, the factors determining whether a cell undergoes apoptosis 
in place of an altered motile/adhesive phenotype are unknown.  However, it is known 
that ligand type and concentration, cell type and intracellular crosstalk, along with RAGE 
oligomeric state likely influence the outcome (Bianchi et al., 2007; Donato, 2007; Leclerc 
et al., 2007; Ishihara et al., 2003; Xie et al., 2013; Ibrahim et al., 2013).  It is possible that 
Dia1 competes with ERK for the RAGE cytosolic domain, displacing ERK1/2 which allows 
it to undergo nuclear translocation.  Therefore, those cells with high levels of cytosolic 
Dia1 such as motile cells, innately promote nucleated ERK1/2 gene transcription that 
favours cell survival. This proposed interplay correlates with the observed 
compartmental regulation of ERK mediated biological outcomes (Mebratu and Tesfaigzi, 
2009).  Although there are studies to support this hypothesis, there are also others in 
disagreement (Wautier et al., 1994; Hudson et al., 2008b; Wautier et al., 2001; Huttunen 
et al., 2000).  A broad study to control for elements such as activating ligand, RAGE 
isoform and cell type, and regulation of signalling crosstalk is required to evaluate this 
hypothesis. 
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Protein kinase B, commonly known as Akt, is a serine/threonine kinase that plays a 
critical regulatory role in glucose metabolism, cell survival, angiogenesis and tumour 
progression (Los et al., 2009).  At low levels of S100B exposure (<500 nM), the PI3K-Akt 
pathways promotes cell survival through phosphorylation of bcl-2 family member BAD 
(Donato, 2007; Huttunen et al., 2000).  Activation of p53 and NF-κB transcription factors 
by Akt also assists in expression of cell growth and survival factors. Alternately, AGE-
RAGE engagement decreases levels of Akt activity in endothelial progenitor cells, leading 
to increased cell apoptosis mediated by dephosphorylated BAD-Caspase-3 (Chen et al., 
2009a).  This has similarly been observed in neuronal cells exposed to micromolar 
concentrations of S100B (Donato, 2007).   
S100B, S100A12 and AGEs induce expression of pro-inflammatory cyclooxygenase-2 
(COX-2) in human monocytic leukemic cells and peripheral blood monocytes 
(Shanmugam et al., 2003).  COX-2 encourages pro-inflammatory outcomes in a number 
of diseases through its effector prostaglandin E2. In studies where RAGE mediates COX-2 
activation, inflammatory outcomes have been abated through inhibition of RAGE, ROS, 
PKC, ERK and p38 MAPK (Shanmugam et al., 2003; Nah et al., 2008).  This suggests that 
significant interplay or redundancy exists amongst these intracellular intermediates in 
what is likely a multi-faceted cellular response, as seen in Rho GTPase signalling.   
Signal transduction by RAGE initiates stress activated protein kinase (SAPK), c-jun N-
terminal kinase (JNK), janus kinase (JAK) and transcription factor signal transducer and 
activator of transcription (STAT) (Taguchi et al., 2000; Shanmugam et al., 2003; Reddy et 
al., 2006; Xie et al., 2013).  The common themes of these intracellular signalling 
intermediates are oxidative stress and activation of gene transcription factors NF-κB, 
CREB, Sp-1 and STAT.  Of those genes up-regulated, a number are pro-inflammatory 
cytokines.  Generally, RAGE activation is associated with increased expression of various 
RAGE isoforms,  early growth response-1, VCAM, matrix metalloproteases (MMP), ICAM-
1, tumour necrosis factor – α (TNF-α), interleukins 1β, 2 and 6, and macrophage colony 
stimulating factor (M-CSF), to name only a few (Yan et al., 2009; Yang et al., 2007; 
Nakamura et al., 2008; Hofmann et al., 2002; Zhang et al., 1990; Hofmann et al., 1999; 
Taguchi et al., 2000; Xie et al., 2013).  These molecules generally facilitate a positive 
feed-back mechanism in which RAGE ligands such as calgranulins and HMGB1 are 
expressed, further activating RAGE and promoting chronic inflammation. 
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Clearly, RAGE signalling promotes inflammation through the activation of classic MAPK 
pathways, the production of reactive oxygen intermediates (ROI), and localised 
expression of pro-inflammatory molecules.  Untangling the complex interplay between 
pathways in differing cell types and contexts requires significant clarification and 
standardisation of methods to allow accurate comparisons.  Furthermore, the presence 
of different RAGE isoforms, ligand type and concentration, cell phenotypes, existing 
inflammatory responses and cellular dysfunction, make it difficult to correlate RAGE 
activation with signalling events and biological outcomes.  Controlling for such factors 
would help elucidate direct RAGE cellular outcomes, as opposed to those influenced by 
crosstalk with various intracellular cascades. 
 
1.5 Pathophysiologies Associated with RAGE 
There is an enormous body of research linking RAGE to a myriad of pathophysiologies 
including Alzheimer’s disease, diabetic complications (such as macrovascular disease), 
kidney disease, rheumatoid arthritis, tumour outgrowth and migration, and 
inflammatory diseases (Matrone et al., 2014; Zhao et al., 2014; Gugliucci and Menini, 
2014; Alghasham and Rasheed, 2014; Salahuddin et al., 2014).  Of particular interest are 
a number of RAGE blockade studies utilizing sRAGE and RAGE-V domain antibodies as 
antagonists. These studies utilized a variety of mouse disease models representing 
diabetic atherosclerosis, inflammatory responses and tumour outgrowth. 
1.5.1 Atherosclerosis 
Atherosclerosis is a chronic disease, with cardiovascular mortality in diabetic’s 2-4 fold 
higher than recorded in the normal population (Mullarkey et al., 1990; Yan et al., 1994).  
The interaction between arterial wall low-density lipoproteins (LDL), hyperglycaemia, 
and hyperinsulinaemia in the formation and progression of atherosclerotic lesions is well 
established (Mullarkey et al., 1990; Wilson et al., 1985).  Oxidatively modified LDL 
(oxLDL), as opposed to normal LDL, interact with aortic endothelium promoting 
recruitment of monocytes to sites of oxLDL accumulation (Quinn et al., 1987; Mullarkey 
et al., 1990).  Endocytosis of oxLDL by monocytes transforms them into foam cells 
commonly associated with atherosclerotic lesions (Quinn et al., 1987; Sparrow et al., 
1989).  
 Page 36 
 
The formation of vascular abnormalities is in part mediated by smooth muscle and 
endothelial cells. Expression of various inflammatory and thrombogenic effectors occurs 
in response to a number of factors including oxidative stress, histamine production, 
cytokines and blood flow (Hogan et al., 1992; Esposito et al., 1989).  An early sign of 
atherogenesis is the proliferation of smooth muscle cells (Ross, 1986). This mitogenic 
process is normally regulated by endothelial nitric oxide (NO) mediated quiescence of 
smooth muscle cells via the guanylate cyclase pathway.  Bucala et al. (1991)   identified a 
mechanism by which AGE molecules directly interact with and quench nitric oxide in 
vitro. Subsequent studies in rats with AGE accumulation and hyperglycaemia identified 
an impaired NO response despite normalizing blood glucose and ketone levels (Bucala et 
al., 1991).   
The development of atherosclerotic plaques extends past the common risk factors of 
dyslipidaemia, hypertension and obesity, to a more specific cellular regulatory element.  
RAGE was identified as a cell surface receptor in smooth muscle and endothelial cells 
that promotes the formation of atherosclerotic lesions in heart and aortic tissue 
following ligation (Daffu et al., 2013; Park et al., 1998; Basta, 2008).  A number of RAGE 
ligands accumulate in vascular lesions, including AGEs, calgranulins and HMGB1 where 
they induce a pro-inflammatory response (Burke et al., 2004; Inoue et al., 2007; Oimomi 
et al., 1989).  Administration of 40µg/day of sRAGE as a ligand decoy to streptozotocin-
induced diabetic mice, reduces the formation and size of lesions to levels seen in non-
diabetic mice (Park et al., 1998). This observation clearly implicates RAGE activation in 
cellular dysfunction associated with lesion development. 
Our understanding of RAGE and its role in atherosclerosis and vasculopathies is now 
better understood.  The clarification of RAGE as a significant progressor of 
atherosclerosis makes it an excellent target for pharmaceutical intervention.  By 
impeding RAGE activation in diabetics and those at risk, significant reductions in 
cardiovascular mortality may be realised. 
1.5.2 Inflammation 
Inflammation is a multifaceted physiological response resulting from, and accompanying 
the “pure” immune response (Stites, 1997).  A number of diseases exhibit inflammatory 
symptoms as a key indicator of progression including colitis, arthritis, sepsis, and 
delayed type hypersensitivity (DTH) (Hofmann et al., 1999; Foell et al., 2007; Chen et al., 
2009b; Chuah et al., 2013; Nogueira-Machado and de Oliveira Volpe, 2012).   
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Using a CF-1 mouse model, Hofmann et al. (1999) observed a DTH response following 
re-challenge with methylated BSA three weeks after initial exposure (Hofmann et al., 
1999).  This response was characterised by an influx of inflammatory immune cells, 
development of localised oedema, erythema, and granuloma (Hofmann et al., 1999). 
Closer examination of tissue at the nidus of injury revealed a six-fold increase in NF-κB 
activity associated with pro-inflammatory gene expression (Hofmann et al., 1999).  
Disruption of S100A12 activation of RAGE in this model reduced NF-κB activation by 
70%, clearly implicating RAGE in the pathology of DTH (Hofmann et al., 1999). 
The progression of colitis is associated with an accumulation of S100 and AGE RAGE 
ligands that are indicative of the degree of inflammation (Clynes et al., 2007; Foell et al., 
2007).  The principle outcome of ligand-RAGE interaction in colitis also involves the 
activation of NF-κB.  Recent studies have similarly implicated HMGB1 in the 
development of colitis and associated colorectal carcinomas in a RAGE-dependent 
manner (Maeda et al., 2007; Clynes et al., 2007).  Inhibition of p38 or the application of 
sRAGE as a ligand decoy in a mouse model of colitis reduces active NF-κB levels and 
inflammation (Andrassy et al., 2006).   
As previously mentioned, the occurrence of the Gly82Ser RAGE SNP is observed in 
disequilibrium with the HLA-DR4 locus implicated in hereditary rheumatoid arthritis 
(RA).  Canonical RAGE activation by HMGB1, S100s and various AGEs is a key factor in 
the progression of rheumatoid arthritis (Rouleau et al., 2003; Chen et al., 2009b; Chen et 
al., 2013).  Serum amyloid A promotes NF-κB activation in fibroblast-like synovial cells 
that invade rheumatoid arthritic joints, where they promote inflammation (Okamoto et 
al., 2008).  Inhibition of RAGE-SAA interaction reduces NF-κB mediated expression of 
pro-inflammatory molecules, reducing invasiveness of immune cells to the site or injury 
that is linked to RA (Okamoto et al., 2008) 
Clearly, RAGE activation following ligation promotes inflammation in a number of 
pathologies.  Although various intermediate signalling molecules involved in propagating 
the inflammatory cascade are known (Section 1.4.1), clear delineation of RAGE signalling 
from crosstalk with other pathways is required to fully understand the role of RAGE in 
inflammation (Figure 7). 
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1.5.3 Cancer and tumour development 
RAGE is known to play a role in a number of cancers and tumour outgrowth and 
metastasis.  Early reports of RAGE signal transduction promoting neurite outgrowth, 
angiogenesis and inflammation, highlighted a possible role of RAGE in cancer and 
tumour metastasis (Huttunen et al., 1999; Sasahira et al., 2007; Taguchi et al., 2000; 
Chen et al., 2014a).  Elevated levels of RAGE and its ligands are observed in pancreatic, 
breast, prostate, and oral square cell carcinoma cancers (Tesarova et al., 2007; 
Arumugam et al., 2005; Fuentes et al., 2007; Bhawal et al., 2005). 
RAGE co-localisation with HMGB1 at the leading edge of advancing tumour cells was one 
of the first reported observations implicating RAGE with cancer (Taguchi et al., 2000). In 
vivo studies by Taguchi et al. (2000) found that intravenously administered sRAGE 
decreases growth and metastasis of both implanted tumours, and induced tumours in 
susceptible mice (Taguchi et al., 2000).  Soluble RAGE reduced tumour size and invasion 
of surrounding tissue, as well as down-regulated p38 and JNK mediated signalling 
cascades associated with tumour proliferation (Taguchi et al., 2000).   
There is a growing body of research into RAGE and cancer progression particularly 
investigating HMGB1 and calgranulin involvement, however, little is known as to the 
role of AGEs or amyloids in these pathologies.  Further studies in this area will likely 
identify roles for RAGE in metastasis, angiogenesis of tumours, and the progression from 
chronic inflammatory states to cancer in a number of tissues. 
1.5.4 Diabetes 
Despite our increasing understanding of diabetes and the plethora of research over the 
last 40 years, diabetics continue to develop serious complications (Brownlee et al., 
1988).  It is known that AGE molecules accumulate within the extracellular matrix of 
vessel walls in correlation with increased glycaemia associated with diabetes and age 
(Brownlee et al., 1988; Schmidt et al., 1993; Singh et al., 2014; Manigrasso et al., 2014). 
Diabetic levels of AGEs in plasma are often 10-45 fold greater than those of non-
diabetics (Brownlee, 1995).  Injection of AGEs into otherwise normal animals induces 
vascular abnormalities in the absence of hyperglycaemia, strongly linking AGEs to 
vascular disease and the progression of diabetic complications (Vlassara et al., 1992). 
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The production of mitogenic cytokines including interleukin-1β and platelet derived 
growth factor (PDGF) is associated with AGE-RAGE interaction in mononuclear 
phagocytes (MP) (Schmidt et al., 1993; Kirstein et al., 1992).  The expression of these 
cytokines is a normal part of the removal of senescent material and ongoing tissue 
remodelling (Kirstein et al., 1992).  Disproportionate expression of these endothelial and 
fibroblast progression factors results in foam cell formation and atherogenesis 
commonly observed in chronic diabetes (Miki et al., 1993).   Early research identified the 
importance of macrophages and monocytes in wound healing through the secretion of 
mitogenic factors and cytokines (Leibovich and Ross, 1975).  Decreased migration of 
monocytes to sites of tissue damage through AGE-RAGE induced cell adherence to 
endothelia, may account for impaired wound healing common to diabetics (Greenhalgh 
et al., 1990).  Transcytosis of AGE moieties from plasma to the endothelial extracellular 
matrix causes intercellular gap formation (Esposito et al., 1989). These gaps result in 
endothelium permeability and increased AGE accumulation in the vascular basement 
membrane (Esposito et al., 1989).   
In addition to increased vascular permeability and impairment of wound healing, 
diabetes is associated with dysfunctional vasodilation and vascular narrowing.  Bucala et 
al. (1991)   observed that increased levels of AGEs reversibly impaired endothelial 
production of nitric oxide (NO) and resultant smooth muscle cell relaxation mediated by 
the guanylate cyclase pathway (Hogan et al., 1992; Bucala et al., 1991).  Additionally, 
glycated collagen fibres facilitate cross-linking of low density lipoprotein (LDL) and 
immunoglobulins in vessel walls (Brownlee, 1995). This leads to narrowing of vascular 
lumen and dysfunction of normal extracellular matrix interactions.  
Intervention of AGE formation using aminoguanidine treatment markedly reduces the 
progression of diabetic retinopathy, hypertension, renal disease, vascular leakage and 
peripheral nerve function in animal models (Huijberts et al., 1993; Hammes et al., 1994; 
Ellis and Good, 1991).  Injection of exogenous AGEs in these animals promotes the rapid 
developed of diabetic vasculopathies, and the deposition of AGEs in vessel walls 
(Vlassara et al., 1992). 
The link between AGEs and thrombogenicity has been well documented following the 
observation that erythrocytes possess non-enzymatically glycated haemoglobin surface 
structures (Esposito et al., 1989; Wautier et al., 1981).  It was hypothesised that the 
formation of thromboses may be in part, mediated by AGE-RAGE binding between 
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endothelial cell surface RAGE and glycated erythrocyte haemoglobin groups (Wautier et 
al., 1994).  This interaction initiates ROS production through autoxidative glycosylation 
and activation of RAGE intracellular signalling pathways (section 1.4.1) (Wolff and Dean, 
1987; Wautier et al., 1994). 
The association between glycated proteins and production of reactive oxygen species 
(ROS) is now well established (Galkina and Ley, 2009; Xie et al., 2013).  RAGE-AGE 
ligation promotes oxidative stress in intravascular spaces following the infusion of AGE 
into rats (Ramasamy et al., 2012; Naka et al., 2004).  These oxidative species elevate the 
levels of malondialdehyde and thiobarbituric acid reactive substances (TBARS), which 
promote vascular permeability and endothelial cell dysfunction (Yan et al., 1994; 
Schmidt et al., 1996).  The quenching of O2- species through self-reduction of Fe3+-CML-
AGE in vitro, reportedly reduces TBARS formation by 30% (Sakurai et al., 1990).  
Therefore, the reducing power of AGEs modulates cell intracellular stress pathways 
independent of RAGE (Sakurai et al., 1990; Wolff and Dean, 1987). 
The biological consequences of advanced protein glycation accumulation manifest in 
impaired vessel tone and wound healing, progression of atherosclerosis, and 
suppression of normal aortic smooth muscle cytostasis (Brownlee, 1995; Hogan et al., 
1992).  Therapies to reduce AGE formation or AGE-RAGE interaction offer significant 
hope in treating the symptoms of diabetes that often manifest as debilitating 
retinopathies, nephropathies and vasculopathies. 
1.5.5 Amyloidoses 
The binding of various amyloid products to RAGE progresses a number of diseases that 
includes Alzheimer’s disease and vascular dementias, amyloid peripheral neuropathies 
and nephropathies (Lue et al., 2005; Matsunaga et al., 2005; Emanuele et al., 2005; 
Deane, 2012; Kook et al., 2012). 
Serum amyloid A (SAA) is a generic term referring to a family of acute-phase proteins 
composed of 12-14 kDa apolipoproteins found predominantly in the high-density 
lipoprotein (HDL) fraction of plasma (Patel et al., 1998; Yan et al., 2008; Yan et al., 2000).  
These peptides are expressed by hepatic and extrahepatic tissues, including cancer cell 
lines in response to inflammatory cytokines such as IL-1, IL-6 and TNF-α (Yan et al., 
2008).  In acute inflammation, these molecules provide a protective benefit in 
promoting homeostasis.  The positive outcomes of SAA expression are similarly 
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mediated by leukocyte secretory interleukins, including IL-8 and IL-10 (Patel et al., 1998).  
Yan et al. (2000) reported that RAGE was the mechanism by which SAA and amyloid-A 
fibrils induce pro-inflammatory outcomes in systemic amyloidoses.  This finding was 
based on the co-localisation of RAGE with amyloid fibrils in splenic tissue in a systemic 
amyloidosis mouse model, and the ability of sRAGE and anti-RAGE IgG to immunise 
these animals against chronic inflammation (Yan et al., 2000). 
Familial amyloid polyneuropathy (FAP) is a neurodegenerative disorder associated with 
the accumulation of transthyretin (TTR) amyloid fibrillary structures in peripheral 
nervous tissue (Sousa et al., 2001).  Sousa et al. (2001) observed that the interaction of 
TTR with RAGE promotes an exaggerated inflammatory response (Sousa et al., 2001).  
Activation of RAGE in FAP patients correlates with significant localised increases in TNF-
α, IL-1β and iNOS, and is followed by a delayed activation of caspase-3 and DNA 
fragmentation (Sousa et al., 2001).  These effects of TTR appear to act largely on 
endothelial and neuron-like Schwann cells, mimicking the effects seen in vitro CNS 
neuronal cell types following challenge with Aβ (Lue et al., 2001b; Sousa et al., 2001).  
The accumulation of amyloid fibrils in FAP kidney tissue is accompanied by RAGE 
activation and AGE accumulation (Matsunaga et al., 2005).  The aggregation of these 
ligands causes significant RAGE activation, promoting chronic inflammation and 
associated kidney dysfunction and disease (Lee and Park, 2013; Matsunaga et al., 2005). 
RAGE is up-regulated in the brain of Alzheimer’s Disease (AD) sufferers (Yan et al., 1996; 
Lue et al., 2001a; Matrone et al., 2014).  As previously mentioned, RAGE binds a number 
of Aβ forms (section 1.3.2), leading to apoptotic signal transduction in microglia, 
endothelia and neurons (Lue et al., 2001a; Yan et al., 1996; Wilson et al., 2009; Sturchler 
et al., 2008; Origlia et al., 2008).  The precise means by which Aβ ligands promote 
apoptosis through RAGE is yet to be clearly delineated.  Complexities in intracellular 
signal crosstalk, alternate activation of Aβ receptors, the presence of differing RAGE 
isoforms, and the ability of various Aβ forms to bind distinct RAGE domains are all 
complicating factors (section 1.3.2).  The role of RAGE as a transporter of Aβ across the 
blood brain barrier has further drawn attention to it as a therapeutic target in the 
treatment of Alzheimer’s disease (Matrone et al., 2014; Sharma et al., 2012).   
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1.6 RAGE as a Target for Pharmaceutical Intervention 
As our understanding of RAGE biology has increased, so too has the search for small 
molecule antagonists.  The use of sRAGE and anti-RAGE/anti-ligand antibodies has 
clearly demonstrated that inhibition of RAGE ligation abates the progression of tumour 
outgrowth, inflammation, neuronal death and the formation of atherosclerotic lesions 
(Taguchi et al., 2000; Hofmann et al., 1999; Park et al., 1998).  Soluble forms of RAGE are 
naturally secreted in both mice and humans, allowing it to be intravenously 
administered without prompting an immune response (Schlueter et al., 2003). The 
limitations of sRAGE as a therapeutic agent are however its inability to cross the blood 
brain barrier for treatment of Alzheimer’s disease and tumour growth.  Additionally, the 
intrinsic costs associated with producing suitable quantities of RAGE, difficulties in 
storing and shipping tend against its use as a viable treatment option. 
The development of potent, small-molecule antagonists of RAGE capable of crossing the 
blood-brain barrier would provide a novel strategy for the inhibition of RAGE.  The 
design of such molecules greatly depends on the elucidation of the receptor structure 
for application to rational drug design methodologies.  It wasn’t until 2010 that the first 
crystal structures of RAGE were published (Park et al., 2010; Koch et al., 2010). In 
combination with a small number of NMR studies, this structural information will 
contribute significantly to the development of antagonists.  Currently a number of 
pharmaceutical companies, including Transtech and Pfizer are developing small 
molecule antagonists such as TTP488 for the treatment of Alzheimer’s disease (Burstein 
et al., 2014).  
Alternative strategies targeting RAGE intracellular signalling intermediates, ROI 
production through antioxidant therapies and RAGE ligand production may also offer 
novel opportunities for pharmaceutical intervention. 
 
1.7 Recombinant Protein Production Hosts 
Since the first recombinant protein was produced in 1977, significant leaps forward in 
the range and complexity of hosts used for heterologous protein production have been 
made (Itakura et al., 1977).   The post-genomic era has placed increasing demands on 
protein expression methodologies and hosts for active, authentically processed 
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enzymes, large eukaryotic multi-subunit complexes and intramembranous, multi-
domain proteins (Fernandez and Vega, 2013; Rosano and Ceccarelli, 2014; Ferrer-
Miralles and Villaverde, 2013).  This has driven the development of specialty vectors 
tailored for the production of proteins with particular transcription, translation and 
post-translational requirements (discussed further in section 4.2).  The use of a host 
organism capable of implementing these functional requirements is pivotal in producing 
recombinant protein of sufficient form, function, yield and space time yield for 
application to modern day structural, functional and pharmacological investigations 
(Porro et al., 2011). 
Bacterial systems are still considered the work horse organism of recombinant protein 
expression due to its unparalleled growth kinetics, versatility, simplicity of manipulation 
and low cost of production (Rosano and Ceccarelli, 2014; Sezonov et al., 2007). The 
current day catalogue of commercially available forms of Escherichia coli (E. coli) is 
immense and is largely based upon the B and K12 background strains used over the last 
30 years (Ferrer-Miralles and Villaverde, 2013).  The last decade has seen the emergence 
of alternative bacterial hosts due to the need for greater metabolic diversity and 
biosynthetic potential as discussed by Ferrer-Miralles and Villaverde (2013).  The lack of 
post-translational modification performed by prokaryotic hosts as discussed in section 
4.3, has ensured eukaryotic organisms such as insect, mammalian, yeast and fungal 
systems have continued to be used and developed for the production of complex 
heterologous proteins (Ferrer-Miralles and Villaverde, 2013).  Today, a wide selection of 
organisms, molecular tools and technologies are commercially available for the 
production of recombinant proteins in both prokaryote and eukaryote hosts, with the 
choice of system often defined by the protein of interest and its intended use (Sahdev et 
al., 2008).  RAGE was almost exclusively expressed in insect cells for the first 10 years 
following its discovery.  Over the last 10 years, RAGE is increasingly expressed in 
prokaryotic hosts (Hofmann et al., 1999; de Arriba et al., 2003; Srikrishna et al., 2002; 
Xue et al., 2011; Park et al., 2010).  With more than 93% of all known three-dimensional 
protein structures being produced by either bacterial or insect hosts, this study focuses 
on the integrity of RAGE and RAGE ligands produced in these systems as representative 
molecules of their endogenous forms (Fernandez and Vega, 2013).  These hosts, their 
characteristics and the implication of these traits for heterologous protein production 
are discussed in detail in sections 4.2 and 4.3. 
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1.8 The Present Study 
The principle aim of this study is to investigate a common method for expressing not 
only RAGE and its many forms, but a number of its ligands as well.  This common 
‘toolbox’ approach has the enormous potential of simplifying the production of the both 
RAGE and it’s common ligands, as well as a means of simply, safely and reliably 
evaluating functionality.  
To date, much of the research investigating the kinetics of interaction between RAGE 
and its ligands has involved combinations of endogenous, bacterial and baculoviral 
expressed RAGE and ligand molecules.  This study aims to:  
1. Evaluate the suitability of a rapid recombinant gene technology for use in insect 
expression as an alternative to baculoviral expression. 
 
2. Evaluate a range of bacterial hosts and factors impacting the heterologous 
production of RAGE. 
 
3. Determine which host organism is optimal for the expression of both RAGE and 
a number of its ligand molecules, in particular S100s and HMGB1. 
 
4. Develop a simplified method for measuring RAGE-ligand binding that is safe, 
flexible and robust.  Use this method to demonstrate the functionality of the 
RAGE and ligand molecules produced through the course of this study. 
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2.1 Materials 
 
Reagent Manufacturer/Supplier 
3M Filter Paper Whatman, Brentford, Middlesex - U.K 
4-16% Precast PAGE gel Gradipore, Sydney, NSW - Australia 
Acetic Acid  
Agarose LE, Analytic Grade Promega, Madison, WI - U.S.A 
Ampicillin Royal Perth Hospital, Perth, W.A. - Australia 
Antibody Goat Anti-Human RAGE - 
Biotinylated R&D Systems, Minneapolis, MN - U.S.A 
Antibody Goat Anti-Mouse IgG Alkaline 
Phosphatase Conjugate Santa Cruz Biotechnology, Santa Cruz, CA - U.S.A 
Antibody Mouse Anti-Human RAGE R&D Systems, Minneapolis, MN - U.S.A 
Antibody Mouse Anti-V5 IgG  Invitrogen, Carlsbad, CA - U.S.A 
Apoprotein Sigma-Aldrich, St Louis, MO - U.S.A 
Aurum Plasmid Purification Kit Bio-Rad, Hercules, CA - U.S.A 
Biacore CM5 Sensor Chip 
GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
Blasticidin S-HCl Invitrogen, Carlsbad, CA - U.S.A 
Borate Sigma-Aldrich, St Louis, MO - U.S.A 
Bovine Serum Albumin Sigma-Aldrich, St Louis, MO - U.S.A 
Cellfectin® Invitrogen, Carlsbad, CA - U.S.A 
Coomassie blue R350 Sigma-Aldrich, St Louis, MO - U.S.A 
Deoxyribonucleotide Triphosphates 
(dNTP’s) 
Invitrogen, Carlsbad, CA - U.S.A 
Dimethyl Sulfoxide Sigma-Aldrich, St Louis, MO - U.S.A 
Dithiothreitol Sigma-Aldrich, St Louis, MO - U.S.A 
D-Ribose Sigma-Aldrich, St Louis, MO - U.S.A 
Ethanolamine Hydrochloride 
GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
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Reagent Manufacturer/Supplier 
Ethidium Bromide Invitrogen, Carlsbad, CA - U.S.A 
Ethylenediaminetetraacetic Acid Sigma-Aldrich, St Louis, MO - U.S.A 
Ex-Cell® 405 Serum Free Media Sigma-Aldrich, St Louis, MO - U.S.A 
Express Five® Serum Free Media Invitrogen, Carlsbad, CA - U.S.A 
Foetal Calf Serum (FCS) Thermo Scientific, Waltham, MA - U.S.A 
Glycerol Ajax Chemicals, Auburn, N.S.W – Australia 
Glycine Sigma-Aldrich, St Louis, MO - U.S.A 
10x glycoprotein denaturation buffer New England Biolabs - USA 
HBS-EP Buffer 
GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
High-Five® Insect Cells (High Five™ ) Invitrogen, Carlsbad, CA - U.S.A 
Human RAGE gene, full length 
University of Helsinki, Rauvala Laboratory - 
Finland 
Hybond™-P PVDF 
GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
Imidazole Sigma-Aldrich, St Louis, MO - U.S.A 
Isopropyl β-D-1-thiogalactopyranoside Sigma-Aldrich, St Louis, MO - U.S.A 
LB Agarose Royal Perth Hospital, Perth, W.A. - Australia 
LB Broth Royal Perth Hospital, Perth, W.A. - Australia 
LB Broth Powder USBiological, Swampscott, MA - U.S.A 
Leupeptin Sigma-Aldrich, St Louis, MO - U.S.A 
Lowry Protein Assay kit Sigma-Aldrich, St Louis, MO - U.S.A 
Magnesium Chloride Sigma-Aldrich, St Louis, MO - U.S.A 
Methanol Merck, Kilsyth, VIC - Australia 
Na2HPO4  Sigma-aldrich – Sydney, NSW - Australia 
NAH2PO4 Sigma-aldrich – Sydney, NSW - Australia 
N-ethyl-N'-(3-dimethylaminopropyl) 
carbodiimide hydrochloride 
GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
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Reagent Manufacturer/Supplier 
N-hydroxysuccinimide GEHealthcare, Little Chalfont, Buckinghamshire, 
U.K 
Nonidet P-40 Roche, Sydney, NSW - Australia 
Origami™ B Escherichia coli EMD Millipore,  Sydney, NSW - Australia 
pcDNA3 Expression Vector Invitrogen, Carlsbad, CA - U.S.A 
PCR Grade Magnesium Chloride Invitrogen, Carlsbad, CA - U.S.A 
PCR Primers Geneworks, Hindmarsh, S.A. - Australia 
PCR Reaction Buffer Invitrogen, Carlsbad, CA - U.S.A 
Phenylmethanesulphonylfluoride  Sigma-Aldrich, St Louis, MO - U.S.A 
Phosphate Buffered Saline Concentrate Invitrogen, Carlsbad, CA - U.S.A 
pIB/V5 His TOPO® TA Vector Invitrogen, Carlsbad, CA - U.S.A 
pIB/V5 His-CAT plasmid Invitrogen, Carlsbad, CA - U.S.A 
Platinum® Taq Polymerase Invitrogen, Carlsbad, CA - U.S.A 
RAGE Duoset ELISA R&D Systems, Minneapolis, MN - U.S.A 
Recombinant Human RAGE-Fc Standard R&D Systems, Minneapolis, MN - U.S.A 
Rosetta-gami™ B EMD Millipore – Sydney, NSW - Australia 
S100A6-GST MBL International, Woburn, MA - U.S.A 
S100B (Bovine) Sigma-Aldrich, St Louis, MO - U.S.A 
S100P-GST MBL International, Woburn, MA - U.S.A 
Sf21 Insect Cells Invitrogen, Carlsbad, CA - U.S.A 
Sf9 Insect Cells Invitrogen, Carlsbad, CA - U.S.A 
Sf9 00™-II Serum Free Media Invitrogen, Carlsbad, CA - U.S.A 
Skim Milk Powder Coles, Tooronga, VIC - Australia 
SOC Media Invitrogen, Carlsbad, CA - U.S.A 
Sodium Acetate (anhydrous) Sigma-Aldrich, St Louis, MO - U.S.A 
Sodium Chloride Merck, Kilsyth, VIC - Australia 
Sodium Dodecyl Sulphate Bio-Rad, Hercules, CA - U.S.A 
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Reagent Manufacturer/Supplier 
Streptavidin Conjugated Horseradish-
Peroxidase 
R&D Systems, Minneapolis, MN - U.S.A 
Sulphuric Acid Merck, Kilsyth, VIC - Australia 
T7 Shuffle® B New England Biolabs - USA 
T7 Shuffle® K12 New England Biolabs - USA 
TMB+ AP Substrate Dako, Carpinteria, CA - U.S.A 
TOP10 Chemically Competent E. coli Invitrogen, Carlsbad, CA - U.S.A 
Trichloroacetic Acid Sigma-Aldrich, St Louis, MO - U.S.A 
Tris Sigma-Aldrich, St Louis, MO - U.S.A 
Trypan Blue Sigma-Aldrich, St Louis, MO - U.S.A 
Tween-20 MP Biomedicals, Solon, OH - U.S.A 
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2.2 Ethics approval 
Animal or Human ethics approval were not required at any stage of this project. 
2.3 Genetically Modified Organism Approval and Safety 
This project utilized commercially available expression systems developed by 
Invitrogen™.  These systems are classified as exempt dealings under parts 1 & 2 of 
Schedule 2 of the Gene Technology Regulations 2001 (Commonwealth Government of 
Australia) due to the well-defined nature of the vectors.  Notice of the use of these 
vectors and the associated genes to be expressed is registered with the Curtin University 
Institutional Biosafety Committee. 
2.4 Molecular Biology Methods  
2.4.1 Primer design 
Forward and reverse primers for use in polymerase chain reaction (PCR) were designed 
using an open source, web based application known as Primer3 (Peters et al., 2008).  
The primers for canonical RAGE gene sequence amplification were designed against the 
RAGE complete coding sequence (2000) (Genbank accession number: AB036432), and 
the optimal forward and reverse products are described in Table 1.  Melting 
temperatures included were determined by the primer manufacturer.  Primers for 
amplification of human HMGB1 were designed against human mRNA for high mobility 
group-1 protein (GenBank accession number X12597), and are described in Table 2.  
Primers for amplification of the endogenous human RAGE V, VC1 and VC1C2 domains for 
expression in a prokaryote system that exclude the leader sequence are described in 
Table 3 and designed against both a synthetic optimised form of the human RAGE gene 
and canonical RAGE (2000) (Genbank accession number: AB036432).  Primers to amplify 
human calgranulins S100B, S100P and S100A6 were designed against GenBank accession 
numbers: BC001766, BC006819 and BC001431 respectively, and are described in Table 
4.  Sequencing primers for the entry vector pENTR SD/D-TOPO were designed against 
the manufacturers provided plasmid sequence. 
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Table 1. Forward and reverse primers used to amplify the V, VC1 and VC1C2 domains of 
human RAGE for expression in insect cells. 
Melting behavior (delta H degree) of the oligomers was calculated as per the method of 
Breslauer et al. (1986). 
Primer Sequence Tm (°C) 
Ins-Forward-RAGE (F1) AGGATGGCAGCCGGAACAGCAGTTG 62 
Ins-Reverse V (R1) GACACGGACTCGGTAGTTGGACTTGGT 62 
Ins-Reverse VC1 (R2) GACACGGGGCTGGATGGGGGC 64 
Ins-Reverse VC1C2 (R3) TTCCTGGGGCCCGTGGCTGGA 64 
 
Table 2. Forward and reverse primers used to amplify full length and truncated human 
HMGB1. 
Primer Sequence Tm (°C) 
Forward-truncHMGB1 TGGGTAAAGGCGATCCGA 55 
Reverse-truncHMGB1 CTTTTTCTTTTTAGATTTTTCTGCTTTCAC 54 
Forward-HMGB1 GCATGCATGGGCAAAGGCGATCCG 62 
Reverse-HMGB1 TTCGTCGTCGTCGTCTTCTTCTTCG 59 
 
Table 3. Forward and reverse primers used to amplify human RAGE V, VC1 and VC1C2 
domains for expression in a prokaryote system. 
Primer Sequence Tm (°C) 
Prok-Forward-RAGE native (N-pF1) ATGGCTCAAAACATCACAGCC 59 
Prok-Forward-RAGE (pF1) ATGGCCCAAAACATTACCGCT 61 
Prok-Reverse V (pR1) TTCCGGTTTGCCCGGAATTT 61 
Prok-Reverse VC1 (pR2) CAACCACCAGTTGCACTTCT 58 
Prok-Reverse VC1C2 (pR3) CAGACCGCTGCCACCAA 59 
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Table 4. Forward and reverse primers used to amplify human calgranulins S100B, 
S100P and S100A6 for expression in a prokaryote system. 
Primer Sequence Tm (°C) 
S100B-Forward  ATGTCTGAGCTGGAGAAGGC 59 
S100B-Reverse  TCACTCATGTTCAAAGAACTCGT 58 
S100P-Forward ATGACGGAACTAGAGACAGCC 59 
S100P-Reverse TCATTTGAGTCCTGCCTTCTCA 59 
S100A6-Forward ATGGCATGCCCCCTGGATC 55 
S100A6-Reverse TCAGCCCTTGAGGGCTTCATT 54 
 
Table 5. Forward and reverse primers used for sequencing pENTR-SD/D-TOPO. 
Primer Sequence Tm (°C) 
pENTR-Forward  GCATGCATGGGCAAAGGAGATCCT 59° 
pENTR-Reverse  AAGCTTTATTCATCATCATCATCA 49° 
 
2.4.2 Transformation of chemically competent Escherichia coli 
Chemically Competent TOP10 or Library Efficiency® DH5 Escherichia coli (E. coli) 
(Invitrogen™) were transformed with plasmid containing various PCR inserts.  A 
microfuge tube containing 50 µL of chemically competent E. coli stored at -80°C, was 
thawed on ice.  Two µL of plasmid (50-150 ng) was added and mixed by gentle vortex.  
This mixture was placed on ice for 25 minutes before being heat shocked for 30 seconds 
without shaking at 42°C in a water bath.  The mixture was immediately placed back on 
ice for 2 minutes and 450 µL of room temperature super optimal broth with catabolite 
repression (SOC) medium added.  The mixture was then shaken for 1 hour (37°C) at 200 
rpm on a horizontal platform shaker.  Aliquots of this mixture were diluted with 
Lysogeny broth (LB) 100-fold, 10-fold and 5-fold to a final volume of 200 µL.  Each 
diluted sample and an undiluted aliquot were plated onto LB agarose containing 100 
µg/mL of an appropriate selective antibiotic (section 2.4.4). 
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2.4.3 Preparation of ampicillin selective LB agarose plates 
Solid 1.2% LB agarose (100 mL) was heated in an 800 W microwave for 5 minutes or 
until melted.  The agarose was allowed to cool to 55°C in a water bath.  Ampicillin, 
kanamycin or chloramphenicol (water soluble) was reconstituted in 1 mL of LB broth to 
a working concentration of 5 mg/mL before being combined with the molten agarose.  
The LB agarose + antibiotic (50 µg/mL), was immediately poured into 60 mm petri dishes 
and allowed to set at room temperature.  Plates were sealed with parafilm and stored at 
4°C until needed. 
2.4.4 Selection of positive TOP10 E. coli using selective media 
LB agarose plates containing a selective antibiotic were prepared as outlined in section 
2.4.3. Onto these plates, 25 µL, 75 µL and 200 µL aliquots of transformed E. coli (section 
2.4.2) were pipetted and gently spread over the agarose surface using a flame sterilised 
glass hockey stick.  Plates were sealed and incubated overnight at 37°C before being 
inspected for colony forming units (cfu).  A flame-sterilised loop was used to pick a cfu 
and inoculate 10 mL of LB broth containing 100 µg/mL of ampicillin. The LB broth 
containing the appropriate antibiotic was then shaken at 160 rpm (37°C) overnight or 
until a spectrometric O.D600nm of 0.8-1 was achieved, representing mid log-phase. 
2.4.5 Whole cell PCR  
A PCR master mix was prepared at 4°C using Invitrogen™ Platinum° Taq DNA Polymerase 
kit components at 1x PCR Buffer, 0.2 mM dNTPs, 2.5 mM MgCl2, 0.25 µM forward and 
reverse primer and 1U of Platinum Taq.  Then, 15 µL of master mix was added to a 
sterile, nuclease free 0.5 mL microfuge tube on ice.  From the LB-Amp+ plates containing 
positive colony forming units (section 2.4.4), single colonies were picked using a sterile 
pipette tip and transferred into each microfuge tube containing master mix.  The tubes 
were immediately capped and labelled, and placed in a PTC-100 thermocycler where 
they were amplified according to the following program: 
1) 10 minutes at 94°C to activate the hot start polymerase and lyse cells 
2) 30x cycles of: 
a. 0.5 minute at 94°C 
b. 0.5 minute at 60°C 
c. 1 minute at 72°C 
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3) 7 minutes at 72°C 
At the end of the program, reaction mixtures were stored at -20°C until needed. 
2.4.6 Plasmid purification 
Plasmid was prepared by inoculating 10 mL LB Amp+ broth (100 µg/mL Ampicillin) with a 
single cfu picked from an LB-Amp+ plate (section 2.4.4), or with a 100 µL aliquot of 
bacterial-plasmid glycerol stock (section 2.4.6). The broth was sealed and shaken at 160 
rpm (37°C ) overnight or until an O.D600nm of 0.6-0.8 was reached.  The culture was then 
centrifuged at 1000 g for 15 minutes at 4°C.  All subsequent steps were performed on 
ice or using buffers stored at 4°C unless otherwise specified.   
The supernatant was carefully poured off and the bacterial pellet gently resuspended in 
250 µL Bio-Rad Aurum™ Plasmid mini-prep spin kit (BAP) resuspension buffer.  The 
mixture was transferred to a 1.5 mL eppendorf tube to which 400 µL of BAP lysis buffer 
was added.  The lysed cell suspension was carefully mixed by inverting the tube 6-8 
times.  BAP neutralization buffer (450 µL) was then added and the tube mixed by gently 
inverting the solution a further 4-6 times.  The suspension was centrifuged at 12,000 g 
for 5 minutes before the clear cell lysate was transferred to a BAP mini-spin column, 
which was centrifuged at 12,000 g for 1 minute.  The flow-through was discarded and 
750 µL of BAP wash buffer was added to the column.  The column was again centrifuged 
at 12,000 g for 30 seconds, and this wash step was repeated a further two times.  The 
BAP mini-spin column was loaded into a sterile 1.5 mL eppendorf tubes and 50 µL of 
ultra-pure water was added to the column.  The column was placed upright for 2 
minutes at room temperature to allow even distribution of the water across the frit 
surface.  The plasmid was then eluted by centrifuging the mini-column at 12,000 g for 2 
minutes.  DNA eluate quality and quantity was evaluated as described in section 2.4.8 
before being stored at -20°C until required.  
2.4.7 PCR amplification and restriction enzyme digest of pGEX-6P1-deltaHMGB1  
PCR amplification of truncated HMGB1 was performed as described in section 2.4.11, 
however, the plasmid used was pGEX-6P1-deltaHMGB1 and the primers are those 
described in Table 2.  Following amplification, a 10 µL aliquot of the PCR reaction 
mixture was added and incubated with 10U of restriction enzymes BamHI and EcoRI 
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over night at 37°C.  The entire mixture was then visualised on a 2% agarose gel as 
described in section 2.4.9. 
2.4.8 Evaluation of plasmid DNA quantity and quality 
Purified plasmid (section 2.4.6) was assessed spectrophotometcially by comparing the 
ratio of absorbance at 260 nm/280 nm.  This ratio was determined by aliquoting 2 µL of 
purified plasmid into 998 µL of high pure DNase free water and gently mixing twice by 
inversion.   The DNA sample was measured against a blank of high pure water. 
2.4.9 DNA agarose gel electrophoresis 
DNA was visualised on a 1.2% agarose gel which was prepared by mixing 3.6 g LE grade 
agarose with 300 mL of Tris Borate EDTA buffer (pH 8.3) (TBE) containing 0.09 M Tris, 
0.09 M borate, 0.0025 M EDTA.  The mixture was heated in an 800 W microwave oven 
for approximately 4 minutes or until it boiled.  The agarose mixture was gently swirled to 
ensure the agarose was completely dissolved and allowed to cool in a 60°C oven until 
needed. 
A gel cassette was sealed on both sides with tape and a 12-well comb placed in position.  
The 1.2% molten agarose was poured into the cassette and the gel allowed to set for 20 
minutes at room temperature.  Once set, the gel was placed into an electrophoresis tank 
which was filled with sufficient TBE buffer (pH 8.3) to completely cover the gel.  A 10 µL 
aliquot of PCR reaction mixture was combined with 5 µL of DNA loading buffer, which 
was then loaded onto the gel.  The gel was subsequently run for approximately 1 hr at 
90 V or until the dye front approached the edge of the gel. 
2.4.10 Visualisation of agarose gel electrophoresis PCR product or plasmid DNA 
The agarose gel and cassette (2.4.9) were removed from the electrophoresis tank and 
the gel carefully submerged in a solution containing 0.5 µg/mL ethidium bromide at 
room temperature.  The gel was allowed to sit for 10-15 minutes before being removed 
from the bath and placed on a UV transilluminator to visualize the DNA bands.  The 
images were captured using a Polaroid camera system. 
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2.4.11 PCR amplification of plasmid inserts 
Amplification of plasmid vector gene inserts was done using the same protocol outlined 
in 2.4.5. The bacterial cell template was substituted with 50-150 ng of purified plasmid 
and the initial Taq activation cycle was 5 minutes instead of 10 minutes. 
2.4.12 Cloning of PCR product into pIB/V5 His TOPO expression vector 
The pIB/V5 HIS vector (Figure 78) mixture contains linearized plasmid in the presence of 
activated topoisomerase-I.  The cloning reaction was setup according to the 
manufacturer’s instructions.  Briefly, in a 0.5 mL sterile microfuge tube, 2 µL of PCR 
product was mixed with 1 µL of salt solution (1.2 M NaCl2, 60 mM MgCl2), 1 µL of pIB/V5 
His TOPO® vector mixture and made up to a final volume of 5 µL with sterile high pure 
water.  The reaction mixture was incubated at room temperature for 10 minutes before 
being placed on ice.  TOP10 E. coli was then transformed with the reaction mixture as 
outlined in protocol 2.4.2.  
2.4.13 Sub-cloning of PCR products in to pGS-21a expression plasmid 
PCR product was produced as outlined in method 2.4.11 and single bands excised and 
purified using a Qiagen QIAquick PCR Purification Kit according to the manufacturer 
instructions.  GenScript pGS-21a plasmid (Figure 77) was produced in TOP10 E. coli and 
purified as outlined in section 2.4.6.  Purified plasmid was linearized by incubating 1 µg 
of pGS-21a with 5U of XbaI and 5U of HindIII Restriction enzymes in NEBuffer (1x final 
working concentration) for a total working volume of 50 µL.  The reaction was incubated 
at 37°C for 60 minutes before being placed on ice.  Vector containing 
RAGE/HMGB1/S100 recombinant protein constructs were similarly digested and 
combined at a molar insert to vector ration of 3:1 and the solution made up to 10 µL in 
ice cold hpH20 and mixed with 10 µL New England Biolabs (NEB) 2x quick ligation buffer.  
To this mixture, 1 µL of NEB Quick T4 DNA Ligase was added and the mixture incubated 
at room temperature for five minutes before being placed back on ice.  The mixture was 
immediately used to transform TOP 10 E. coli as outlined in 2.4.2 and the culture plated 
out on selective media. 
2.4.14 Preparation of ultra-low temperature bacterial glycerol stocks 
Colonies identified by PCR as containing correctly oriented gene inserts were used to 
inoculate 10 mL of LB Amp+ broth (100 µg/mL ampicillin).  The LB Amp+ broth was 
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shaken at 160 rpm (37°C) until an O.D600nm of 0.6-0.8 was achieved.  The cultures were 
then diluted two-fold with sterile 80% glycerol in 1.5 mL sterile eppendorf tubes in 1 mL 
aliquots.  The glycerol stocks were stored at -72°C until needed. 
2.5 Cell Culture Methods 
2.5.1 Thawing of Sf9 and Sf21 insect cells 
Stocks of Sf9 , Sf21 and Tn5 insect cells were sealed in 1.5 mL cryovials containing 1x107 
cells and stored in liquid nitrogen (vapour phase) until required.  A frozen cryovial was 
rapidly thawed by placement in a 27°C water bath until the cell pellet was almost 
completely thawed.  The cell suspension was immediately transferred to a 10 mL 
centrifuge tube containing 9 mL of pre-warmed Sf9 00-II serum free medium (SFM) 
containing 16 mM L-glutamine.  A 3 mL aliquot of this mixture was transferred to a 75 
cm2 Nunclon™ tissue culture flask and left to sit for 20 minutes at 28°C.  The cell media 
was subsequently aspirated and replaced with 10 mL of Sf9 00-II SFM, 2.5% FCS, 16 mM 
L-glutamine (28°C) and then kept at 27°C in a non-humidified incubator until cells 
reached confluency.  
2.5.2 Thawing of Tn5 Insect Cells 
Tn5 insect cells were thawed and seeded using the same steps outlined in section 2.5.1, 
however the Sf9 00-II SFM was substituted with Express Five® SFM supplemented with 
16 mM L-glutamine. 
2.5.3 Freezing of insect cells 
The medium used for freezing insect cells was prepared by mixing equal volumes of 
conditioned culture medium with fresh culture medium, dimethyl sulphoxide (DMSO) to 
a final concentration of 7.5% v/v and Foetal Calf Serum (FCS) to a working concentration 
of 5% v/v.  Cells were grown to 80% confluence (sections 2.5.4, 2.5.6) with cell viability 
and total count determined as described in section 2.5.7.  The cell suspension was 
centrifuged at 50 g for 5 minutes and the supernatant decanted. The cell pellet was 
resuspended to a cell density of 1x 107 cells/mL in the medium described above chilled 
to 4°C.  The cell suspension was quickly aliquoted (1 mL) into 1.5 mL Nunc cryovials and 
then refrigerated at -20°C for 30 minutes, followed by -80°C for 24 hr, before being 
placed into liquid nitrogen for long-term storage. 
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2.5.4 Passaging Sf9, Sf21 and Tn5 insect cells in adherent culture 
Sf9 00-II media was used to culture Sf9 and Sf21 insect cells, and Ex-Cell 405 or Express 
Five® SFM media was used to culture Tn5 insect cells. Conditioned media containing cell 
debris was aspirated from an 80% confluent insect cell monoculture grown in a 75 cm2 
culture flask.  Five millilitres of pre-warmed (27°C) medium was added to the culture and 
gently washed across the surface of the flask by tipping it back and forth, before being 
aspirated.  After being washed, 10 mL of culture media was streamed directly over the 
adhered cells 3-4 times at maximum output using an electronic transfer pipette until 
>90% of the cells were sloughed from the surface.  The cell culture was split five-fold, 
with 2 mL of the cell suspension being added to a new 75 cm2 culture flask containing 8 
mL of fresh media.  The cells were left to adhere to the flask surface for 20 minutes 
before the media and cellular debris were aspirated and 10 mL of fresh media added.  
The culture was left to grow at 27°C in a non-humidified incubator until confluent.   
2.5.5 Adaptation of Lepidoptera insect cells from adherent to suspension culture 
Cells were cultured to confluence and >95% cell viability in 75cm2 monoculture flasks as 
described in section 2.5.4, with one flask on average producing 1x107 viable cells.  
Sufficient flasks were cultured to yield 5x107 viable cells.  Sloughed cells suspensions 
were combined in a 50 mL Falcon centrifuge tube, with cell density and viability 
determined as outlined in section 2.5.7.  The suspension was centrifuged at 50 g for 5 
minutes to pellet the insect cells.  The supernatant was removed and the cells 
resuspended in 10 mL of suitable serum-free culture media (Sf9 00-II medium for Sf9 
and Sf21 or Express Five® SFM media for Tn5 insect cells).  The cell suspension was then 
transferred to a 250 mL Erlenmeyer shaker flask containing 90 mL of pre-warmed (27°C) 
culture medium to yield a final cell density of 5x105 viable cells/mL.  The shaker flask was 
incubated at 27°C with constant orbital agitation of 100 rpm.  Cells were considered 
confluent at 2x106 cells/mL and passaged according to section 2.5.6. 
2.5.6 Passaging Sf9, Sf21 and Tn5  insect cells in suspension culture 
Cells were grown in suspension to a density of 2x106 viable cells/mL.  The culture was 
transferred to two 50 mL centrifuge tubes and centrifuged at 50 g for 5 minutes.  The 
supernatant was collected and stored at 4°C for further analysis if required.  The cell 
pellet was resuspended in 10 mL of fresh culture media (Sf9 00-II medium for Sf9 and 
Sf21 or Express Five® SFM media for Tn5 insect cells).  From the cell suspension, 2.5 mL 
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was transferred to a 250 mL spinner flask containing 97.5 mL fresh media yielding a final 
cell density of 5x105 viable cells/mL.  Samples were taken from each freshly seeded flask 
to ensure correct seeding density and cell viability greater than 95% was observed.  
Cultures were grown at 27°C with constant orbital agitation at 90 rpm until confluent. 
2.5.7 Determining cell density and viability 
A 0.4% trypan blue solution was prepared using an isotonic phosphate buffered saline 
(pH 7.4) (PBS).  To 100 µL of cell suspension, 10 µL of trypan blue solution was added. 
Ten microliters of the cell suspension-trypan mixture was then loaded onto a 
haemocytometer.   The number of blue stained cells and the number of total cells in a 
single large chamber were counted and the cell viability and density determined 
according to the following formula: 
Cell viability (%) = [1.00 – (Number of blue cells / Number of total cells) x 100] 
Cell density (cells/mL) = number of viable cells x 104 x 1.1 
2.5.8 Transient expression of RAGE domain constructs in Lepidoptera insect cell 
cultures 
A transfection mixture was prepared (1 mL serum free cell culture media, 1 µg of 
pIB/V5-His-TOPO-hRAGE construct and 20 µL Cellfectin®reagent) in a 1.5 mL microfuge 
tube and gently mixed for 10-15 seconds before being incubated at room temperature 
for 30 minutes (Bierhaus et al., 1997).  A positive control transfection mixture using 
pIB/V5-His-TOPO-CAT in place of the human RAGE (hRAGE) expression vector was 
similarly prepared and used alongside the hRAGE constructs.   
Insect cells were seeded the day before into a 60 mm culture dish so that 60% 
confluence would be achieved within 24 hr.  The media from these cultures was 
carefully aspirated and the transfection mix added drop wise evenly over the monolayer.  
The culture dish was incubated at room temperature for 4 hr on a side-to-side rocking 
platform at two side motions per minute.  Following the incubation period, 2 mL of 
serum-free culture media (27°C) was carefully added and the dish incubated for 48 hr at 
27°C in a humidified incubator.  Conditioned media was then collected and evaluated for 
the presence of recombinant protein.  Cells were carefully sloughed from the surface of 
the 60 mm culture dish with 2 mL of suitable pre-warmed (27°C) media and transferred 
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to T-75 flasks containing 8 mL of the appropriate media.  Cells were grown to confluency 
and media was collected for evaluation of secretory recombinant protein expression. 
2.5.9 Stable expression of RAGE domain constructs in Lepidoptera insect cell cultures 
Transfected insect cells were grown to confluence before being sloughed from the 
monoculture flask surface using 10 mL of the conditioned media.  The cell suspension 
was split into four T-75 culture flasks containing 7.5 mL of fresh culture media for a total 
volume of 10 mL.  The cells were allowed to attach for 1 hour at room temperature and 
adherence determined using an inverted microscope.  Selective media was prepared by 
dissolving Blasticidin-S HCl in culture media to a working concentration of 80 µg/mL.  
Media was aspirated from the cultures and replaced with 10 mL of selective media pre-
warmed to 27°C.  Cells were incubated at 27°C for 3-6 days depending on the cell line, or 
until large foci formed.  Cells were then passaged as outlined in section 2.5.4, using 
selective culture media every third passage to maintain selection. 
2.5.10 Lysis of insect cells 
Cells from monocultures were sloughed from the flask surface and transferred to a 
centrifuge tube before being centrifuged at 50 g for 5 minutes.  The cell pellet was 
gently resuspended in 5 mL of PBS chilled to 4°C, and again centrifuged at 50 g for 5 
minutes.  The supernatant was again decanted and the cell pellet resuspended in 250 µL 
of ice cold lysis buffer (50 mM Tris (pH 7.8) containing 150 mM NaCl, 1% Nonidet P-40, 1 
mM PMSF, 1 µM Leupeptin and 0.1 µM aprotinin) before being vortexed for 1 minute.  
The cell suspension was allowed to sit for 30 minutes on ice.  Cellular debris was 
removed by centrifugation at 11,000 g (4°C) for 30 minutes.  The supernatant was 
collected and analysed for the presence of recombinant protein. 
2.6 Protein Expression and Purification  
2.6.1 Prokaryote transformation and expression of human RAGE V, VC1 and VC1C2 
extracellular domains  
Lysogeny Broth (LB) was prepared by mixing 7.75 g of LB powder (USBiological) with 500 
mL of high-pure H2O before being autoclaved at 121°C for 15 minutes.  The broth was 
allowed to cool to room temperature before ampicillin was added to a final 
concentration of 100 µg/mL.  The LB + Amp mixture was stored at 4°C until needed.  
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TOP10 E. coli were transformed with both optimised and canonical V, VC1 and VC1C2 
domain constructs in pGS-21a as described in section 2.4.2 and plasmid purified and 
quantified as outlined in section 2.4.6.  Expression host strains to be transformed were 
BL21 (DE3), Rosetta-gami™ B, Origami™ B, T7 Shuffle® K12 and T7 Shuffle® B.  Their 
respective genotypes are described in Table 10. 
A vial of each prokaryote expression strain was thawed on ice for 10 minutes. Fifty 
nanograms of purified pGS-21a RAGE construct was added to each vial, which was gently 
mixed by flicking.  The mixture was placed back on ice for 30 seconds before being heat 
shocked for 30 seconds at 42°C and then returned to ice for five minutes.  Super optimal 
broth with catabolite repression (SOC) was warmed to room temperature and 950 µL 
added to each vial before each mixture was incubated at 30°C for 60 minutes with 
vigorous shaking (250 rpm).  Serial dilutions of each vial were made and then plated on 
selective media and incubated overnight at 37°C.  After 24 hours, individual colonies 
were screened for the presence of the expected gene insert by PCR before being used to 
inoculate starter cultures comprising 5 mL Lysogeny Broth and 100 µg/mL ampicillin.  
Starter cultures were incubated overnight at 30°C with 250 rpm agitation.  A 1 L 
preparation of LB containing 100 µg/mL ampicillin was inoculated with the starter 
culture and agitated at 250 rpm at 30°C until the culture reached an O.D600 of 0.6-0.8. A 
liquid stock of 250 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the 
culture to achieve a final concentration of 1 mM to induce recombinant protein 
expression.  The culture was then shaken at 200 rpm at 30°C for six hours.  The entire 
culture was subsequently split into four 250 mL centrifuge pots and centrifuged at 
12,000 g for 30 minutes.  The supernatant was discarded and the cell pellets 
resuspended in 10 mL of ice cold PBS before being combined in a single 50 mL centrifuge 
tube which was centrifuged again at 12,000 g for 30 minutes.  The supernatant was 
discarded and the cell pellet which contained the expressed protein was stored at -20°C 
until needed.  
2.6.2 Microplate culturing of Escherichia coli transformed with RAGE V, VC1 and 
VC1C2 extracellular domains. 
Lysogeny Broth was prepared by mixing 7.75 g of LB powder (USBiological) with 500 mL 
of high-pure H2O before being autoclaved at 121°C for 15 minutes.  The broth was 
allowed to cool to room temperature before ampicillin was added to a working 
concentration of 100 µg/mL.  200 µL of Luria broth was added to each well on a round 
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bottom 96-well sterile microtitre culture plate (Greiner) and the plate warmed to 30°C in 
a humidified cabinet.  Wells were inoculated in triplicate with 20 µL aliquots of log-
bacterial expression hosts transformed with a range of pGS-21a expression vectors for 
RAGE, HMGB1 and S100s.  A gas permeable adhesive seal (Thermo Scientific) was placed 
over the plate and the plate agitated at 400rpm, with growth monitored photometrically 
at 600 nm.  The culture was induced using IPTG at a working concentration of 1 mM 
once an O.D600 of 0.6-0.8 was achieved.  Cultures were induced for 6 hours (RAGE) or 2.5 
hr (HMGB1).  Individual well cultures were  transferred to 0.5 mL microfuge tubes 
containing 250 µL of 50 mM Tris-HCl (pH 7.5) containing 50 mM NaCl, 5 mM DTT (Lysis 
Buffer) with Roche COmplete™ Protease Inhibitor Cocktail (EDTA-free) and lysed on a 
thermocycler at 95°C for 20 minutes.  Samples were centrifuged at, 9,000 g for 15 
minutes at 4°C.  The concentration of RAGE expressed within the soluble fraction of each 
well was determined by ELISA (Section 2.6.19) and visualised on a denaturing SDS-PAGE 
gel (section 2.6.16) by Coomassie staining (section 2.6.17) and Western blotting (section 
2.6.18). 
2.6.3 Lysis of prokaryote cells by sonication 
Prokaryote cell pellets stored at -20°C were thawed on ice for 10 minutes before being 
resuspended in ice cold 50 mM Tris-HCl (pH 7.5) containing 50 mM NaCl and 1 mM DTT 
(Lysis Buffer) with Roche COmplete™ Protease Inhibitor Cocktail (EDTA-free) following 
the manufacturer instructions.  Lysis buffer was added at a ratio of 1:3 cell wet weight to 
buffer volume.  The mixture was gently vortexed to ensure thorough re-suspension of 
the cell pellet and left on ice for 10 minutes.  The mixture was loaded into the sonication 
chamber and immersed in an ice bath before being sonicated 10 times for 10 second 
bursts with 20 second intervals to prevent over-heating.  Care was taken to prevent 
frothing or heating of the mixture.  Upon completion, the mixture was centrifuged at 
20,000 g for 15 minutes at 4°C to pellet the insoluble cell debris, leaving the soluble 
fraction containing the expressed recombinant protein.  The soluble fraction was filter 
sterilised using a 0.22 µm syringe filter before being snap frozen in liquid nitrogen and 
then stored at -80°C until needed.  If the fraction was to be used within 24 hr, the 
filtered sample was stored at 4°C. 
2.6.4 Prokaryote expression of S100B, S100P and S100A6 
The expression of S100B, S100P and S100A6 was done using the same methodology 
employed in the expression of RAGE constructs in section 2.6.1.  The calgranulin gene 
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sequences were optimised for prokaryote expression and synthesised by GenScript 
before being supplied in pUC57 cloning vector and subsequently sub-cloned into pGS-
21a as described in section 2.4.13.  The vector was transformed in to T7 Shuffle® K12 as 
described in section 2.6.1 and expressed as outlined in section 2.6.1.  Cells were pelleted 
and lysed as described in 2.6.3. 
2.6.5 Prokaryote expression of HMGB1  
The expression of full length and truncated HMGB1 was done using the same 
methodology employed in the expression of RAGE constructs in section 2.6.1.  Truncated 
HMGB1 was expressed using the canonical human sequence for HMGB1, kindly provided 
by the Rauvala laboratory, Helsinki in pGEX-6P1-deltaHMGB1.  Full length HMGB1 was 
optimised and synthesised by GenScript and supplied in pUC57 cloning vector.  The gene 
insert was sub-cloned into pGS-21a as described in section 2.4.13.  Both plasmids were 
transformed in to T7 Shuffle® K12 and expression carried out as described in section  
2.6.1 with a number of variations.  Induction took place at O.D600nm of 1.0 and expression 
was only allowed to continue for 2.5 hr before cells were pelleted and lysed as described 
in 2.6.3. 
2.6.6 Perchloric acid extraction of HMGB1 
All steps in this section were performed at 4°C except where otherwise specified.  The 
cell pellet produced in section 2.6.3 was thawed out in a 25°C water bath for 10 minutes.  
For each gram of cell pellet, 3 mL of 6% perchloric acid solution was added and the cell 
pellet completely resuspended by vortexing.  The mixture was centrifuged at 12,000 g 
for 10 minutes and the supernatant transferred to a 15 mL centrifuge tube on ice.  One 
part 10x 20 mM Tris (pH 7.4) containing 50 mM NaCl, 0.5 mM DTT and protease 
inhibitor cocktail (Roche) was added to 9 parts of the perchloric acid fraction, and the pH 
adjusted to 7.4 by adding 2 M NaOH drop-wise. 
2.6.7 De-glycosylation of recombinant RAGE 
Samples of conditioned culture media containing each RAGE construct were filtered 
using a 0.22 µm syringe filter before being concentrated to a final volume of 100 µL 
using an Amicon Ultra-4 centrifugal filter unit (nominal molecular weight limit of 3 kDa).  
Nine microliters of each RAGE construct was mixed with 1 µL of 10x glycoprotein 
denaturation buffer (New England Biolabs) and heated at 100°C for 10 minutes.  The 
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mixture was allowed to cool at room temperature for 10 minutes before adding 2 µL of 
10x G7 Reaction Buffer supplied with the glycosidase, 2 µL of 10% NP40, 10U of 
PNGaseF and 4 µL of high pure water.  The mixture was incubated for 2 hours at 37°C.  
The reaction mixture was then prepared and run on an SDS PAGE gel as outlined in 
section 2.6.16. 
2.6.8 Generation of ribose-AGE (Advanced Glycation End products) 
A 5.4 mg/mL BSA in 400 mM sodium phosphate buffer (pH 7.4) containing 500 mM D(-) 
Ribose was filter-sterilised using a 0.22 µm syringe filter.  The ribose-BSA solution was 
stored in a dark container at 37°C for 10 weeks as described in the method of Valencia et 
al (2004), before being separated into 0.5 mL aliquots and stored at -20°C until needed.  
AGE content was determined by taking optical measurements (OD405) as previously 
described by Muench et al (2004). 
2.6.9 Phenyl Sepharose® chromatography 
All chromatography is performed at 4°C unless otherwise indicated.  A 1 mL column pre-
packed with phenyl Sepharose CL-4B (GE) was connected to a Bio-Rad Biologic FPLC and 
pre-equilibrated with 20 column volumes (CV) of 20 mM sodium phosphate buffer (pH 
7.4) containing 150 mM NaCl, 1 mM DTT and 5 mM CaCl2 (column buffer). The soluble 
fraction of T7 Shuffle® K12 induced to express S100B, S100P or S100A6 was 
supplemented with a working concentration of 5 mM CaCl2 and applied to the column at 
0.25 mL/min.  The column was washed at 0.25 mL/min with 5-7 CV of column buffer or 
until a stable O.D280nm base line was reached.  Bound protein was eluted by washing the 
column with column buffer plus 2 mM EGTA and collected in 1 mL fractions. 
2.6.10 Heparin-Sepharose® affinity chromatography 
Sample containing recombinant RAGE was filtered using a 0.45 µm syringe filter 
immediately before being applied to the chromatography column.  A 5 mL pre-packed 
heparin Sepharose® HiTrap™ column (GE Healthcare) was connected to a Bio-Rad 
Biologic FPLC system and pre-equilibrated with 25 mL of 50 mM Tris-HCl buffer (pH 7.5) 
containing 50 mM NaCl and 1 mM DTT (binding buffer) at a flow rate of 1 mL/min.  The 
recombinant RAGE samples were applied to the column at 0.5 mL/min with a single pass 
and the flow-through retained for analysis of unbound RAGE.  The column was washed 
with 25 mL of binding buffer at a flow rate of 1 mL/min.  The column was eluted at a 
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flow rate of 1 mL/min using binding buffer with different concentrations of NaCl in a 
step gradient as outlined in Table 6. 
 
Table 6. Step gradient used for the elution of protein bound to a heparin-Sepharose® 1 
mL column 
Step Concentration NaCl (mM) Elution time (min) 
1 50 15 
2 150 15 
3 250 15 
4 500 15 
5 1000 15 
 
The column was regenerated by applying 10 mL of binding buffer containing 0.01% SDS, 
followed by 20 mL of binding buffer and 5 mL of 20% ethanol prepared in high pure 
water at 1 mL/min.  The column was stored in 20% ethanol at 4°C until needed. 
2.6.11 Size exclusion chromatography 
A HiPrep 16/60 Sephacryl S-200 (GE) column was connected to an AKTA Purifier FPLC 
(GE) and equilibrated with 15 mL distilled water followed by 60 mL of 50 mM sodium 
phosphate buffer (pH 7.2-7.4) containing 150 mM NaCl and 1 mM DTT (wash buffer) at 
0.5 mL/min.  The sample to be fractionated was concentrated using an Amicon® Ultra 
centrifugal filter to 0.5-1 mL and injected onto the column using a 50 mL superloop (GE).  
The sample was washed through the column using wash buffer at 0.5 mL/min and 
eluates collected in 2 mL fractions. 
2.6.12 Nickel Sepharose® affinity chromatography 
A 1 mL pre-packed HisTrap HP column (GE Healthcare) was equilibrated with 10 column 
volumes (CV) of 20 mM Sodium Phosphate (pH 7.4) containing 500 mM NaCl, 25 mM 
imidazole and 1 mM DTT (buffer A) at a flow rate of 0.5 mL/min.  Pooled heparin 
Sepharose® eluates containing RAGE were applied to the column at a flow rate of 0.25 
mL/min and the flow through collected for analysis of unbound RAGE.  The column was 
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washed with 10 CV of buffer A or until a stable O.D280nm base line was reached.  The 
column was then eluted by washing the column with 10 CV of buffer A containing 250 
mM imidazole at 0.5 mL/min.  Eluates were collected in 1 mL fractions and RAGE 
content determined by ELISA (section 2.6.19).  The column was regenerated after 4-5 
purifications at a flow rate of 0.5 mL/min using 10 mL of buffer C containing 50 mM 
EDTA, followed by 10 mL of distilled water.  The resin was recharged with nickel by 
injecting 1 mL of 100 mM NiSO4 onto the column and incubating for 10 minutes.  The 
column was washed with 10 mL of distilled water and stored in 20% ethanol at 4°C. 
2.6.13 Glutathione S-transferase affinity chromatography 
A 1 mL prepacked GSTrap column (GE) was connected in-line with a Bio-Rad Biologic 
FPLC system and equilibrated with 5 column volumes of 25 mM sodium phosphate (pH 
7.4) containing 140 mM sodium chloride, 2.7 mM potassium chloride and 1 mM DTT 
(wash buffer).  Clarified cell lysates from bacteria expressing recombinant protein in 
pGEX-6P vectors were prepared as described in section 2.6.3, ensuring the protease 
cleavage site is in-frame.  The sample was applied to the column at a flow rate of 0.3 
mL/min with the system housed in a refrigerated cabinet at 4°C.  The column was then 
washed with 5 column volumes of wash buffer and the flow through collected in 1 mL 
fractions at a flow rate of 1 mL/min.  The system was paused and the GSTrap column 
carefully removed.  Using a syringe, 20U of PreScission Protease in wash buffer was 
added to the column, with a 1 mL HisTrap column connected in series to the bottom of 
the GSTrap to bind the protease upon elution.  Both columns were re-connected to the 
FPLC system and left for 4 hours at 4°C.  The system was resumed at a flow rate of 0.5 
mL/min and the eluates collected in 1 mL fractions.  
2.6.14 Bradford microtitre protein assay 
Bio-Rad Bradford 1x dye solution was gently inverted to ensure it was evenly mixed 
before 150 µL of the dye was added to 150 µL of sample or standard in triplicate in wells 
of a 96-well microtitre plate.  The plate was gently mixed on a plate shaker for 5 minutes 
at room temperature, and read in a microplate reader at a 595 nm wavelength. The 
concentration of samples was determined relative to the standards loaded on the plate.  
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2.6.15 Modified Lowry protein assay 
Assay samples were diluted to a total volume of 1 mL with ddH2O and mixed with 100 
µL of sodium deoxycholate (1.5 mg/mL). The diluted samples were vortexed before 
being left to stand for 10 minutes at 22°C.  To each sample, 100 µL of 72 % w/v 
trichloroacetic acid was added before the solution was left to stand at 22°C for 10 
minutes.  The samples were subsequently centrifuged at 11,000 g for 15 minutes and 
the supernatant aspirated off to leave the pellet.  The pellet was suspended in 1 mL of 
Lowry reagent for 30 minutes at 22°C.  Folin & Ciocalteaus phenol reagent (0.5 mL) was 
then added to each tube with vigorous mixing, and the samples again left at 22°C for 30 
minutes. The absorbance of each sample was measured at 660 nm using a Shimadzu 
UVmini-1240 UV-Vis spectrophotometer. The sample absorbance readings were 
compared against a bovine serum albumin standard curve. 
2.6.16 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
A 4-16 % pre-cast polyacrylamide gel was placed into a Bio-Rad™ electrophoresis tank 
filled with 25 mM Tris-HCl (pH 8.3) containing 250 mM glycine and 0.1 % SDS.  The first 
well was loaded with 10 µL of a broad range pre-stained molecular weight marker.  
Samples to be run on the gel were prepared by mixing 10-15 µL of starting material that 
was made up to 20 µL using 25 mM Tris-HCl,  (pH 8.3) containing 6 % SDS, 20 % glycerol, 
0.05 % bromophenol blue and 200 mM dithiothreitol.  This mixture was heated for 5 
minutes at 99°C before being loaded onto the gel.  The gel was run at 90 V (constant 
current) for approximately two hours, or until the dye front reached the base of the gel.   
2.6.17 Coomassie staining of SDS-PAGE gel 
A Coomassie staining solution was prepared by dissolving 0.4 g of Coomassie blue R350 
in 200 mL of 40% (v/v) methanol in distilled water.  The staining solution was filtered 
through Whatman filter paper before adding 200mL of 20% (v/v) acetic acid.  The 
staining solution had a final concentration of 0.1% (w/v) Coomassie blue R350, 20% (v/v) 
methanol, and 10% (v/v) acetic acid.  Destaining solution stock consisted of 50% (v/v) 
methanol and 10% (v/v) acetic acid.   Following completion of PAGE (section 2.6.16), the 
precast gel was removed from the plastic cassette and immediately placed into a 
solution comprising 50% stain and 50% destain solutions so that the gel was completely 
covered.  The gel was allowed to stain overnight with gently agitation at room 
temperature.  The staining mixture was poured off and replaced with 100% of the 
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destain solution.  This was replaced every 30 minutes or when needed until the desired 
level of clarity was achieved.  The gel was wrapped in plastic film and stored at 4°C until 
needed. 
2.6.18 Western blot 
An SDS-PAGE gel prepared as described in section 2.6.16 was immediately placed into 
ice-cold 1.25 M glycine (pH 8.3), containing 0.125 M Tris, 0.1 % SDS and 20 % methanol 
(transfer buffer) for 15 minutes at 22C.  A sheet of PVDF membrane and two pieces of 
3M filter paper were cut so that they were just larger than the polyacrylamide gel.  The 
PVDF membrane was then rinsed for 5 seconds in methanol, followed by two 30-second 
washes in 100 mL high pure water.  The membrane was then left in transfer buffer until 
needed.   All components were pre-washed with transfer buffer before being placed into 
the PAGE transfer sandwich.  The transfer sandwich assembly was then loaded into an 
electrophoresis transfer tank filled with ice-cold transfer buffer.  The entire unit was 
placed on ice to maintain the temperature below 4C.  A small magnetic stirrer was 
placed into the electrophoresis tank and gently rotated for the duration of the run.  The 
transfer was run at a constant current of 90 V for 75 minutes.  The primary antibody was 
prepared by diluting the antibody stock 100-fold in 0.125 M Tris (pH 8.0) containing 5 % 
w/v skim milk powder, 0.15 M NaCl and 0.05 % Tween-20.  The primary antibody 
solution was kept at 4C until needed.  Once the transfer was completed, the PVDF 
membrane was removed from the transfer sandwich and placed in 15 mL of 0.125 M 
Tris (pH 8.0) containing 5 % w/v skim milk powder, 0.15 M NaCl and 0.05 % Tween-20 
(blocking buffer) for 60 minutes at 4C with gentle shaking.  The membrane was then 
placed into a shallow tray containing the primary antibody solution and incubated over 
night at 4C with gentle shaking.  Following this, the membrane was washed 3 times for 
10 minutes in 15 mL of blocking buffer at 4C.  The secondary detection antibody 
conjugated to alkaline phosphatase was diluted in blocking buffer according to the 
manufacturer directions.  The PVDF membrane was incubated in 20 mL of this solution 
with gentle agitation for 45 minutes at 22C.   The membrane was again washed three 
times for ten minutes in blocking buffer.  The colorimetric reaction solution was 
prepared by mixing 800 l of 25 x alkaline phosphatase colour development buffer (Bio-
Rad™), with 200 l of Solution A (Bio-Rad™), 200 l of Solution B (Bio-Rad™) and 10 mL 
of colour reaction buffer (Bio-Rad™).  The membrane was washed for 10 minutes with 
10 mL of the colorimetric reaction solution until the desired band intensity was 
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achieved.  The membrane was washed with high pure water to stop the colour 
development, and the membrane was air dried for two hours at room temperature. 
2.6.19 RAGE enzyme-linked immunosorbent assay (ELISA) 
A mouse anti-human extracellular RAGE domain capture antibody (R&D Systems) was 
reconstituted in phosphate buffered saline (pH 7.4) to 180 µg/mL and a biotinylated 
goat anti-human RAGE detection antibody (R&D Systems) was reconstituted in 
phosphate buffered saline (pH7.4) (PBS) to 36 µg/mL.  The capture antibody was further 
diluted to a working concentration of 1 µg/mL and 100 µL added to each well on a 96-
well NUNC Maxisorp plate.  The antibody was left to stand overnight at room 
temperature to adsorb to the well surface.  The wells were washed three times with PBS 
containing 0.05% Tween-20 (wash buffer) and blocked with 300 µL of phosphate 
buffered saline (pH 7.4) containing 2% BSA (reagent diluent) for 2 hours at room 
temperature.  The wells were aspirated and 100 µL of sample containing RAGE was 
added to each well.  The plate was incubated at room temperature for 2 hours before 
being carefully washed three times with 300 µL of wash buffer per well.  A 100 µL 
aliquot of biotinylated goat anti-human RAGE detection antibody was incubated with 
each well for 2 hours at room temperature.  The wells were subsequently washed three 
times with 300 µL of wash buffer before 100 µL of Streptavidin-Horse Radish Peroxidase 
(HRP) conjugate was added and allowed to bind to the detection antibody for 20 
minutes at room temperature.  Each well was then washed three times with 300 µL of 
wash buffer before 100 µL of TMB containing HRP substrate chromogen was added to 
each well.  The plate was allowed to sit for a maximum of 20 minutes at room 
temperature or until sufficient colour development was observed.  Colour development 
was stopped by adding 50 µL of 2N sulphuric acid to each sample. Wells were read at 
450 nm on a microplate reader and compared to a human RAGE standard (R&D 
systems). 
2.7 Receptor-Ligand Binding and Kinetic Evaluation 
2.7.1 AGE-RAGE colorimetric microwell binding assay 
RAGE ligand was diluted in 20 mM phosphate buffer (pH 7.4) containing 150 mM NaCl 
and 1 mM DTT (PBS) to a working concentration of 20 µg/mL.  A 100 µL aliquot was 
added to each well of a 96-well NUNC Maxisorp plate and allowed to adsorp at 4°C 
overnight.  The wells were aspirated and blocked with 300 µL of PBS containing 1% BSA 
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w/v (reagent diluent) for two hours at room temperature.  The wells were again 
aspirated and washed three times with 150 µL of reagent diluent.  RAGE recombinant 
protein was serially diluted in reagent diluent to 300 nM, 200 nM, 100 nM, 50 nM, 30 
nM and 15 nM.  A 100 µL of each RAGE concentration was added in triplicate to the 
ligand coated wells and the plate left overnight a 4°C to allow binding to reach 
equilibrium.  Each well was carefully washed three times with 100 µL of ice-cold reagent 
diluent and 100 µL of goat anti-human RAGE polyclonal antibody conjugated to horse 
radish peroxidase added to each well and left to incubate for four hours at 4°C.  The 
wells were then aspirated and washed three times with 300 µL of ice cold reagent 
diluent.  A 100 µL of TMB+ substrate was added to each well and the plate left to 
develop for a maximum of 20 minutes at room temperature or until sufficient colour 
was present.  Colour development was stopped by adding 50 µL of 2 N sulphuric acid to 
each well.  The plate was read at 450 nm on a Bio-Rad 3550 micro plate reader and 
compared to a human RAGE standard (R&D systems) developed on the same plate.  
2.7.2 Circular dichroism (CD) 
Prior to all CD experiments, all protein constructs were dialyzed into 10 mM phosphate 
buffer (pH 7.4) to remove interfering additives.  The CD instrument used for this 
experiment was a JASCO J-815 spectropolarimeter. All runs were performed with 
standard sensitivity (100 mdeg), data pitch of 1 nm, continuous scanning mode with 
speed of 100 nm/min, response of 1 s and band width of 1 nm.  Absorbance was 
monitored over the range of 260-185 nm. A 10 mm path length rectangular Spectrosil(R) 
Quartz cuvette (Starna®) was blanked over 5 accumulated scans using 400 µL of 10 mM 
phosphate buffer (pH 7.4). CD measurement of proteins was conducted in the same 
solution as the blank and the CD absorption spectrum was accumulated over five scans.  
The secondary structure components of the protein constructs were evaluated using 
online analysis website DichroWeb [DichroWeb references] with an optimized 
wavelength range of 185-240 nm used as reference. CONTIN, a ridge regression method 
was used for analysis, generating a linear combination of known spectra of reference 
proteins with known conformations.  Only reference proteins with similar spectral 
characteristics were used to give a best fit for the sample. A Normalized Root Mean 
Square Deviation (NRMSD) value is given as a parameter to determine whether the 
Circular Dichroism profile is reliable.  
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2.7.3 Beta amyloid 1-42 preparation for surface plasmon resonance immobilisation 
Human synthetic beta amyloid 1-42 (Aβ42) peptide was purchased from W.M. Keck 
Biotechnology Resource Laboratory.  Stock Aβ42 was prepared by dissolving lyophilised 
peptide in 10% dimethyl sulfoxide (DMSO) to a concentration of 1 mg/ml. The stock was 
diluted in 0.01 M HEPES buffered saline (pH 7.4) containing 3 mM EDTA,  0.15 M NaCl, 
and 0.005% vol/vol surfactant polysorbate 20 (P20)) (HBS) to a working concentration of 
10 ng/mL immediately before use to ensure monomeric and not aggregated Aβ42 was 
the principal form immobilised. 
2.7.4 Surface plasma resonance  
A Biacore 3000 and Biacore T200 were used for all surface plasma resonance methods 
referred to within this thesis.  A CM5 amine coupling chip (GE Healthcare) was prepared 
using flow cell 1 and or 3 as blank surfaces.  The blank cell was prepared using the built-
in method in which the dextran matrix was activated by passing a mixture of 0.4 M N-
ethyl-N'-(3-dimethylaminopropyl) carbodimide hydrochloride (EDC) and 0.1 M N-
hydroxysuccinimide (NHS) across the flow cell.  Following esterification of the dextran 
matrix, the chip surface was blocked by passing 1 M ethanolamine hydrochloride-NaOH 
(pH 8.0), across the flow cell for three minutes at a flow rate of 5 µL/min.  Where beta-
amyloid was to be immobilised as the target ligand, a scrambled beta-amyloid 42 amino 
acid peptide was first immobilised to flow cells 1 and 3.  Any remaining unreacted sites 
where then blocked with 1 M ethanolamine hydrochloride-NaOH (pH 8.0), across the 
flow cell for three minutes at a flow rate of 5 µL/min.  The chip was washed with 10 mM 
sodium acetate buffer (pH 5.0) containing 1 M NaCl for 30 seconds at 30 µL/min to 
remove any non-specific binding of blocking agent. 
RAGE constructs or RAGE ligands were immobilised to cells 2 or 4 following their 
activation using a mixture of 0.4 M EDC and 0.1 M NHS as per the blank cell surfaces.  
For insect expressed RAGE SPR binding assays, mouse Anti-V5 monoclonal antibody 
(Invitrogen™) was diluted to a working concentration of 1 g/mL in degassed 10 mM 
sodium acetate buffer (pH 5.0).  The antibody mixture was passed across the activated 
flow cell using an adaptive immobilisation strategy at 5 µL/min until 300 response units 
(RU) was achieved. For all other SPR assays with other RAGE ligands, a working 
concentration of 100 ng/mL was prepared in the running buffer immediately before 
immobilisation.  Where less than 10 RU cell loading was required, as was the case with 
beta-amyloid, samples were prepared at 10 ng/mL.  Following immobilisation of ligand,  
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Figure 8.  Principles of surface plasmon resonance (SPR).    
A molecule (ligand) is immobilised to a dextran matrix while a second molecule in 
solution (analyte) is passed across the surface.  As analyte binds, the change in 
reflectance at the opto-interface a) is directly proportional to the change in mass at the 
chip surface and recorded as response units b).  Where an already captured analyte 
dissociates and immediately rebinds (avidity) or is simultaneously bound by a second 
ligand molecule, no change in mass or response units is registered. 
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as per the blank cells, remaining unreacted sites on the surface was blocked by passing 1 
M ethanolamine hydrochloride-NaOH (pH 8.0) across the flow cell at 5 µL/min for three 
minutes.  Unreacted ethanolamine was eluted by passing 10 mM sodium acetate buffer 
(pH 5.0) containing 1 M NaCl across the flow cell at 30 µL/min for 30 seconds.  The flow 
cell was then pre-equilibrated with 0.01 M HEPES buffered saline (pH 7.4) containing 3 
mM EDTA,  0.15 M NaCl, and 0.005% vol/vol surfactant P20) (HBS) in preparation for 
binding and kinetic assays.  Where binding required the presence of divalent cation co-
factors such as Ca2+, HBS without EDTA was used (HBS-N). 
2.7.5 Surface plasma resonance multi-cycle and single-cycle kinetics analysis 
Both single and multi-cycle analysis of surface plasmon resonance response data utilise 
measurements across a range of analyte concentrations. The predominant difference is 
that single-cycle kinetics involves the sequential injection of increasing concentrations of 
analyte without the need to regenerate the chip surface between cycles.  Single-cycle 
kinetic method increase the likelihood for slow interactions to approach equilibrium and 
are significantly shorter in total run time due to removal of intermediate regeneration 
steps.  However, it is more sensitive to drift due to the long cycle duration and is limited 
in the complexity of interactions that it is appropriate for.  The multicycle method 
regenerates the chip surface between cycles, removing all bound analyte before 
injecting another sample.  This method is therefore significantly longer and may degrade 
the immobilised molecule through exposure to harsh regeneration conditions, however, 
it is the traditional format for investigating kinetics of interaction by surface plasmon 
resonance analysis.   
For single-cycle, five concentrations of analyte are prepared in series in 10 mM HEPES 
(pH 7.4) containing 150 mM NaCl, 3 mM EDTA and 0.005% v/v Surfactant P20 (HBS-EP).  
A start-up cycle injects HBS-EP three times in place of sample to equilibrate the system 
followed by regeneration of the chip surface with 10 mM NaOH for 10 seconds.  Sample 
is injected in sequence from the lowest to highest concentration without intermediate 
regeneration.  Samples are injected across immobilised flow cells at 30 µL/min and 
allowed to associate for 120 seconds with no stabilisation period.  Following the 
injection of all five sample concentrations, bound analyte is allowed to dissociate for 600 
seconds before the surface is regenerated by the injection of 10 mM NaOH through the 
flow path. 
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Multi-cycle analysis involved the preparation of 5-12 concentrations of a sample 
molecule such as RAGE VC1C2 for use as an analyte.  The system is first equilibrated by 
injecting HBS-EP across the flow path for association/dissociation times of 120 seconds 
and 600 seconds respectively before being regenerated using 10 mM NaOH.  This is 
repeated for all samples with two being performed in duplicate.  Following the 
association and dissociation of each sample, the flow path is regenerated by injecting 10 
mM NaOH across the flow path for 10 seconds.  All models of interaction are designed 
and fitted using Biaevaluate 4.0 (GE).  
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3.0  RESULTS 
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3.1 Development of human RAGE insect cell expression constructs 
3.1.1 Verification of full length human RAGE in pcDNA3 plasmid 
The gene encoding full length human RAGE was provided in a mammalian expression 
vector, pcDNA3 (Invitrogen™).  Sequencing primers for pcDNA3 were used to amplify 
the insert to confirm the presence of the full length gene (section 2.4.11).  A product of 
approximately 1400 bp was observed following agarose gel electrophoresis, correlating 
with an expected size of 1364 bp (Figure 9). 
3.1.2 Transformation of TOP10 E. coli with pcDNA3-hRAGE 
The pcDNA3-hRAGE plasmid was transformed into chemically competent TOP10 E. coli 
for the purpose of plasmid replication.  Whole-cell PCR amplification (section 2.4.5) of 
individual colonies was performed using RAGE forward primer F1 in combination with 
reverse primer R2 (Table 1) to ensure that the plasmid containing hRAGE was retained 
by transformed cells.  All six colonies selected displayed a PCR product of approximately 
650 bp, corresponding with the expected product of 687 bp (Figure 10).  These PCR 
amplicons confirmed the presence of pcDNA3-RAGE and the presence of the RAGE 
leader sequence, to which the F1 forward primer is complementary.   
3.1.3 Amplification of RAGE extracellular domains V, VC1 and VC1C2 
Purified pcDNA3-hRAGE plasmid was used as template in the PCR amplification of gene 
segments encoding the V, VC1 and VC1C2 RAGE extracellular domains (section 2.4.11) 
(Figure 11).  Primer combination F1-pR1 (lane 2) produced a band representing the 
RAGE V domain, while F1-R2 amplified the VC1 domains (lane 3) and F1-R3 amplified 
extracellular domains VC1C2 (lane 4) (Table 1).  The three products resolved using a 1.2% 
agarose gel were approximately 350 bp (lane 2), 700 bp (lane 3), and 950 bp (lane 4) 
(Figure 11).  These products correspond with the expected sequence lengths of 351 bp 
for the V domain, 687 bp for VC1, and 936 bp for VC1C2.  No other PCR products were 
present, confirming the suitability of the primers and product for sub-cloning. 
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Figure 9.  Amplification of the full length gene encoding human RAGE. 
Mammalian expression plasmid pcDNA3 (Invitrogen™) containing the gene for human 
RAGE (hRAGE) was amplified using forward and reverse pcDNA3 sequencing primers 
(lane 2).  A negative control without template was also amplified (lane 3).  The reaction 
products were run on a 1.2% agarose gel against a log-2 (New England Biolabs®) base 
ladder (lane 1).   
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Figure 10.  Selection of TOP10 E. coli transformed with pcDNA3-hRAGE by PCR.   
TOP 10™ E. coli transformed with pcDNA3-hRAGE were cultured on LB + Amp agarose 
(section 2.4.4).  Whole cell PCR screening of six colonies chosen at random was carried 
out with amplification products representing colonies 1-6 respectively (lanes 2-7), run 
on a 1.2% agarose gel against a log-2 base ladder (lane 1) (New England Biolabs®) as 
described in section 2.4.9. 
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Figure 11.  Amplification of human RAGE extracellular domains V, VC1 and VC1C2. 
Purified pcDNA3-hRAGE was used as a template in PCR reactions amplifying the V (lane 
2), VC1 (lane 3) and VC1C2 (lane 4) extracellular domains of RAGE as described in section 
2.4.11.  PCR products were visualised on a 1.2% agarose gel as outlined in section 2.4.9.  
A log-2 base pair ladder (New England Biolabs®) was loaded in lane 1 to help 
approximate product size. 
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3.1.4 Identification of transformed TOP10 colonies containing correctly oriented 
RAGE domain inserts in pIB/V5-HIS TOPO® 
Following successful amplification of the RAGE V, VC1 and VC1C2 extracellular domain 
segments, the PCR products were cloned into an insect pIB/V5-HIS expression vector as 
described in section 2.4.12.  Identification of colonies containing vector with product 
inserted in the correct orientation was performed by whole cell PCR using pIB/V5 
forward sequencing primer (Invitrogen™) and reverse primers R1, R2 and R3 for V1, VC1 
and VC1C2 respectively.  Of the colonies containing the RAGE V domain, colony 10 in lane 
11 (Figure 12) resulted in a PCR product of approximately 450 bp, with this domain 
construct having a transformation efficiency of 1.25x105 cfu/μg DNA. Colonies 1, 2 and 7 
in lanes 2, 3 and 8 respectively (Figure 13) were transformed with pIB/V5-HIS-VC1, 
producing a PCR product of approximately 800 bp, with a transformation efficiency of 
3.12x103 cfu/μg DNA.  RAGE pIB/V5-HIS-VC1C2 had the lowest transformation efficiency 
of 9.24x102 cfu/μg DNA, with only colony 25 having a gene insert in the correct 
orientation (Figure 14).  All positive colonies were sent for sequencing.  Both the V and 
VC1C2 single colonies were confirmed as containing the correct RAGE construct 
sequences. Colonies 1 and 7 containing VC1 both returned correct sequences.  Colony 2 
(lane 3, Figure 13) of the positive pIB/V5-HIS-VC1 transformants was discarded due to 
the presence of a single point mutation in the V domain that resulted in an amino acid 
shift.  This finding is surprising because the V domain had the highest rate of 
transformation with only 6% of colonies ligating in the correct orientation.  The VC1 and 
VC1C2 constructs had 43% and 4% respectively of colonies with inserts in the correct 
orientation.  
3.2 Development of RAGE and ligand constructs for prokaryote expression 
3.2.1 PCR amplification of synthetic RAGE V, VC1 and VC1C2 domain constructs 
optimised for prokaryote expression. 
Human RAGE V, VC1 and VC1C2 domain constructs were optimised for prokaryote 
expression by modifying codon bias, GC content and possible secondary structures using 
the GenScript OptimumGene™ algorithm.  The gene sequences were synthesised by 
GenScript and provided in pUC57 vectors, which were used as PCR template.  Single 
bands of approximately 300, 600 and 1000 bp were visible following PCR amplification   
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Figure 12.  PCR screening of TOP10 E. coli transformed with pIB/V5-hRAGE-V. 
TOP10 E. coli were transformed with pIB/V5-HIS TOPO® insect expression vector 
(Invitrogen™) containing a human RAGE V domain insert.  Transformants were plated on 
selective LB agarose plates (section 2.4.4) and 15 randomly selected colonies screened 
by whole-cell PCR (section 2.4.5).  PCR reaction mixtures were loaded into lanes 2-16 of 
a 1.2% agarose gel along with a log-2 base pair ladder (New England Biolabs®) (lane 1) 
and then visualised (section 2.4.9).  
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Figure 13.  PCR screening of TOP10 E. coli transformed with pIB/V5-hRAGE-VC1. 
TOP10 E. coli were transformed with pIB/V5 insect expression vector (Invitrogen™) 
containing extracellular RAGE domains VC1 (sections 2.4.2 and 2.4.12).  The 
transformation mixture was spread over a selective agarose media (section 2.4.4).  
Seven colonies were picked at random and screened by PCR using pIB forward 
sequencing vector and the RAGE-VC1 reverse primer (R2) for correct insert orientation 
(section 2.4.5, Table 1).  The PCR reactions representing the seven colonies were loaded 
in wells 2-8 respectively on a 1.2% agarose gel alongside a log-2 base ladder (lane 1) 
(New England Biolabs®).  The gel was run and visualised as described in section 2.4.9. 
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Figure 14.  PCR screening of TOP10 E. coli transformed with pIB/V5-hRAGE-VC1C2. 
TOP10 E. coli were transformed with pIB/V5 insect expression vector (Invitrogen™) 
containing hRAGE-VC1C2 and grown on selective media (section 2.4.4).  A 20 µL pipette 
tip was used to transfer randomly selected colonies into separate PCR reaction mixtures 
containing pIB/V5 forward sequencing vector (Invitrogen™) and RAGE-VC1C2 reverse 
primer (R3) (section 2.4.5, Table 1). This was repeated for 24 colonies.  PCR product for 
colonies 16-26 were loaded into lanes 2-12 respectively of an 1.2% agarose gel, 
alongside a log-2 base ladder (lane 1) (New England Biolabs®), and visualised according 
to section 2.4.9. 
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for pUC57-RAGE_V, pUC57-RAGE_VC1 and pUC57-RAGE_VC1C2 respectively, closely 
approximating the theoretical sizes of 312 (V), 666 (VC1) and 957 (VC1C2) base pairs 
(Figure 15).  The pUC57 plasmids containing the RAGE inserts were subsequently 
digested with XbaI and HindIII with the gene fragments sub-cloned into pGS-21a as 
described in section 2.4.13. 
3.2.2 PCR amplification of TOP10 E. coli transformed with RAGE V, VC1 and VC1C2 
domain constructs containing the native gene sequences. 
Synthetic human RAGE V, VC1 and VC1C2 domain constructs were sub-cloned into pGS-
21a and used to transform TOP10 E. coli as outlined in method 2.4.13.  To identify 
colonies with the RAGE gene insert, RAGE/vector primers were used in whole-cell PCR 
screening of transformants according to section 2.4.5.  All five colonies transformed with 
the V-domain had a single band of approximately 500 bp, with colonies 8, 9, 11 and 12 
(RAGE-VC1) and 14, 15, 18 (RAGE- VC1C2) all producing a single band of 850 and 1150 bp, 
respectively (Figure 16).  Factoring in the additional 160 bp added by the sequencing 
primer, these bands approximated the expected size of RAGE V, VC1 and VC1C2.  The 
percentage of positive clones followed the standard dogma of decreasing sub-cloning 
efficiency as the insert size increases with 100%, 80% and 60% of clones positively 
identified to contain their respective V, VC1 and VC1C2 inserts (Figure 16).  Similarly the 
canonical sequence for the identical gene segments encoding V, VC1 and VC1C2 were 
synthesised with the same XbaI and HindIII digest sites.  Following sub-cloning and 
preliminary screening, one positive clone for each domain construct was used as PCR 
template in whole-cell amplifications of the complete V, VC1 and VC1C2 insert.  Figure 17 
shows the presence of three single bands that each correspond with the expected size 
of the three domain constructs, confirming that a single insert approximating the 
expected gene size is present in each clone.  Sequencing of the pGS-21a-nativeV, pGS-
21a-nativeVC1 and pGS-21a-nativeVC1C2 confirmed that the inserts had ligated and 
replicated without error when compared to Genbank accession number AB036432 and 
the sequence submitted to GenScript. 
3.2.3 Verification of the truncated HMGB1 gene insert in expression vector pGEX-
6P1. 
Plasmid pGEX-6P1-deltaHMGB1 (ΔHMGB1) was kindly supplied by Dr Rouhiainen 
(University of Helsinki, Finland).  A restriction digest was performed as described in 
section 2.4.7 to quickly confirm the presence of HMGB1 in the pGEX-6P1 vector.   
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Figure 15.  PCR amplification of prokaryote optimised human RAGE V, VC1 and VC1C2 
domain constructs. 
The sequence for human RAGE V, VC1 and VC1C2 domain constructs was optimised for 
prokaryote expression, synthesised and provided in a pUC57 plasmid by GenScript.  To 
confirm the identity of the gene inserts, primers specific to the three domains were used 
to amplify each construct.  Lane 1 was loaded with a 100 bp ladder (Fisher Biotec), with 
VC1C2, VC1 and V PCR product loaded into lanes 2, 3 and 4 respectively on a 1.2% 
agarose gel and visualised by translumination. 
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Figure 16.  Whole cell PCR screening of TOP10 E. coli transformed with RAGE domain 
constructs sub-cloned into pGS-21a expression vector.   
Cloning vector pUC57 containing optimised synthetic human RAGE V, VC1 and VC1C2 
gene sequences were sub-cloned into pGS-21a expression vector and subsequently 
transformed into TOP10 E. coli as described in sections 2.4.13 and 2.4.2.  Transformants 
were screened by whole cell PCR for the presence of V, VC1 and VC1C2 gene inserts 
(section 2.4.5).  PCR product from five V, VC1 and VC1C2 transformants was loaded into 
wells 2-6, 8-12 and 14-18 respectively on a 1.2% agarose gel.  Lane 1 was loaded with a 
100 bp ladder (Fisher Biotec).  The gel was visualised as described in section 2.4.10. 
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Figure 17.  Amplification of native gene sequences for human RAGE extracellular 
domains V, VC1 and VC1C2 in pGS-21a expression vector. 
TOP10 E. coli transformed with pGS-21a containing the canonical sequences for human 
RAGE domains V, VC1 and VC1C2 was used as template in whole cell PCR reactions 
(section 2.4.5). Primers designed to amplify each of the RAGE gene inserts end-to-end 
were used, with the reaction products for V, VC1 and VC1C2 loaded into lanes 2, 3 and 4 
respectively on a 1.2% agarose gel.  A 1kb DNA ladder (Promega) was loaded into lane 1 
to allow estimation of PCR amplicon sizes. 
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Two products of approximately 290 bp and 3900 bp (Figure 18) were visualised following 
electrophoresis of the digest mixture on a 1.2% agarose gel (section 2.4.9), correlating 
with expected digest products based on sequence analysis. PCR amplification of 
truncated human HMGB1 was performed using the forward and reverse primers 
described in section 2.4.7 with pGEX-6P1-deltaHMGB1 used as template.  PCR product 
was visualised on a 1.2% agarose gel, with a single PCR product of approximately 380 bp 
visible in lane 3, alongside a negative control in lane 2 and a 100 bp DNA ladder in lane 1 
(Figure 19).  A product of 374 bp was expected for HMGB1 based upon its known 
sequence (Accession number NM_002128) and the primers designed.  The synthetic 
human HMGB1 gene insert was provided by GenScript in a pUC57 cloning vector and 
sub-cloned into pGS-21a utilising the identical methodology used to produce the three 
RAGE domain constructs (section 2.4.13). A positive clone was used as template, with a 
single PCR product of approximately 470 bp visible in lane 3, alongside a negative 
control in lane 2 and a 100 bp DNA ladder in lane 1 (Figure 20).  A product of 464 bp was 
expected based upon the primers used, correlating well with the band observed in lane 
3 (Table 2) (Figure 20).  The insert was subsequently verified by sequencing as a 100% 
match to the synthetic sequence provided to GenScript, with a synonymous primary 
amino acid sequence to human HMGB1 (Accession number NM_002128). 
3.2.4 PCR amplification of S100B, S100P and S100A6 cloned into vector pGS-21a. 
The gene sequences encoding human calgranulins S100B, S100P and S100A6 were 
optimised for prokaryotic host expression and synthesised by GenScript.  The restriction 
digest sites for XbaI and HindIII designed into synthetic RAGE and HMGB1 were similarly 
incorporated into each of the calgranulin gene inserts, which were then provided in 
pUC57 cloning vectors by GenScript.  The inserts were sub-cloned into pGS-21a and 
subsequently transformed and screened in TOP10 E. coli using the identical methods 
used for RAGE and HMGB1 (sections 2.4.2 to 2.4.5).  Primers designed for end-to-end 
amplification of the three calgranulin sequences were used in whole-cell PCR to confirm 
the presence of a single gene insert in the pGS-21a vector.  All three reactions produced 
well defined, single bands approximately 300 base pairs in size which approximates the 
expected sequence sizes of 276 bp (S100B), 285 bp (S100P) and 270 bp (S100A6) 
respectively (Figure 21).  Sequencing of plasmid collected from these three clones 
confirmed the inserts were a match to the sequences submitted to GenScript for 
synthesis.   
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Figure 18.  Restriction enzyme digests of pGEX-6P1-deltaHMGB1. 
pGEX-6P1-deltaHMGB1 was harvested from transformed TOP10 E. coli as described in 
section 2.4.6.  A restriction enzyme digest of pGEX-6P1-deltaHMGB1was performed 
according to section 2.4.7 and the reaction mixture visualised on a 1.2% agarose gel 
(section 2.4.9).  Digest mixtures for BamHI + EcoRI + pGEX-6P1-deltaHMGB1 was loaded 
into lane 1, EcoRI + pGEX-6P1-deltaHMGB1 in lane 4, with a 100 bp (Promega) and 1000 
bp ladder (EZ Bioresearch) loaded in lanes 2 and 3 respectively.  
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Figure 19.  PCR Amplification of truncated human HMGB1. 
Amplification of truncated human HMGB1 was performed as outlined in section 2.4.7 
using primers designed against HMGB1 amino acids 1-185 (Table 2).  PCR reaction 
mixture containing pGEX-6P1-deltaHMGB1 as template was loaded into lane 3 on a 1.2% 
agarose gel, along with a 100 bp ladder (Promega) in lane 1, and negative control in lane 
2.  
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Figure 20.  PCR amplification of full length human HMGB1. 
PCR amplification of synthetic human HMGB1 cloned into pGS-21a expression vector 
was performed as outlined in section 2.4.7 (Table 2).  PCR product from reaction 
mixtures with and without pGS-21a-hHMGB1 as template, were loaded into lanes 3 and 
2, respectively on a 1.2% agarose gel.  A 100 bp ladder (Promega) was loaded into lane 1 
and the samples visualised as described in section 2.4.9. 
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Figure 21.  PCR amplification of human S100B, S100P and S100A6 in pGS-21a 
expression vector. 
Synthetic genes encoding human S100B, S100P and S100A6 ligated into pGS-21a and 
subsequently transformed into TOP10 E. coli was used as template in whole cell PCR.  
Primers amplifying up the entire length of the gene inserts were used, with reaction 
products for S100B, S100P and S100A6 loaded into lanes 2, 3 and 4, respectively on a 
1.2% agarose gel.  A 100 bp base ladder (Promega) was loaded into lane 1 along with a 
negative control containing no template in lane 5. 
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3.3 Cell culture and recombinant protein expression 
3.3.1 Transient expression of pIB/V5 RAGE constructs in insect cells. 
Lepidoptera cell lines Sf9, Sf21 and High Five™ (Tn5) were transfected with pIB/V5 
vector containing canonical human RAGE V, VC1 and VC1C2 extracellular domains as 
outlined in section 2.5.8.  Cells were incubated at 27°C and the conditioned media 
collected 48 hours post-transfection.  Western blots of Sf9 (Figure 22) and Sf21 (Figure 
23) conditioned media confirmed the presence of pairs of RAGE immunoreactive bands 
for V, VC1 and VC1C2 that were 20-22 kDa, 30-32 kDa and 46-48 kDa in size, respectively.  
Tn5 expressed recombinant RAGE appeared as single bands for the V, VC1 and VC1C2 
constructs of 21 kDa, 31 kDa and 45 kDa, respectively (Figure 24).  Accounting for the 
additional amino acids encoding the V5 and 6xHis tag which add approximately 7 kDa, 
the size of the immunoreactive proteins correlates closely to the theoretical molecular 
weights of 14, 24 and 38 kDa for V, VC1 and VC1C2, respectively.  Optimisation of the 
DNA transfection quantity was done using the Tn5 host for all three domain constructs 
(Figure 25).  It was observed that as the quantity of DNA increased past 4 µg, the culture 
viability decreased significantly, with cultures transfected with 8 µg of vector becoming 
unviable.  The optimal amount of vector for use in transfection without impeding 
survival rates post-transfection was 4 µg for all constructs (Figure 25).   Although the 
cultures frequently survived when 6 µg was used, the passage times and molecular 
burden placed on the hosts resulted in unhealthy cultures with ongoing issues of poor 
viability and long passage times (data not shown). 
3.3.2 Stable expression of pIB/V5 RAGE constructs in insect cells 
Sf9, Sf21 and High Five™ insect cells confirmed to be transiently expressing RAGE 
constructs V, VC1 and VC1C2 were grown to confluency before being passaged as 
described in section 2.5.8.  The monocultures were grown to approximately 40% 
confluency before the nucleoside antibiotic Blasticidin was added at a 80 µg/mL working 
concentration to select for chromosomally incorporated transfectants (section 2.5.9) 
(Figure 24). Approximately 40% of the transfected cell cultures were dead 48 hr post-
administration of Blasticidin, with foci of resistant cells clearly visible in e), h) and k) of 
Figure 26, after only 24 hr.  The untransfected control culture (Figure 26a-c) was extinct 
48 hr post-selection, with membrane blebbing and cytosolic vacuols visible within 24 hr 
(Figure 26b).  The high concentration of selective antibiotic ensured cells containing 
multiple inserts were successfully selected and maintained as stable transfectants.   
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Figure 22.  Western blot for the presence of pIB/V5 RAGE constructs in conditioned 
media 48 hr post-transfection of Sf9 cells. 
Sf9 insect cells grown in monocultures were transfected with pIB/V5 human RAGE 
constructs described in section 3.1.4.  Cultures were grown for 48 hr before being 
passaged.  Samples of conditioned media from all transfected cultures was prepared for 
visualisation on an SDS-PAGE 4-12% precast gradient gel as described in section 2.6.16.  
Lane 1 was loaded with broad range prestained molecular weight standards, while mock 
transfectant media was loaded into lane 3 (lane 2 left blank).  Denatured RAGE VC1C2, 
VC1, and V domain samples were loaded into lanes 4, 5 and 6 respectively and 
electrophoresed.  A Western blot was performed on the gel as outlined in section 2.6.18 
using an anti-V5 specific monoclonal detection antibody (Invitrogen™).  
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Figure 23.  Western blot for the presence of pIB/V5 RAGE constructs in conditioned 
media 48 hr post-transfection of Sf21 cells. 
Sf21 insect cells grown in monocultures were transfected with pIB/V5 human RAGE 
constructs described in section 3.1.4.  Cultures were grown for 48 hr before being 
passaged.  Samples of conditioned media from all transfected cultures was prepared for 
visualisation on an SDS-PAGE 4-12% precast gradient gel as described in section 2.6.16.  
Lane 1 was loaded with broad range prestained molecular weight standard (Bio-Rad).  
Denatured RAGE V, VC1 and VC1C2 conditioned media samples were loaded into lanes 2, 
3 and 4, respectively and electrophoresed.  A subsequent Western blot was performed 
on the gel as outlined in section 2.6.18 using an anti-V5-specific monoclonal antibody for 
detection (Invitrogen™).  
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Figure 24.  Western blot for the presence of pIB/V5 RAGE constructs in conditioned 
media 48 hr post-transfection of Tn5 insect cells. 
Tn5 insect cells grown in monocultures were transfected with pIB/V5 human RAGE 
constructs described in section 3.1.4.  Cultures were grown for 48 hr before being 
passaged.  Samples of conditioned media from all transfected cultures was prepared for 
visualisation on an SDS-PAGE 4-12% precast gradient gel as described in section 2.6.16.  
Lane 1 was loaded with broad range prestained molecular weight standard (Bio-Rad).  
Denatured RAGE V, VC1, and VC1C2 conditioned media samples were loaded into lanes 2, 
3 and 4, respectively and electrophoresed.  A Western blot was performed on the gel as 
outlined in section 2.6.18 using an anti-V5 monoclonal detection antibody (Invitrogen™). 
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VC1C2 VC1 V 
cDNA µg/L %survival µg/L %survival µg/L %survival 
2ug 450 62% 280 58% 42 67% 
4ug 715 50% 362 55% 65 58% 
6ug 226 30% 52 24% 12 36% 
8ug 4 unviable 2 unviable <1 unviable 
 
Figure 25.  Bubble plot of transient protein expression levels and cell survival rates 
following transfection of Tn5 cells with different quantities of DNA. 
Tn5 insect cells were transfected with 2 µg, 4 µg, 6 µg and 8 µg of high pure pIB/V5-
nativeV, pIB/V5-nativeVC1 and pIB/V5-nativeVC1C2 cDNA using a lipid transfection 
system.  Cell survival was evaluated by trypan blue exclusion and viable cells manually 
counted using a haemocytometer (2.5.8).  The size of the bubble is indicative of the level 
of expression (µg/L) as determined by RAGE ELISA.  The corresponding data is tabulated 
below the chart.  
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Figure 26.  Selection of Tn5 insect cells stably expressing human RAGE extracellular 
domain constructs V, VC1 and VC1C2. 
Tn5 insect cell cultures were transfected with human RAGE V, VC1, VC1C2 and mock 
pIB/V5 vector (Figure 24) as described in section 2.5.4.  The cultures were allowed to 
adhere to the flask surface before treatment with the nucleoside antibiotic Blasticidin 
(80 µg/mL working concentration) to select stable transfectants and cultured as 
described in section 2.5.9.  Cells were imaged at 0, 24 and 48 hrs post-treatment with 
Blasticidin with image e) highlighting the formation of normal cell foci.   
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3.3.3 De-glycosylation of recombinant RAGE constructs expressed in insect cells. 
Sf9 and Sf21 expressed recombinant RAGE (Figures 21-22) was treated with N-
glycosidase to evaluate the heterogeneity of glycosylation as described in section 2.6.7.   
Western blotting before and after digest demonstrated the reduction of the two bands 
to a single band approximately 26 kDa, 38 kDa and 46 kDa in size respectively (Figure 
27).  Deglycosylation of Tn5 expressed recombinant RAGE similarly produced V, VC1 and 
VC1C2 RAGE proteins approximately 2 kDa smaller in size (data not shown).  This 
confirms that the recombinant RAGE constructs expressed by all Lepidoptera cell lines 
were glycosylated, with Tn5 cells producing homogeneously glycosylated recombinant 
protein. 
3.3.4 Quantitative analysis of recombinant RAGE constructs expressed by Sf9, Sf21 
and Tn5 insect cells in suspension culture. 
The Sf9, Sf21 and Tn5 cultures stably expressing recombinant V, VC1 and VC1C2 were 
adapted to suspension culture as outlined in section 2.5.5.  Shaker flasks with 50 mL of 
serum free media were seeded and allowed to grow to confluence before total 
recombinant RAGE in each culture was determined by ELISA (section 2.6.19).  Sf9 cells 
expressed 1.10 ± 0.05 µg, 1.43 ± 0.28 µg, and 2.16 ± 0.12 µg of V, VC1 and VC1C2 
respectively over a 4 day period (Figure 28).  Sf21 cells expressed 1.10 ± 0.22 µg, 3.56 ± 
0.41 µg, and 5.03 ± 0.19 µg of V, VC1 and VC1C2 respectively over a single passage (Figure 
28).  Tn5 cells produced 3.16 ± 0.17 µg, 14.49 ± 0.57 µg, and 20.8 ± 2.28 µg of V, VC1 and 
VC1C2 respectively over a three day single passage (Figure 28).  A positive correlation 
between increasing levels of expression and protein size was observed for all cell lines. 
Sf21 levels of VC1 and VC1C2 expression were approximately 2-fold higher than those of 
Sf9, with no significant difference between V domain levels. The Tn5 cells expressed V, 
VC1 and VC1C2 recombinant RAGE proteins at levels 2.5-fold, 5-fold and 4-fold higher 
than Sf21 over a single passage, clearly demonstrating that Tn5 is the most efficient 
Lepidoptera cell line for expressing homogeneous glycosylated recombinant human 
RAGE constructs with the greatest yield. 
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Figure 27.  Western blot of de-glycosylated recombinant human RAGE constructs 
expressed in Sf21 insect cells. 
Recombinant RAGE expressed by Sf21 insect cells transfected with the V, VC1 and VC1C2 
constructs was denatured and incubated with the N-glycosidase, PNGaseF (New England 
Biolabs®) as described in section 2.6.7.  Glycosylated V, VC1 and VC1C2 recombinant 
protein was prepared for denaturing SDS-PAGE (section 2.6.16), and loaded into lanes 2, 
4 and 6, respectively.  Corresponding de-glycosylated forms of V, VC1 and VC1C2 RAGE 
were loaded into lanes 3, 5 and 7, with a broad-range molecular weight standard (Bio-
Rad) run in lane 1.  Western blot analysis of the gel was performed as described in 
section 2.6.18, using an anti-V5 monoclonal antibody (Invitrogen™).  
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V VC1 VC1C2 V VC1 VC1C2 
Sf9 5% 7% 15% <1% <1% <1% 
Sf21 5% 17% 71% <1% <1% 2% 
Tn5 15% 23% 100% <1% <1% 3% 
 Culture Media Cytosolic Fraction 
 
 
 
 
 
 
 
 
 
 
 
Figure 28.  Total recombinant VC1C2 RAGE expressed by Sf9, Sf21 and Tn5 insect cells 
over a single passage in suspension culture (mean ± se). 
a) Heat map showing levels of expression as a percentage of the highest expressing 
RAGE construct (VC1C2) for both secreted and cytosolic located protein (n=3), with the 
colour intensity correlating with the relative level of expression b) Sf9, Sf21 and Tn5 
insect cells stably expressing recombinant RAGE constructs V, VC1 and VC1C2, were 
grown in 50 mL suspension cultures as described in section 2.5.6.  Once cells reached 
confluence, conditioned media was collected and total recombinant RAGE determined 
by ELISA (section 2.6.19).  Samples were measured in triplicate. 
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3.3.5 Comparison of insect cell growth rates in suspension culture. 
Sf9, Sf21 and Tn5 cells stably transfected with V, VC1 and VC1C2 recombinant RAGE 
constructs were grown in 50 mL cell suspension cultures according to section 2.5.6.  
Viable cell counts were performed every 24 hours to assess culture health and growth 
rates between constructs (section 2.5.7).  No discernible difference was observed in 
growth rates of either Sf9 or Sf21 cells expressing different constructs, with a maximum 
cell density of approximately 2.7x106 viable cells/mL achieved after 96 hr (Figure 29 and 
Figure 30).  Similarly, no differences were observed in growth rates of the Tn5 cells 
expressing the different RAGE constructs, with a maximum cell density of 2.87x106 
viable cells/mL 72 hr post-seeding (Figure 31).  This demonstrated that Tn5 insect cells 
go through a single passage 33% faster (24 hr) than both Sf9 and Sf21 cells transfected 
with identical RAGE constructs.  As such, all further work was carried out using only Tn5 
stable transfectants due to their homogeneous glycosylation of recombinant protein, 
faster passage times and higher levels of RAGE expression.  Further optimisation of 
media exchange regimes and brand of culture media were carried out using Tn5.  
Approximately 40% higher cell densities for Tn5 cells were achieved after 72 hours in 
culture using Ex-Cell 405™ media in comparison to Express Five™ (Figure 32).  Passaging 
of cells into conditioned media was done to evaluate nutrient exhaustion and cell 
viability under poor media conditions, again demonstrated that Tn5 cells grown in Ex-
Cell 405™ had both higher viability and cell density under adverse conditions.  This was 
clearly demonstrated by the non-viability of the p3 culture grown in Express Five™ 
media, with the Ex-Cell 405™ culture returning to normal growth kinetics in p4 (Figure 
32).  The levels of protein expression of VC1C2 as an archetypal RAGE domain construct 
in the two different media were 19% greater in yield for cultures grown in Ex-Cell 405™ 
media compared to those grown in Express Five™ (Figure 33).  This clearly demonstrated 
that Ex-Cell 405™ is the preferred Lepidoptera culture media in suspension culture, 
producing not only more viable cultures with higher cell densities, but 19% higher levels 
of protein expression relative to the Express Five™ media. 
  
 Page 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Growth rate of Sf9 insect cells in suspension culture expressing different 
soluble RAGE domain constructs.     
Sf9 insect cells stably transfected with V, VC1 and VC1C2 recombinant RAGE domain 
constructs were grown in parallel in suspension culture (section 2.5.6) using Express 
Five™ (Invitrogen™).  Total viable cell counts were performed as described in section 
2.5.7. 
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Figure 30. Growth rate of Sf21 insect cells in suspension culture expressing different 
soluble RAGE domain constructs.     
Sf21 insect cells stably transfected with V, VC1 and VC1C2 recombinant RAGE domain 
constructs were grown in parallel in suspension culture (section 2.5.6) using Express 
Five™ (Invitrogen™).  Total viable cell counts were performed as described in section 
2.5.7. 
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Figure 31. Growth rate of Tn5 insect cells in suspension culture expressing different 
soluble RAGE domain constructs.     
Tn5 insect cells stably transfected with V, VC1 and VC1C2 recombinant RAGE domain 
constructs were grown in parallel in suspension culture (section 2.5.6) using Express 
Five™ serum free media (Invitrogen™).  Total viable cell counts were performed as 
described in section 2.5.7. 
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Figure 32.  Growth rate of Tn5 insect cells in different media over multiple passages. 
Tn5 insect cells were grown in suspension as described in section 2.5.6.  Two cultures 
were grown in parallel using Express Five™ SFM (Invitrogen) and Ex-Cell™ 405 (Sigma) 
media.  Passages 1 and 2 had a single media change when cultures were split. Passage 3 
was split and seeded at the same cell densities as p1 and p2. However, conditioned 
media from passage 2 was used for the culture media of p3.  Cells were finally allowed 
to grow to extinction in passage 4 in fresh media.   
V
ia
b
le
 C
e
lls
 (
1
0
6 /
m
L)
 
.5 
 1  2 3 4 
Passage 
1 
1.5 
2.0 
0 
2.5 
3.0 
3.5 
 Ex-Cell™ 405 Express Five 
 Page 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  Insect cell expression of recombinant VC1C2 RAGE under different culture 
media conditions. 
Tn5 insect cells stably expressing recombinant VC1C2 were grown in suspension as 
described in section 2.5.6.  Levels of recombinant protein expressed every 24hr of 
culture were measured by ELISA (2.6.19). Two cultures were grown in parallel using 
Express Five™ SFM (Invitrogen) and Ex-Cell™ 405 (Sigma) media.  Passages 1 and 2 had a 
single media change when cultures were split. Passage 3 was split and seeded as per p1 
and p2, however, conditioned media from p2 was used for the culture media of p3. 
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3.3.6 Prokaryote expression of human RAGE V, VC1 and VC1C2 extracellular domains. 
Prokaryote protein expression strains BL21 (DE3), Rosetta-gami™ B, Origami™ B, T7 
Shuffle® K12 and T7 Shuffle® B were transformed with optimised human RAGE domain 
constructs pGS-21a-optV, pGS-21a-optVC1 and pGS-21a-optVC1C2 as outlined in section 
2.4.2.  The Rosetta-gami™ B, Origami™ B and T7 Shuffle® K12 were similarly transformed 
with pGS-21a-nativeV, pGS-21a-nativeVC1 and pGS-21a-nativeVC1C2 and cultured as 
outlined in method 2.6.2.  Each culture was induced to express, with samples from T7 
Shuffle® K12 collected for reducing PAGE, Coomassie staining (method 2.6.17) and 
Western blotting with anti-RAGE antibody (method 2.6.18).  The pGS-21a-optV construct 
did produce a visible band by Coomassie post-induction of approximately 18 kDa in size.  
The native V-domain construct similarly showed the presence of a band approximately 
the same size as the synthetic construct, with Western blot confirming immunoreactivity 
of the post-induction bands with anti-RAGE antibody (Figure 34).  T7 Shuffle® K12 
transformed with pGS-21a-optVC1 and pGS-21a-nativeVC1 produced single bands post-
induction visible by Coomassie of approximately 32 kDa and 28 kDa (Figure 35).  This 4 
kDa difference in size is likely due to differences in PAGE conditions, apparatus used, 
gels and running buffers, as the electrophoresis of the native and optimised samples 
were done separately with a significant period of time elapsing between runs.  Similarly, 
T7 Shuffle® K12 transformed with pGS-21a-optVC1C2 and pGS-21a-native VC1C2 
produced prominent single bands post-induction of approximately 47 kDa and 49 kDa in 
size respectively (Figure 36). Western blot analysis demonstrated the presence of a 
strong immunoreactive band of approximately 50 kDa when probed with an anti-RAGE 
antibody, confirming the expressed protein was recombinant RAGE (Figure 36).  Rosetta-
gami, Origami™ B and T7 Shuffle® K12 were the only hosts transformed with native gene 
sequence constructs for RAGE.  The Shuffle® strain expressed canonical RAGE constructs 
at levels 4-fold, 3-fold and 0.5-fold lower than those of optimised RAGE constructs for 
VC1C2, VC1 and V, respectively (Figure 37).  Rosetta-gami™ B produced V, VC1 and VC1C2 
at levels 4-fold, 3-fold and 2-fold higher than those of its parent strain, Origami™ B 
(Table 7).  The soluble fraction of each culture following collection, sonication and 
clarification (section 2.6.3) was assayed for recombinant RAGE by ELISA (method 2.6.19).  
The BL21 strain contained most of the expressed RAGE in the insoluble fraction, with 
very low levels of recombinant protein in the soluble fraction (Table 7).  A significant 
reduction in levels of RAGE expression was observed in all strains with the deletion of C-
domains in both the native and optimised constructs (Table 7).    
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Figure 34.  Coomassie and Western blot analysis of both native and optimised 
recombinant RAGE V domain expressed in E. coli T7 Shuffle® K12. 
T7 Shuffle® K12 E. coli transformed with a) pGS-21a-optV and b) pGS-21a-nativeV were 
induced and the soluble fractions pre and post-induction induction loaded into lanes b) 
2 and 3; or a) lanes 6 and 7 of reducing SDS-PAGE gels respectively (section 2.6.1).  Gels 
a) and b) were Coomassie stained as outlines in section 2.6.17, while gel c) was 
transferred to nitrocellulose for Western blotting with an anti-RAGE antibody (NEB) as 
described in 2.6.18.  Lane 1 of each gel was loaded with a prestained broad range 
marker (Life Technologies). 
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Figure 35.  Coomassie and Western blot analysis of both native and optimised RAGE 
VC1 recombinant expression in E. coli T7 Shuffle® K12. 
T7 Shuffle® K12 E. coli transformed with a) pGS-21a-optVC1 and b) pGS-21a-nativeVC1 
were induced and the soluble fractions pre and post-induction induction loaded into 
lanes b) 2 and 3; or a) lanes 4 and 5 of reducing SDS-PAGE gels respectively (section 
2.6.1).  Gels a) and b) were Coomassie stained as outlines in section 2.6.17, while gel c) 
was transferred to nitrocellulose for Western blotting with an anti-RAGE antibody (New 
England Biolabs®) as described in 2.6.18.  Lane 1 of each gel was loaded with a 
prestained broad range marker (Life Technologies). 
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Figure 36.  Coomassie and Western blot analysis of both native and optimised RAGE 
VC1C2 domain constructs expressed in E. coli T7 Shuffle® K12. 
T7 Shuffle® K12 E. coli transformed with a) pGS-21a-optVC1C2 and b) pGS-21a-
nativeVC1C2 were induced and the soluble fractions pre and post-induction induction 
loaded into lanes 2 and 3 of reducing SDS-PAGE gels respectively (section 2.6.1).  Gels a) 
and b) were Coomassie stained as outlines in section 2.6.17, while gel c) was transferred 
to nitrocellulose for Western blotting with an anti-RAGE antibody (New England 
Biolabs®) as described in 2.6.18.  Lane 1 of each gel was loaded with a prestained broad 
range marker (Life Technologies). 
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Figure 37.  Expression of canonical and optimised RAGE gene sequences encoding 
different forms of the RAGE extracellular domains in Escherichia coli strain T7 Shuffle® 
K12 (mean ± se). 
Escherichia coli strain T7 Shuffle® K12 was transformed with pGS-21a plasmid containing 
either the canonical or optimised gene encoding human RAGE VC1C2, VC1 or V domains 
as described in (2.6.1).  Micro cultures were prepared and induced (section 2.6.2), with 
the quantity of soluble recombinant forms of each RAGE domain construct measured by 
ELISA (section 2.6.19) (n=3). 
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Table 7. The expression of endogenous and optimised human RAGE V, VC1 and VC1C2 
domain constructs in various bacterial hosts.   
Bacterial strains were transformed with either optimised or native RAGE gene sequence 
constructs, and grown to equivalent densities before being induced as described in 
section 2.6.2. Cultures were lysed by sonication and the total recombinant RAGE in the 
soluble fraction quantified by ELISA and recorded in mg/L.  See Table 8 for comparison 
with expression in insect cells. 
 
 
Optimized Sequence Native Sequence 
Host V VC1 VC1C2 V VC1 VC1C2 
T7 Shuffle® B 0.1 1.15 14.9 
   
T7 Shuffle® K 0.27 2.04 13.1 0.18 0.72 2.8 
Rosetta-gami™ B 0.04 0.71 4.4 0.04 0.7 4.1 
Origami™ B 0.09 0.96 3.725 0.02 0.21 0.9 
BL21(DE3) 0.08 0.06 0.18 
   
 
  
 Page 114 
 
As the V domain had the lowest level of expression, the T7 Shuffle® K12 strain which 
expressed this construct at levels three-times greater than all other strains, was selected 
as the preferred host for use in further RAGE expression of the V, VC1 and VC1C2 
recombinant proteins.  
3.3.7 Prokaryote expression of full length human HMGB1  
T7 Shuffle® K12 was transformed with pGS-21a-hHMGB1 and induced with IPTG as 
described in section 2.6.3.  During the course of this study, it was found that HMGB1 
was bactericidal, causing the rapid drop-off in culture growth post-induction (Figure 38).  
Comparison of induced and uninduced hHMGB1 transformants confirmed that tight 
regulation of the T7 RNA Polymerase was suppressing basal expression of hHMGB1, with 
no reduction in growth between cultures containing mock-pGS-21a transformants and 
pGS-21a-hHMGB1 (Figure 38).  The soluble fraction of samples pre and post-induction 
were collected and clarified as described in section 2.6.3.  The induced soluble fraction 
was loaded in lane 2 of a 4-12% PAGE gel, with lane 3 loaded with the un-induced 
soluble fraction of the same culture.  Coomassie staining shows the presence of a 
significant band in lane 2 of approximately 30 kDa which strongly correlates with the 
expected size of full length human HMGB1 being 28 kDa (Figure 39).  Western blotting of 
a parallel SDS-PAGE gel with an anti-HMGB1 antibody detected a single band of 
approximately 30 kDa in the post-induction soluble fraction, confirming the presence of 
full length recombinant human HMGB1 in the soluble fraction of T7 Shuffle® K12 
transformed with pGS-21a-hHMGB1.   
3.3.8 Prokaryote expression of truncated human HMGB1 
T7 Shuffle® K12 E. coli transformed with pGEX-6P1-deltaHMGB1 was induced by the 
addition of IPTG as outlined in section 2.6.5 and allowed to express for 2.5 hr.  The 
soluble fractions from this culture pre and post-induction were collected as described in 
section 2.6.3.  The presence of a protein post-induction of approximately 50 kDa in size 
was observed in a Coomassie stained SDS-PAGE gel loaded with both soluble fractions 
(Figure 40).  This correlates very closely with the expected size of truncated HMGB1 (24 
kDa) tagged with GST (25 kDa), estimated to be 49 kDa (Figure 40).   Western blotting 
with an anti-HMGB1 antibody detected a single 50 kDa band post-induction, confirming 
the expression of hHMGB1-GST.  
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Figure 38.  Growth rates of T7 Shuffle® K12 transformed with full length human 
HMGB1 pre and post induction. 
T7 Shuffle® K12 was transformed with pGS-21a-hHMGB1 containing the human HMGB1 
gene or pGS-21a without a gene insert as described in section 2.6.5.  Two cultures 
containing no insert (mock insert) and one with hHMGB1 (induced) were induced to 
express by the addition of IPTG.  A second culture transformed with HMGB1 (not 
induced) was not induced.  Growth was measured at O.D600 every hour. 
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Figure 39.  Western blot and Coomassie stain of full length human HMGB1. 
T7 Shuffle® K12 E. coli pGS-21a-hHMGB1 was induced with the addition of IPTG to 
express full length human HMGB1 (section 2.6.5).  Lane 1 contains a broad range 
molecular weight marker (Life technologies).  Soluble fractions from pre and post-
induction were loaded into lanes 2 and 3 respectively of 4-12% SDS-PAGE gels.  Gel a) 
was Coomassie stained as described in 2.6.17, with the second gel transferred to 
nitrocellulose for b) Western blotting with anti-human HMGB1 (Merck Millipore) 
(section 2.6.18).   
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Figure 40.  Western blot and Coomassie staining of truncated human HMGB1-GST. 
T7 Shuffle® K12 E. coli transformed with pGEX-6P1-deltaHMGB1 was induced for 2.5 hr 
as described in section 2.6.5 before being sonicated and clarified (method 2.6.3).  
Soluble cell fractions pre (lane 3) and post (lane 2) induction were loaded onto two 4-
12% SDS-PAGE gels and subsequently a) Coomassie stained and transferred to 
nitrocellulose for b) Western blotting with anti-human HMGB1 (Merck Millipore) 
(section 2.6.18).  Lane 1 contains a broad range molecular weight marker (Life 
technologies).   
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3.3.9 Prokaryote expression of human S100B, S100P and S100A6  
T7 Shuffle® K12 was transformed with pGS-21a-S100B, pGS-21a-S100P and pGS-21a-
S100A6 and induced to express recombinant protein as described in method 2.6.4.  
Soluble fraction aliquots from pGS-21a-S100B pre and post-induction were collected and 
clarified (section 2.6.3), before being loaded onto a 4-12% SDS-PAGE gel (Figure 41a).  A 
band approximately 10 kDa in size was visible post-induction with subsequent Western 
blotting confirming this band was immunoreactive to an anti-S100B antibody (Figure 
41b).  A second lighter band approximately 20 kDa in size also demonstrated 
immunoreactivity to the anti-S100B antibody with no other prominent band visible.  The 
pGS-21a-S100P soluble fractions pre and post-induction were similarly collected and 
loaded onto a 4-12% SDS-PAGE gel.  A very faint band was visible by Coomassie post-
induction of approximately 10 kDa, with the corresponding Western blot confirming the 
identity of this band as S100P (Figure 42b).  Again, an additional faint band was visible by 
Western blot of approximately 20 kDa in size that was not visible by Coomassie staining.  
T7 Shuffle® K12 culture transformed with pGS-21a-S100A6 was induced, lysed and 
clarified, with the subsequent pre and post-induction soluble fractions again loaded 
onto a 4-12% SDS-PAGE gel.  Following Coomassie staining, a band approximately 10 kDa 
in size was visible in the post-induction fraction (Figure 43a).  Western blotting with anti-
S100A6 antibody confirmed the identity of the induced 10 kDa band as S100A6, with a 
minor band approximately 20 kDa in size once again visible (Figure 43b).  Collectively, T7 
Shuffle® K12 transformed with these three calgranulin expression vectors and cultured 
as outlined in section 2.6.4, produced 10.6 mg/L, 14.4 mg/L and 6.9 mg/L of S100B, 
S100A6 and S100P respectively post-purification (Figure 44). 
3.4 Protein Purification  
3.4.1 Heparin chromatography of prokaryote RAGE domain constructs V, VC1 and 
VC1C2 
RAGE domain constructs V, VC1 and VC1C2 were expressed as outlined in section 2.6.1 
and the bacterial soluble fraction clarified through sonication and centrifugation as 
described in 2.6.3.  A protease inhibitor cocktail was used to minimise proteolytic 
degradation of the recombinant protein along with 0.5 mM dithiothreitol (DTT) to 
prevent oxidation of recombinant RAGE.  The soluble fraction for each domain was 
applied to a 5 mL Heparin column at 1 mL/min and the flow through collected.  Analysis   
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Figure 41. Coomassie and Western blot of prokaryote expressed recombinant human 
S100B. 
T7 Shuffle® K12 E. coli was transformed with pGS-21a-S100B and expression induced by 
the addition of IPTG (section 2.6.4). Soluble fractions collected pre (lane 2) and post 
(lane 3) induction were loaded on two denaturing 4-12% SDS-PAGE gels.  Gel a) was 
Coomassie stained while gel was transferred to PVDF membrane for b) Western blotting 
with an anti-S100B antibody (Abcam).  The first lane of each gel was loaded with a broad 
range, pre-stained molecular weight marker (Life technologies). 
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Figure 42.  Coomassie and Western blot of prokaryote expressed recombinant human 
S100P. 
S100P was recombinantly expressed in T7 Shuffle® K12 E. coli using the vector pGS-21a-
S100P (section 2.6.4).  Soluble fraction samples pre (lane 2) and post (lane 3) induction 
were collected and loaded on two identical 4-12%SDS-PAGE gels.  Gel a) was Coomassie 
stained, with gel b) Western blotted and probed with an anti-S100P antibody (Abcam). 
The first lane of each gel was loaded with a broad range, pre-stained molecular weight 
marker (Life technologies). 
  
M
o
le
cu
la
r 
W
ei
gh
t 
(k
D
a)
 
Lane 
 1 2 3  
Lane 
 1 2 3 
10 
3.5 
15 
20 
30 
40 
50 
60 
80 
110 
160 
260 
10 
15 
20 
30 
40 
50 
60 
80 
110 
160 
260 
a) b) 
 Page 121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43.  Coomassie and Western blot of prokaryote expressed recombinant human 
S100A6. 
T7 Shuffle® K12 transformed with pGS-21a-S100A6 was induced and soluble fractions 
pre and post-induction collected as outlined in section 2.6.4 and loaded into lanes 2 and 
3 respectively on two 4-12% SDS-PAGE gels.  Gel a) was Coomassie stained as described 
in section 2.6.17, while gel was transferred to a PVDF membrane and b) Western blotted 
with an anti-S100A6 antibody (Abcam) (section 2.6.18).  Both gels had a broad range 
pre-stained marker loaded in lane 1 (Life technologies). 
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Figure 44.  Yields of human S100B, S100P and S100A6 expressed in T7 Shuffle® K12 
following phenyl Sepharose® purification. 
T7 Shuffle® K12 was used as an expression host for pGS-21a-S100B, pGS-21a-S100P and 
pGS-21a-S100A6 as described in section 2.6.4.  Following induction, host cells were lysed 
by sonication and the clarified soluble fraction applied to a phenyl Sepharose® column 
(2.6.9).  Eluates were estimated to contain recombinant calgranulins at >95% purity by 
Coomassie (data not shown), with the concentration of eluates measured by modified 
Lowry (2.6.15) (n=1). 
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of the starting soluble fractions and flow-throughs by ELISA revealed approximately 80% 
of RAGE present in the bacterial lysate bound and was eluted from the heparin resin.  
Multiple elution peaks were seen in the purification of V, VC1 and VC1C2 (Figure 45, 
Figure 46 and Figure 47 respectively), correlating with the five isocratic steps of 
increasing ionic strength used for elution as outlined in section 2.6.10.  The V domain of 
RAGE eluted using 1 M NaCl (Figure 45), while VC1 and VC1C2 were eluted by 500 mM 
NaCl (Figure 46 and Figure 47 respectively).  The fractions were subsequently assayed by 
polyacrylamide gel electrophoresis, dot blot or ELISA for the presence of RAGE, with only 
those fractions containing the recombinant protein retained for further analysis.  Those 
fractions containing RAGE were subsequently applied directly to nickel Sepharose® 
without buffer exchange.  
3.4.2 Nickel chromatography of prokaryote RAGE domain constructs V, VC1 and 
VC1C2 
Recombinant V, VC1 and VC1C2 RAGE domain constructs eluted from heparin Sepharose 
were applied to a nickel HisTrap column (GE) as described in section 2.6.12 and the 
column washed to remove unbound protein.  Approximately 70% of RAGE VC1C2 eluted 
from the nickel column in fractions 17 to 19 (Figure 48) with an overall recovery of 56% 
of VC1C2 recovered in a two-step purification strategy that yielded approximately 7 mg/L 
of purified RAGE VC1C2.  Approximately 65% of RAGE VC1 present in the starting heparin 
eluate was recovered using nickel chromatography (Figure 49), with a final yield of 
approximately 1.1 mg/L of pure protein.  Approximately 70% of the heparin eluted V 
domain of RAGE was recovered in elution fractions 17-19 of the HisTrap nickel column, 
with a yield of approximately 0.2 mg/L as determined by ELISA (Figure 50).  The final 
purified V, VC1 and VC1C2 recombinant RAGE domains were estimated to be greater than 
95% pure as determined by Coomassie (Figure 51).  Following elution of bound protein, 
fractions containing RAGE were dialysed into HEPES buffered saline (HBS) in the 
presence of 2 mM EDTA.  Interestingly in the absence of EDTA, a white flocculate 
appeared in the dialysis cassettes that correlated with a loss of much of the soluble 
eluted protein.  It is reasonable to speculate that nickel ions leeching from the column 
are co-ordinating the histidine tags at the C-terminus of the eluting RAGE to promote 
aggregation.  The inclusion of EDTA to chelate any co-eluting nickel ions, followed by 
dialysis, circumvented the precipitation of the VC1C2 and VC1 domains.  The V domain 
eluate still formed a small amount of white flocculate even in the presence of EDTA, 
however, this resulted in almost no loss of protein.   
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Figure 45.  Heparin Sepharose® purification of prokaryote expressed V RAGE domain 
construct. 
T7 Shuffle® K12 E. coli expressing recombinant RAGE V domain was clarified as outlined 
in section 2.6.3.  This soluble fraction was a) applied to a Heparin HiTrap™ column (GE) 
on an AKTA Purifier FPLC (GE).  The column was washed and eluted using five isocratic 
steps with increasing salt concentrations to a maximum of 1 M NaCl as detailed in 
method 2.6.10.  The V domain was eluted in peak b) and yield determined by ELISA 
(section 2.6.19). 
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Figure 46.  Heparin Sepharose® purification of prokaryote expressed VC1 RAGE 
domain. 
The clarified soluble fraction of T7 Shuffle® K12 E. coli containing recombinant RAGE VC1 
was a) applied to a Heparin HiTrap™ column (GE) on an AKTA Purifier FPLC (GE).  The 
column was washed before bound VC1 domain RAGE was eluted in fraction b) using 
isocratic steps with a final eluting salt concentration of 1 M as detailed in method 2.6.10 
with the yield of RAGE VC1 determined by ELISA (section 2.6.19).   
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Figure 47.  Heparin Sepharose® purification of prokaryote expressed RAGE VC1C2 
domain. 
The soluble fraction of T7 Shuffle® K12 E. coli expressing recombinant RAGE VC1C2 was 
clarified as outlined in section 2.6.3 before being applied to a heparin Sepharose® HP 
column (GE) on an AKTA Purifier FPLC (GE).  The column was a) washed before bound 
RAGE was eluted in fraction b) using five isocratic salt concentrations ranging from 50 
mM to a final concentration of 1 M as detailed in method 2.6.10 with the yield of RAGE 
VC1C2 determined by ELISA (section 2.6.19).   
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Figure 48.  Nickel Sepharose® purification of 6xhis tagged prokaryote expressed VC1C2 
RAGE domains. 
Heparin Sepharose® fractions containing RAGE VC1C2 were pooled and applied to a 
Nickel Sepharose® HisTrap HP column (GE) on a Bio-Rad Biologic FPLC.  The column was 
washed and then eluted with a 250 mM imidazole buffer as described in section 2.6.12. 
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Figure 49.  Nickel Sepharose® purification of 6xhis tagged prokaryote expressed VC1 
RAGE domains. 
Heparin Sepharose® eluate containing RAGE VC1 was loaded onto a HisTrap HP column 
(GE) connected to a Bio-Rad Biologic FPLC. The column was washed and protein eluted 
using 250 mM imidazole buffer, as detailed in section 2.6.12.   
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Figure 50.  Nickel Sepharose® purification of 6xhis tagged prokaryote expressed V 
RAGE domain. 
Heparin Sepharose eluate containing V domain recombinant protein was loaded onto a 
HisTrap HP column (GE) connected to a Bio-Rad Biologic FPLC.  The column was washed 
and protein eluted using a 250 mM imidazole buffer (pH 7.4) as described in 2.6.12.   
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Figure 51.  Coomassie stain of purified recombinant V, VC1 and VC1C2 RAGE domains. 
RAGE recombinant proteins present in the soluble fractions of T7 Shuffle® K12 pre and 
post-induction was loaded into lanes 3 and 2, respectively of gels a) VC1C2, b) VC1 and c) 
V, respectively.  The recombinant proteins of each RAGE construct, purified by 
successive heparin and nickel affinity chromatography (Figure 45 to Figure 47, and 
Figure 48 to Figure 50 respectively) are shown in lane 4 of each gel.  Lane 1 of each gel 
was loaded with a prestained broad range marker (Life technologies).  All gels were run 
as described in method 2.6.16 before being Coomassie stained (section 2.6.17).  
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3.4.3 Purification of full length and truncated human HMGB1 
Full length HMGB1 in subcloned into pGS-21a was expressed in T7 Shuffle® K12, with the 
pelleted culture subsequently solubilised using perchloric acid as outlined in method 
2.6.6.  The protein retained in the acid soluble fraction was visualised on a reducing SDS-
PAGE gel and Coomassie stained to evaluate the heterogeneity of remaining protein 
(Figure 52, lane 3).  A main band of approximately 28 kDa was apparent, along with 
some minor, low molecular weight species also visible.  Subsequent size exclusion 
chromatography (SEC) of this soluble fraction demonstrated the presence of a single 
main peak collected in fractions B2 and B3 (Figure 53), with further Coomassie gel 
analysis showing a single band representing HMGB1 of greater than 95% purity (Figure 
54). Approximately 1.8 mg/L of full length HMGB1 was purified from a 1 litre starting 
culture. 
Truncated human HMGB1 (ΔHMGB1) was kindly provided by the Rauvala laboratory, 
Helsinki and is the only recombinant protein not expressed using vector pGS-21a.  
Following induction for 2.5 hours, T7 Shuffle K12 transformed with pGEX-6P1-
deltaHMGB1 was sonicated and the soluble fraction clarified as described in 2.6.3.  A 
1mL GSTrap column was connected to a Bio-Rad Biologic FPLC before loading the soluble 
fraction and continuing to wash the column until all unbound protein was eluted.  The 
system was paused (Figure 55a) and the GSTrap column carefully removed for the 
addition of protease.  This disconnection is reflected by an upward shift in the 
absorbance base line.  Following cleavage of the GST tag as described in section 2.6.13, a 
number of fractions were collected, with fraction 18 containing a large peak (Figure 55) 
shown to mostly consist of a single protein approximately 24 kDa in size (Figure 56), as 
visualised by Coomassie stain on a reducing gel. This fraction was further purified by 
perchloric acid extraction (section 2.6.6) and loaded alongside T7 Shuffle® K12-ΔHMGB1 
samples pre and post-induction (Figure 57).  Figure 57, lane 4 showed the presence of 
ΔHMGB1, with the minor bands previously seen no longer visible.  Approximately 2.4 
mg/L of ΔHMGB1 was purified from a 1 litre starting culture (Figure 58). 
3.4.4 Purification of S100B, S100P and S100A6 
Baudier et al (1982) reported the use of phenyl Sepharose® for the selective purification 
of S100B through the use of zinc dications to induce conformational change that enable 
some calgranulins to bind hydrophobic moieties.  T7 Shuffle® K12 was used to express  
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Figure 52.  Perchloric acid purification of full length HMGB1. 
T7 Shuffle® K12 transformed with pGS-21a-hHMGB1 was induced to express full length 
HMGB1.  An aliquot of total protein in the induced culture immediately prior to acid 
solubilisation is shown in lane 2, with a broad range molecular weight marker present in 
lane 1 (Life technologies). The culture was pelleted and solubilised in perchloric acid as 
described in section 2.6.6.  The soluble fraction was loaded in lane 3 and the SDS-PAGE 
gel Coomassie stained (section 2.6.17). 
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Figure 53.  Purification of full length HMGB1 by size exclusion chromatography. 
Perchloric acid purified HMGB1 was titrated back to pH 7-7.4 and concentrated to 0.5 
mL.  The HMGB1 fraction was applied to a HiPrep 16/60 Sephacryl S-200 (GE) on an 
AKTA Purifier (GE) and fractionated as described in section 2.6.11. 
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Figure 54.  Coomassie stain of purified full length human HMGB1. 
Recombinant HMGB1 was expressed by T7 Shuffle® K12.  Soluble fractions pre and post 
induction were loaded in lanes 2 and 3, respectively. HMGB1 purified by successive 
perchloric acid and size exclusion steps (Figure 52 and Figure 53 respectively) is shown in 
lane 4.   A molecular weight marker was loaded in lane 1 (Life technologies).  The 
samples were run on a reducing SDS-PAGE gel and Coomassie stained as described in 
section 2.6.17.  
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Figure 55.  Glutathione affinity chromatography and on-column cleavage of 
recombinant truncated human HMGB1-GST. 
T7 Shuffle® K12 transformed with pGEX-6P1-deltaHMGB1 was induced as outlined in 
section 2.6.5. The soluble fraction was applied to a GSTrap™ HP column on a Bio-Rad 
Biologic FPLC and washed until the 280 nm absorbance was steady.  The system was 
paused a) and PreScission Protease manually injected onto the column.  A HisTrap 
column was connected in series to the end of the GSTrap column and the two columns 
re-connected to the FPLC to incubate for 4 hours at 4°C (section 2.6.13).  The wash was 
then resumed and the eluates collected.  
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Figure 56.  Glutathione chromatography eluates containing truncated HMGB1. 
GSTrap HP fractions 16-20 (Figure 55) were run on a 4-12% SDS-PAGE reducing gel in 
lanes 3-7 respectively, before being Coomassie stained (section 2.6.16).  A broad range 
molecular weight marker was loaded in to lane 1 (Life technologies). 
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Figure 57.  Coomassie stain of purified truncated human HMGB1. 
Truncated HMGB1 was expressed by T7 Shuffle® K12 using pGEX-6P1-deltaHMGB1, with 
samples pre and post induction loaded in lanes 2 and 3 of an SDS-PAGE gel respectively.  
Fractions 19 and 20 from GST affinity chromatography (Figure 56) were pooled, 
perchloric acid purified as outlined in section 2.6.6, and loaded into lane 4.  The samples 
were run on a reducing SDS-PAGE gel with a broad range molecular weight marker in 
lane 1 (Fermentas) and Coomassie stained as described in section 2.6.17.  
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Figure 58.  Yields of full length HMGB1 and truncated HMGB1 from T7 Shuffle® K12 
following acid precipitation of the host. 
T7 Shuffle® K12 was used as an expression host for pGS-21a-hHMGB1 (full length) and 
pGEX-6P1-deltaHMGB1 (truncated).  Following induction, cells were harvested and 
solubilised using 6% perchloric acid as described in section 2.6.6.  The clarified, soluble 
fraction was titrated back to pH 7-7.4 and protein content estimated by the Bradford 
method (2.6.14) (n=1).  
 
  
R
e
co
m
b
in
an
t 
p
ro
te
in
 e
xp
re
ss
ed
 (
m
g/
L)
 
 Page 139 
 
S100B, S100P and S100A6 as described in section 2.6.4. The clarified soluble fractions 
were purified by phenyl Sepharose® chromatography (Figure 59 to Figure 61) on a Bio-
Rad Biologic FPLC as described in section 2.6.9.  All three calgranulins eluted in the 
presence of wash buffer containing 2.5 mM EGTA (buffer B) and appeared as single 
peaks in fraction 17 for both S100B (Figure 59) and S100P (Figure 60), with S100A6 
eluting as part of a large single peak across fractions 17 and 18 (Figure 61).  The flow-
through and fraction 17 of the S100B and S100P phenyl Sepharose® eluates was run on 
an SDS-PAGE and Coomassie stained as described in section (2.6.17).  A single band of 
approximately 10 kDa in size was visible in the fraction 17 eluates for both S100B (Figure 
62a) and S100P (Figure 62b), with no equivalent band present in either flow-through.  
Similar Coomassie staining of S100A6 phenyl Sepharose® samples (Figure 62c), did show 
the presence of a notable 10 kDa band in the flow-through, along with a prominent 
single protein of the same size in fraction 17.  This likely indicates saturation of the 
phenyl Sepharose® resin.  The binding capacity for phenyl Sepharose® CL-4B varies 
between 5-20 mg/mL of resin depending on the protein species bound.  It is likely that 
for calgranulins, the binding capacity is approximately 14 mg/mL.  The concentration of 
each purified calgranulin was 10.6 mg/L, 14.4 mg/L and 6.9 mg/L respectively as 
determined by the Bradford assay (section 2.6.14). 
3.5 Protein Purification and Function 
3.5.1 Binding of insect and bacterial expressed RAGE recombinant domain 
constructs to ribose-AGE 
A novel assay was developed to evaluate whether RAGE constructs expressed in insect 
cells were able to bind one of their key ligands, ribose-AGE (section 2.7.1).  Briefly, 
ribose-AGE was adsorbed onto NUNC Maxisorp plate well walls with unabsorbed surface 
subsequently blocked with a PBS + casein solution.  Conditioned media from insect cells 
stably secreting RAGE V, VC1 and VC1C2 was added to the wells in triplicate and allowed 
to bind to the ribose-AGE.  The media was removed and free RAGE removed by gentle 
washing of the wells with PBS+casein.  Anti-RAGE antibody conjugated to horse radish 
peroxidase (HRP) was used to detect bound RAGE, with free antibody removed by gentle 
washing.  The amount of antibody present was determined in a similar manner to an 
ELISA, using a TMB HRP substrate mixture to generate a chromogen.  The amount of   
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Figure 59.  Phenyl Sepharose® purification of S100B. 
Human S100B was expressed in T7 Shuffle® K12 and the soluble fraction clarified as 
described in section 2.6.3.  Calcium chloride was added to the soluble fraction for a final 
working concentration of 5 mM and the solution applied to a 1 mL phenyl Sepharose® 
column at 0.25 mL/min as described in section 2.6.9.  The column was washed and 
eluted with a) 100% buffer B (wash buffer containing 2.5 mM EGTA) as described in 
section 2.6.9. 
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Figure 60.  Phenyl Sepharose® purification of S100P. 
Human S100B was expressed in T7 Shuffle® K12 and the soluble fraction clarified as 
described in section 2.6.3.  Calcium chloride was added to the soluble fraction for a final 
working concentration of 5 mM and the solution applied to a phenyl Sepharose® column 
as described in section 2.6.9.  The column was washed and eluted with a) 100% buffer B 
(wash buffer containing 2.5 mM EGTA) and fractions collected as described in section 
2.6.9. 
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Figure 61.  Phenyl Sepharose® purification of S100A6. 
T7 Shuffle® K12 transformed with pGS-21-S100A6 was induced and the clarified soluble 
fraction supplemented with a working concentration of 5 mM CaCl2.  This sample was 
immediately applied to a phenyl Sepharose® column as described in section 2.6.9.  The 
column was washed and eluted with a) 100% buffer B (wash buffer containing 2.5 mM 
EGTA), with fractions collected as described in section 2.6.9. 
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Figure 62.  Phenyl Sepharose® purified S100B, S100P and S100A6. 
a) S100B, b) S100P and c) S100A6 fractions from phenyl Sepharose® (Figure 59 to Figure 
61 respectively), were loaded onto a reducing 4-12% SDS-PAGE gel.  Lanes 2 on each gel 
was loaded with a sample of flow through, alongside fraction 17 in lane 3.  A broad 
range marker was loaded in lane 1 of each gel ( a) and b) Life technologies, c) 
Fermentas) and run as outlined in section 2.6.16, before being Coomassie stained 
(method 2.6.17). 
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chromogen generated was proportional to the amount of bound RAGE and was 
measured at 450 nm spectrophotometrically.  Both RAGE VC1 and VC1C2 expressed in 
insect and prokaryotic hosts bound in a concentration dependent manner with a 
saturation effect at the higher concentrations of RAGE suggesting specificity of binding 
to ribose-AGE (Figure 63, Figure 64).  Insect expressed RAGE VC1C2 (KD ≈ 58nM ± 11nM) 
(Figure 63a) and VC1 (KD ≈ 71nM ± 13nM) (Figure 63b), bound ribose-AGE with slightly 
higher affinities than the corresponding prokaryote expressed VC1C2 (KD ≈ 80nM ± 
13nM) (Figure 64a) and VC1 (KD ≈ 89nM ± 28nM) (Figure 64b); however the differences 
are not statistically significant.  The V domain expressed by both insect (Figure 63c) and 
bacterial hosts (Figure 64c), did demonstrate a concentration effect, however, affinities 
were in the micromolar molar range (KD ≈ 1.6-4.3 µM) with ambiguous fits.  The 
interaction was specific for RAGE binding to ribose AGE as there was no demonstrable 
binding in any of the control wells (data not shown).  
3.5.2 Binding of insect expressed RAGE recombinant domain constructs to ribose-
AGE 
Calgranulins S100B, S100P and S100A6 were expressed in T7 Shuffle® K12 and purified 
as described in section 2.6.9.  Calcium  chloride  was  added  to stock solutions of each 
S100 and left to form multimeric homodimers, before being used to coat the wells of a 
96-well NUNC MaxiSorp® T7 Shuffle® K12 RAGE VC1C2 bound all immobilised S100 
proteins in a dose dependent, saturable manner (Figure 65) using the novel plate based 
binding assay described in section 2.7.1.  Nonlinear regression analysis using the least 
squares fitting method, along with Scatchard  analysis of S100B-VC1C2 (Figure 65a), 
S100P-VC1C2 (Figure 65b) and S100A6-VC1C2 (Figure 65c), generated estimates of affinity 
in the order of KD ≈ 36.3 ± 22 nM, KD ≈ 19.8 ± 6 nM and KD ≈ 154 ± 41 nM respectively.  
All Scatchard insets had an approximate y value of 6 when x=0, indicating that all wells 
were evenly coated with their respective S100 molecules. 
3.5.3 Binding of bacterial expressed recombinant RAGE domain constructs V, and 
VC1C2 to HMGB1 
Purified HMGB1 expressed in T7 Shuffle® K12 was absorped to the surface of NUNC 
MaxiSorp wells overnight as described in section 2.7.1.  Purified V and VC1C2 RAGE 
expressed in the T7 Shuffle® K12 host, along with VC1C2 produced in Tn5 insect cells was 
serially  diluted  as described  in section 2.7.1 and added to  the  plate  in triplicate, along   
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Figure 63.  Microtitre plate binding assay of insect expressed RAGE V, VC1 and VC1C2 to 
ribose-AGE (mean ± se). 
Culture media conditioned by Tn5 insect cells and containing secreted human RAGE a) 
VC1C2, b) VC1 or c) V recombinant forms, was added to wells on a 96-well NUNC 
Maxisorp microplate coated with ribose-AGE at various concentrations (section 2.7.1).  
The ribose-AGE - RAGE interaction was allowed to reach equilibrium, before the media 
was aspirated (section 2.7.1).  Bound RAGE was measured as described in section 2.7.1 
and GraphPad Prism used to generate a non-linear regression and Scatchard plot 
(insets).  Three replicates per concentration were used.  
Construct: VC1C2 
KD : 58 ± 11.68 nM 
a) 
b) 
c) 
Construct: VC1 
KD : 71.6 ± 13.9 nM 
Construct: V 
KD : 1600 ± 5500 nM (Ambiguous) 
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Figure 64.  Microtitre plate binding assay of prokaryote expressed RAGE V, VC1 and 
VC1C2 to ribose-AGE (mean ± se). 
Human RAGE domains a) VC1C2, b) VC1 and c) V, and were expressed in T7 Shuffle® K12 
as described in section 2.6.1.  Serial dilutions of each form of recombinant RAGE was 
added in series to wells on a 96-well NUNC Maxisorp microplate coated with ribose-AGE 
(section 2.7.1).  The ribose-AGE - RAGE interactions came to equilibrium and free RAGE 
removed by washing before bound RAGE was measured as described in 2.7.1.  The data 
was fitted by non-linear regression and Scatchard analysis (inset) in GraphPad Prism 
using three replicates per concentration.   
a) 
b) 
c) 
Construct: VC1C2 
KD : 79.8 ± 13.78 nM 
Construct: VC1 
KD : 88.9 ± 28.7 nM 
Construct: V 
KD : 4.3 ± 64 µM (Ambiguous) 
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Figure 65.  Microtitre plate binding assay of prokaryote expressed RAGE VC1C2 to 
S100B, S100P and S100A6 (mean ± se). 
Prokaryote expressed RAGE VC1C2, was serially diluted and added to a 96-well 
microplate coated with a) S100B, b) S100P or c) S100A6 (section 2.7.1).  The S100-RAGE 
interaction was allowed to reach equilibrium as described in section 2.7.1 before the 
media was aspirated.  Bound RAGE was measured as described in 2.7.1 and the data 
fitted by non-linear regression and Scatchard analysis (inset) in GraphPad Prism using 
three replicates per concentration.  
a) 
b) 
c) 
Ligand: S100B 
KD : 36.3 ± 22 nM 
Ligand: S100P 
KD : 19.8 ± 6 nM 
Ligand: S100A6 
KD : 154 ± 41 nM 
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with RAGE ELISA standards.  The binding of RAGE to HMGB1 was evaluated by nonlinear 
regression and Scatchard analysis, returning estimates of affinity for V, and VC1C2 of KD ≈ 
486 ± 845 nM and KD ≈ 58.6 ± 19 nM; with insect VC1C2 binding HMGB1 with a KD ≈ 64.3 
± 14 nM.  There was no statistically significant difference in the affinity of interaction 
between VC1C2 expressed in bacterial or Tn5 for HMGB1 (p=0.9425, two-tailed t-test).  
The V domain bound with approximately 8-fold lower affinity (KD ≈ 486 ± 845 nM) than 
bacterial VC1C2, which is statistically significant (p=0.045, two-tailed t-test) (Figure 66c).  
The x-axis intercept at y=0 for all three Scatchard plots was consistent (Figure 66), 
indicating the wells were evenly coated and the interaction was specific for HMGB1. 
3.5.4 Circular dichroism (CD) of prokaryote expressed RAGE VC1V2 and full length 
HMGB1  
Purified VC1C2 is the most complex of the three RAGE domain constructs, having three 
intra-domain disulphide bonds and three immunoglobulin type domains requiring 
correct folding.  HMGB1 is also a complex protein comprising two boxes and highly 
charged acidic tail and basic region.   Therefore, circular dichroism was completed as 
described in section 2.7.2 with the subsequent spectra (Figure 67a) analysed using the 
circular dichroism online analysis program DichroWeb.  Both RAGE and HMGB1 
appeared to be largely -helical dominated proteins with significant unordered 
components (Figure 67 and Figure 68, respectively). 
3.5.5 Surface plasmon resonance analysis (SPR) of RAGE VC1 binding to beta-amyloid 
1-42 
RAGE binds amyloids and, in particular, is reported to interact with β-amyloid (Aβ1-42) 
to progress a range of inflammatory diseases (Lue et al., 2001a; Yan et al., 1996; Wilson 
et al., 2009; Sturchler et al., 2008; Origlia et al., 2008).  Lyophilised synthetic Aβ1-42 
peptide was reconstituted using a method that resuspends the peptide in its monomeric 
form in solution (section 2.7.3).  Monomeric Aβ1-42 was immediately immobilised on 
the surface of a CM5 chip (GE) at very low levels to prevent on-chip aggregation.  To 
confirm Aβ1-42 was accessible, an anti- Aβ1-42 antibody was passed across the chip 
surface, binding with an estimated KD ≈ 0.5nM using a 1:1 Langmuir fit (Figure 69a).  
Purified bacterial VC1C2 was subsequently passed across the chip surface using a single-
cycle methodology (section 2.7.5) and the affinity of interaction estimated using a two-
state model (Figure 69b).  The RU range over which binding was observed is very small 
due to the diffuse loading of peptide to minimise on-chip aggregation of A    
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Figure 66.  Microtitre plate binding assay of V, VC1 and VC1C2 RAGE domains with 
HMGB1 (mean ± se). 
A 96-well NUNC Maxisorp microplate was coated with HMGB1 before serial dilutions of 
a) insect and b) prokaryote expressed VC1C2 and c) prokaryote expressed V-domain were 
added and allowed to reach binding equilibrium (section 2.7.1). Unbound RAGE was 
removed by washing and bound RAGE measured as described in 2.7.1. Data fitted by 
non-linear regression and Scatchard analysis (inset) in GraphPad Prism using three 
replicates per concentration.  
Ligand: HMGB1 
Receptor: VC1C2
Tn5 Insect 
KD : 64.3 ± 14 nM 
a) 
Ligand: HMGB1 
Receptor: VC1C2
Prokaryotic 
KD : 58.6 ± 19 nM 
b) 
Ligand: HMGB1 
Receptor: VProkaryotic 
KD : 486 ± 845 nM 
c) 
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Figure 67.  Circular dichroism profile of prokaryote expressed RAGE VC1C2. 
The secondary structure composition of purified RAGE VC1C2 was determined by circular 
dichroism as described in section 2.7.2.  The spectral profile a) was analysed using 
DichroWeb to estimate the α-helix, β-sheet, turn and unordered composition a) (in 
collaboration with Wresti Anggayasti). 
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Figure 68.  Circular dichroism profile of prokaryote expressed human HMGB1. 
The a) CD spectra of purified HMGB1 was determined by circular dichroism at 25°C as 
described in method 2.7.2 and compared to the b) CD spectra of HMGB1 published by 
Belgrano et al (2013). c) The secondary structure composition was determined using 
DichroWeb (section 2.7.2) (in collaboration with Wresti Anggayasti). 
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Figure 69.  Single-cycle kinetic evaluation of prokaryote expressed RAGE VC1 binding to 
immobilised beta amyloid 1-42. 
Beta amyloid was prepared as described in 2.7.3 and immediately immobilised as ligand 
on Fc 4 of a CM5 chip (GE Healthcare).  a) Anti Aβ1-42 antibody was used to confirm 
availability of the immobilised β-amyloid1-42 for binding with b) serial dilutions of RAGE 
VC1 passed across flow cells 3 and 4 at 30 µL/min using a single-cycle method to 
determine kinetics of interaction.  
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Despite this, an estimate of affinity of KD ≈ 0.9 nM was calculated with an acceptable 
Chi2 value of 0.02 (Figure 69b).  The binding was specific as demonstrated by an absence 
of binding to a control flow cell immobilised with a randomly scrambled Aβ1-42 peptide.  
These controls were subtracted from the response flow cells in the analysis of binding. 
3.5.6 Surface plasmon resonance analysis (SPR) of RAGE VC1 binding to ribose-AGE  
The binding of Tn5 insect or T7 Shuffle® K12 expressed VC1 to ribose-AGE was 
investigated through the use of surface plasmon resonance.  Briefly, VC1 was passed 
across the chip surface and captured by an immobilised V5 antibody as described in 
section 2.7.4.  Ribose-AGE was passed across the surface at a range of concentration 
using a multicycle methodology (section 2.7.5).  Evaluation of the kinetics of interaction 
of the Tn5 derived VC1 with a 1:1 Langmuir model  did not best describe the observed 
binding data, with a Chi2 of 0.38 (Figure 70a).  Further analysis using BIAevaluation 4.0 
(GE) to fit a custom tetrameric analyte model yielded an affinity estimate of KD ≈ 1.9 µM 
and a much smaller Chi2 of 0.1 (Figure 70b).  The same tetrameric model was fitted to 
the observed binding between bacterial VC1 and ribose-AGE to produce an estimate of 
KD ≈ 1.16 µM which is not significantly different from that observed for insect VC1 
(p=0.31 two-tailed t-test) (Figure 71).  This estimate of affinity only describes the first 
encounter binding event, with subsequent interactions not contributing additional 
response units. The drifting baseline was approximately 0.6 RU/min and was a result of 
RAGE dissociating from the immobilised anti-V5 antibody. 
3.5.7 Surface plasmon resonance analysis (SPR) of HMGB1-RAGE and HMGB1-DNA 
binding.  
Full length human HMGB1 was immobilised on the surface of a CM5 chip as described in 
section 2.7.4.  A single-cycle method of kinetic evaluation was used to measure the 
binding of pBluescript II KS(–) (analyte) as archetypal DNA to immobilised HMGB1.  
Applying five increasing concentrations of analyte to HMGB1 produced a response that 
was best described by a 1:1 Langmuir model of binding with a KD ≈ 3.1 pM and Chi
2 of 
0.02 using Biaevaluate 4.0 (GE) (Figure 72).  Following regeneration of the chip (section 
2.7.5), a multicycle analysis of bacterial produced VC1C2 binding to the immobilised 
HMGB1 was carried out, with a two-state model estimate of KD ≈ 54 nM providing the 
best fit to the observed data (Figure 73).    
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Figure 70.  Multi-cycle surface plasmon resonance analysis of insect expressed RAGE 
VC1 binding to ribose-AGE with different models of interaction. 
RAGE VC1 conditioned insect cell media was captured at the surface of a CM5 chip by 
immobilised anti-V5 antibody on a Biacore 3000 instrument (GE Healthcare) (section 
2.7.4). Ribose generated AGE molecules were subsequently passed across the cells and 
following the association and dissociation phases of each cycle, the chip surface was 
regenerated.  Analysis of the multi-cycle kinetic response was done using Biaevaluate 
software to fit a) 1:1 Langmuir model and b) a tetrameric ligand model used to best fit 
the interaction of ribose-AGE with immobilised RAGE VC1.  
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Figure 71.  Multi-cycle surface plasmon resonance analysis of prokaryotic expressed 
RAGE VC1 binding to ribose-AGE with a tetrameric model of interaction. 
Monoclonal anti-V5 antibody was immobilised onto the surface of a CM5 chip, using a 
Biacore 3000 instrument (GE Healthcare) (section 2.7.4).  Conditioned insect cell media 
was passed across the chip surface and RAGE VC1 captured by immobilised antibody.  
Ribose generated AGE molecules were subsequently passed across the cells and 
following the association and dissociation phases for each concentration, the chip 
surface was regenerated as described in section 2.7.5.  Analysis of the multi-cycle kinetic 
responses was done using Biaevaluate 4.0 (GE) software and a tetrameric model used to 
best fit the interaction of ribose-AGE with immobilised RAGE VC1.  
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Figure 72.  Single-cycle surface plasmon resonance analysis of prokaryote expressed 
human HMGB1 - DNA kinetics of interaction. 
Prokaryote expressed human HMGB1 was immobilised on a CM5 chip (GE) using a T200 
Biacore as described in section 2.7.4, with increasing concentrations of pBluescript II 
KS(–) cloning vector passed across the chip surface at 30 µL/min. The kinetics of 
interaction was measured using a T200 Biacore applying a single-cycle kinetics method, 
with the response file analysed using Biaevaluate 4.0 (GE) (collaboration with Wresti 
Anggayasti). 
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Figure 73.  Multicycle kinetics of human HMGB1 interacting with prokaryote expressed 
RAGE VC1C2. 
Prokaryote expressed human HMGB1 was immobilised on a CM5 chip (GE) using a 
Biacore T200 instrument (GE Healthcare) (section 2.7.4).  Multiple cycles with different 
concentrations of prokaryote expressed RAGE VC1C2 were performed with the chip 
surface regenerated between cycles as outlined in section 2.7.5.  Binding was measured 
as response units over time with the result file analysed using BIAevaluation 4.0 (GE).  A 
1:1 Langmuir binding model was fitted with the residuals indicating quality of fit. 
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4.0  DISCUSSION 
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4.1 Recombinant Protein Expression – The past, the present and the future 
In 1978, somatostatin was the first recombinant protein to be manufactured through 
biotechnology (Itakura et al., 1977).  Since these early days of recombinant gene 
technology, broad leaps have been made in both our understanding of the microbial 
factories used and the underlying genetic and proteomic characteristics required for 
successful protein expression.  
The post-genomic era has placed increasing demands on protein expression 
methodologies and techniques where little may be known about a protein targeted for 
heterologous expression.  Traditional approaches become onerous where a large 
number of alternate constructs, vectors, hosts and tags need to be developed and 
evaluated.  This has seen the development of rational approaches that leverage the 
emerging field of biostatistics and systems based analysis of likely outcomes 
(Papaneophytou and Kontopidis, 2014; Carinhas et al., 2012).  Multi-parallel protein 
expression is a high throughput empirical method for the evaluation of two or more host 
types, gene assemblies, expression conditions and platforms such as TOPO, Gateway™ 
or whole-gene synthesis (Hunt, 2005). 
Bacterial systems are still considered the work horse organism of recombinant protein 
expression due to its unparalleled growth kinetics, with a doubling time of about 20 
minutes in optimal environmental conditions (Rosano and Ceccarelli, 2014; Sezonov et 
al., 2007). Today, a wide selection of organisms, molecular tools and technologies are 
commercially available for the production of recombinant proteins in both prokaryote 
and eukaryote hosts, with the choice of system often defined by the protein of interest 
and its intended use (Sahdev et al., 2008).  Escherichia coli mediated protein expression 
is perhaps the host most commonly used for first expression screens due to low costs, 
simplicity of manipulation and speed of production (Rosano and Ceccarelli, 2014).  
Where the target protein is complex in its assembly or structure, multi-domained, post-
translationally modified or if prokaryote yields are low or of poor quality, then 
eukaryotic systems such as baculoviral insect expression are frequently used. 
Much of the early work investigating the role and function of the Receptor for Advanced 
Glycation End-products (RAGE) from 1996 through to 2005, utilised protein expressed in 
Sf9 insect cells using a baculoviral system (Hofmann et al., 1999; Park et al., 1998; 
Valencia et al., 2004).  However, some groups preferred to purify RAGE from animal 
tissue including mouse and bovine lung due to questions as to the quality of 
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recombinantly expressed human RAGE, and the role of post-translational modifications 
such as N-linked glycans in RAGE biology (Srikrishna et al., 2002; Hanford et al., 2004).  A 
myriad of RAGE ligands such as S100 and HMGB1 proteins were also produced in a range 
of hosts including various prokaryote and insect cell systems (Huttunen et al., 2000; 
Fages et al., 2000; Park et al., 1998; Arumugam et al., 2004). This heterogeneity of RAGE 
receptor/ligand combinations that have been used adds to the complexity of data 
interpretation and raises some concern as to whether or not some observations are 
truly reflective of the endogenous RAGE-ligand paradigm.  Indeed, estimates of 
ligand/receptor affinity and pathophysiological outcomes vary significantly between 
studies (Srikrishna et al., 2010; Hofmann et al., 1999; Leclerc et al., 2009; Xie et al., 
2007; Dattilo et al., 2007; Valencia et al., 2004).  Further confounding the myriad of 
ligand/receptor combinations in use is the discovery that RAGE not only has a number of 
alternative splice variants, but polymorphisms and post translational modifications 
influencing its structure and function (Hudson et al., 2008a).  The efficacy and 
complexity of assays used to verify functionality of the recombinant RAGE isoforms is 
also broad and inconsistent across the field. Radiolabelled ligand/receptor competition 
and saturation binding assays, luminescence and fluorescence imaging, quenching and 
proximity based assays utilising chimeric RAGE alongside surface plasmon resonance are 
just some of the techniques reported (Srikrishna et al., 2010; Hofmann et al., 1999; 
Leclerc et al., 2009; Xie et al., 2007; Dattilo et al., 2007; Valencia et al., 2004).    This 
added complexity to unravelling the intimate interactions of RAGE with its ligands 
means that 20 years after its discovery, our understanding of RAGE and the physiological 
consequence of its activation is far from complete. 
This project set out to address this complexity by undertaking a multi-parallel protein 
expression pathway, evaluating the emergent method of stable insect cell expression 
against traditional prokaryote protein expression.   
Since all insect expressed RAGE has been previously produced using lytic baculoviral 
systems, this project set out to address some fundamental questions: 
1. Is a plasmid based insect expression system able to produce recombinant RAGE 
with a greater degree of protein homogeneity in terms of post-translational 
modifications than the published lytic systems? 
2. Can a non-lytic, non-viral system produce suitable quantities of RAGE for future 
structural, functional or in vivo studies? 
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3. Are there differences in yields based upon insect cell types or culture methods 
and conditions? 
A number of E. coli strains optimised for recombinant protein expression are 
commercially available, however, few have been used for the expression of RAGE.  This 
is likely due to, in part, the challenges of expressing proteins containing complex 
immunoglobulin type domains such as those found in RAGE (Papaneophytou and 
Kontopidis, 2014; Rosano and Ceccarelli, 2014).  
This project further investigated the suitability of prokaryote strains traditionally used to 
express RAGE and two additional strains with greater degrees of modification to support 
heterologous protein expression.  The primary considerations around the prokaryote 
expression systems used include: 
1. Whether functional forms of the RAGE V, VC1 and VC1C2 extracellular domains 
are expressed by the prokaryotic host. 
2. Which strain characteristics lead to the highest yields in terms of quality and 
quantity of protein produced. 
4.2 A Monk and Two Peas | Construct Development 
Gregor Johan Mendel is often claimed as the father of modern genetics, heralding in the 
era of hereditable traits and the concept of a genetic legacy possessed by all living 
things.  Today, our knowledge of genetics is continuing to expand with an increasingly 
complex arsenal of technologies and molecular machinery that is enabling our ability to 
translate genes into proteins. 
RAGE is located near the junction of the major histocompatibility complex classes II and 
III on chromosome 6 and possesses the high variability in alternate splice variants 
common to many genes within this region (Sugaya et al., 1994; Park et al., 2004a; 
Hudson et al., 2008a).  To study the protein outcomes of this variability, we require 
accurate, agile and dynamic strategies for the production of gene constructs that encode 
and express these alternate isoforms.  Hudson et al (2008) characterised and expressed 
a number of these spliced variants in HEK293 cells using a recombinatorial 
topoisomerase (TOPO) system.  Considerations surrounding the use of TOPO vectors 
included the cost of TOPO expression plasmid conversion, whether to use a blunt-end, 
TA overhang or directional insert, and the size of the gene insert, with poor 
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incorporation rates for inserts over 1500bp (Hunt, 2005).  Other rapid recombinant 
technologies are available such as Gateway and Univector to name a few; however, the 
vast majority of RAGE constructs reportedly used over the last 20 years leverage 
traditional sub-cloning methodologies (Park et al., 2004a; Park et al., 2010; Xie et al., 
2008; Wilton et al., 2006; Ostendorp et al., 2007).  
4.2.1 Insect expression vector development 
In this project, an alternative system not previously reported for the expression of RAGE 
was used that leverages both a rapid recombinant clone-in mechanism (TOPO), and the 
non-lytic, non-viral stable insect expression plasmid pIB/V5-HIS TOPO (Invitrogen™).   
The VC1C2 domains of an open reading frame (ORF) clone of human RAGE was amplified 
by PCR and ligated into Gateway pENTR-SD/D-TOPO and pIB/V5-HIS TOPO (Figure 12 - 
Figure 14).  Although expensive to initially purchase, both TOPO based expression 
systems were fast and simple to use.  The Gateway vector had good TOPO incorporation 
of RAGE V, VC1 and VC1C2 PCR products, however, the inserts were not successfully 
recombined into the destination vector pYES2-DEST52 despite considerable 
troubleshooting and effort.  Alternatively, RAGE V, VC1 and VC1C2 were successfully 
recombined into the pIB/V5 expression plasmid which was selected as the preferred 
vector for RAGE expression. 
It was expected that the smallest V RAGE domain construct would yield the highest rate 
of incorporation, with decreasing rates of success as inserts increased in size (Litterer, 
2009).  Although the transformation efficiency for RAGE V was high, only 7% of colonies 
screened contained the insert in the correct orientation (section 3.1.4). Although no 
secondary DNA structures, palindromic sequences or other gene elements were 
identified, there is clearly an unknown association or element promoting the 
unfavourable orientation of the insert to the vector (Reuter and Mathews, 2010).  The 
VC1 and VC1C2 DNA fragments did adhere to the established TOPO dogma of decreasing 
transformation efficiencies with increasing insert size.  Interestingly, the frequency of 
correctly orientated inserts varied greatly between the VC1 and VC1C2 construct - 42% 
and 4% respectively (3.1.4).  This is potentially due to inserts forming non-linear 
structures that obscure either the 3’ or 5’ ends.  In lieu of this observation, care should 
be taken in the future to utilise directional overhangs in similar rapid recombination 
systems to ensure efficiency of ligation and transformation.  Despite these challenges, 
the amount of time from PCR amplification to the propagation of insect plasmid 
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expression vectors containing human RAGE V, VC1 and VC1C2 ready for transfection, was 
a matter of days.  Traditionally, baculoviral systems take weeks to complete homologous 
recombination and viral assembly, plaque selection, purification and production of viral 
progeny per construct (Kitts and Possee, 1993; Jarvis, 2009; Rosano and Ceccarelli, 
2014).   
With the exception of two research groups reporting the use of TOPO vector systems, 
there are no groups we are aware of that have expressed RAGE using a rapid TOPO 
recombinant expression vector for insect cells (Hudson et al., 2008a; Monteiro et al., 
2006).  In contrast to Sf9-baculoviral expression traditionally used in RAGE research, this 
study reports the successful production of multiple RAGE insect expression vectors in 
quick succession. The plasmid based TOPO insect expression system used here 
represents a simple, one-step means of generating multiple expression vectors for the 
production of recombinant RAGE. 
4.2.2 Bacterial expression vector development 
The use of prokaryotic systems to produce RAGE for functional and physiological 
investigations increased in popularity from 2004 onwards.  Despite the significant body 
of research relating to RAGE since this time, there is no definitive methodology that 
defines which strains, vectors or residues are optimal for the expression of RAGE V, VC1 
and VC1C2 in E. coli.  Wilton et al (2006) described the bacterial expression of 
recombinant VC1C2 RAGE (a.a 23-340) using pASK40, which traffics expressed protein to 
the periplasmic domain of gram-positive hosts by incorporating an OmpA signal peptide 
at the N-terminus of recombinant proteins. This vector has been used to successfully 
express other proteins with immunoglobulin type variable domains similar to those 
found in RAGE (Stevens et al., 1995; Raffen et al., 1998).  Today, there are a number of 
techniques that enable the targeting of recombinant protein to a range of bacterial 
compartments.  The oxidizing potential and chaperones of the bacterial periplasmic 
space were utilised by Wilton et al (2006) to ensure that the internal disulphide bonds of 
expressed RAGE were not reduced (Schmidt et al., 1998).  In contrast, we expressed 
RAGE using prokaryotic strains with favourable oxidising cytosolic environments through 
the elimination of native reductases (section 3.3.6) (discussed in section 4.3.2). This 
allowed for the selection of a generic vector from an enormous catalogue of plasmids 
without the need to alter either our inserts or vector to include a periplasmic signal 
peptide.   
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There are a dizzying number of vectors and vector modifications available to enhance 
expression, particularly in the 5’ untranslated region where transcription and translation 
factors are located.  Plasmid pGS-21a (GenScript) was chosen as our archetypal vector 
for cytosolic expression due to familiarity with its use, along with promoter and 
cleavable tag characteristics similar to RAGE expression vectors previously used (Dattilo 
et al., 2007; Allmen et al., 2008; Xue et al., 2011).  During the process of sub-cloning our 
RAGE, HMGB1 and calgranulin sequences, the N-terminus GST fusion protein was 
removed leaving only the carboxyl terminus 6xHis tag.   
Not only is the transcription and translation of heterologous proteins heavily influenced 
by the vector carrying the insert, but the intrinsic genetic characteristics and structure of 
the gene itself. 
4.2.3 Gene sequence optimisation for bacterial expression 
With gene sequence information becoming increasingly accessible and the expansion of 
cost-effective commercial gene synthesis services, the use of synthetic genes for 
recombinant protein expression is increasing (Welch et al., 2009; Fath et al., 2011; 
Rosano and Ceccarelli, 2014).  However, there has been no reported optimisation of the 
human RAGE gene sequence to enhance levels of protein expression, with only a few 
groups reporting the use of Rosetta/Codon Plus host cells to address potential codon 
bias (Park et al., 2010; Penumutchu et al., 2014; Xue et al., 2011).  
The human RAGE gene sequence returned a poor codon adaptation index (CAI) value of 
0.58, with 11% of codons identified as low frequency (OptimumGene™, GenScript).  
Additionally, one negative cis-element, a number of low frequency tandem codons and 
two segments of high GC content were identified.  All of these factors can potentiate 
pauses in translation and disengagement of encoding mRNA from the ribosome and 
thus, significantly reduce yields.  As an alternative to onerous point mutation correction 
of these deficiencies, a gene synthesis service (GenScript™) was used for the production 
of optimised RAGE V, VC1 and VC1C2 synthetic gene inserts.  Optimisation of the gene 
sequence for E. coli expression increased CAI estimates to 0.90, 0.93 and 0.89 for V, VC1 
and VC1C2 respectively; eliminating all previously identified genetic traits with the 
potential to confound translation. 
Side-by-side expression of optimised and canonical RAGE gene sequences in the E. coli 
strain T7 Shuffle® K12 led to 6-fold, 3-fold and 1.5-fold increases in the quantities of 
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RAGE VC1C2, VC1 and V produced from the optimised sequence (Figure 37).  Codon 
optimisation can improve the kinetics of translation and associated yields of 
recombinant protein.  Expression of some membrane bound proteins following gene 
optimisation has, however, led to decreases in yield (Cortazzo et al., 2002; Schlegel et 
al., 2012).  Translational pauses may in fact be required to allow the formation of 
intermediate structures essential for correct folding, with their removal significantly 
reducing recombinant protein activity and yields (Komar et al., 1999).  No 
distinguishable increases in the production of insoluble recombinant RAGE isoforms 
from optimised gene sequences were observed in this project (data not shown).  If 
functionality of purified protein proves to be poor (discussed in section 4.4), evaluation 
of endogenous and optimised gene sequences may point to translational rates as a 
cause of mis-folding and associated lack of functionality.   
A number of E. coli strains such as BL21 (DE3) Codonplus (Strategene), Rosetta (DE3) 
(Novagen) and Rosetta-gami™ B (Millipore) have been engineered to address codon bias 
associated with the expression of heterologous proteins. These systems often 
incorporate additional copies of low frequency tRNAs such as argU, ileY and leuW, which 
can become depleted during overexpression of recombinant protein.  This project 
expressed the native human gene sequence for V, VC1 and VC1C2 RAGE domains in both 
Rosetta-gami™ B and Origami™ B.  Rosetta-gami™ B did indeed express V, VC1 and VC1C2 
at levels 2-fold 3-fold and 4.5-fold higher, respectively, than Origami™ B (Table 7).   
Codon optimisation dogma of ‘one amino acid - one codon’ that utilises the most 
abundant tRNAs within a host is increasingly being displaced by more complex 
algorithms that consider codon context, harmonization, stable free energy of mRNA and 
RNA instability motifs (ARE), to name a few (Gao et al., 2004; Angov, 2011).  The efficacy 
of such codon optimisation services such as OptimumGene™ and GeneArt® for 
heterologous expression is highly variable and dependent on the host and protein in 
question.  This project found that T7 Shuffle®K12 transformed with optimised gene 
inserts expressed V, VC1 and VC1C2 at levels 4.6-fold, 2.8-fold and 1.4 fold higher, 
respectively, than those of canonical human RAGE gene inserts (Figure 37).  
Interestingly, the levels of expression from insert optimisation or through the use of a 
rare codon optimised host was consistently VC1C2 > VC1 > V (Table 7).  Speculation as to 
the cause of this reduction in yields with the removal of C-domains focused on possible 
mRNA instability or secondary structure formation (discussed in section 4.3.1), or mis-
folding and aggregation of recombinant protein (discussed in section 4.4). 
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The prokaryotic hosts and vectors used in the development of RAGE domain constructs 
were similarly applied to the production of expression vectors containing HMGB1, 
ΔHMGB1 (C-terminus acidic tail truncated), S100B, S100P and S100A6.  By utilizing 
common strategies for the production of both insect and bacterial forms of RAGE and its 
ligands, this study was able to generate 14 vectors for expression in eight hosts quickly, 
reliably and cost effectively (Table 8). 
Table 8.  Matrix of organisms transformed/transfected by expression vector and 
quantity expressed post-purification (bacterial) and pre-purification (insect) as 
determined by ELISA (mg/L).        
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VC1C2 - Native (pIB/V5)      
.06 .1 .42 
V – Native (pGS-21a) 
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VC1 – Native (pGS-21a)  .7 .21  .72    
VC1C2 - Native (pGS-21a)  4.1 .9  2.8    
V – Optimized (pGS-21a) .08 .04 .09 .1 .27 
   
VC1 – Optimized (pGS-21a) .06 .72 .96 1.2 2.0    
VC1C2 – Optimized (pGS-21a) .18 4.4 3.72 14.9 13.1    
HMGB1 – Optimized (pGS-21a)     1.8    
ΔHMGB1 – pGEX-6P-1     2.4    
S100B – Optimized (pGS-21a) 
    
10.6 
   
S100P – Optimized (pGS-21a) 
    
6.9 
   
S100A6 – Optimized (pGS-21a) 
    
14.4 
   
 
This approach has provided a flexible, adaptive and systematic toolbox of methods, 
hosts and vectors, significantly reducing the complexities and nuances of expression 
vector development of RAGE and its ligands.  This enables the research focus to be on 
the application of the expressed protein rather than the underlying molecular biology 
required for its production.  Optimisation of the gene sequence for prokaryotic 
expression of RAGE did mitigate codon bias as predicted by the increased codon 
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adaptive index scores.  Whether the quantities and functionality of the molecules 
produced are suitable for all possible research intents is clearly a consideration requiring 
further clarification. 
4.3 From Gene to Protein 
Despite RAGE being associated with multifarious disease states through its activation 
and interaction with a raft of ligands, it was nearly 16 years after its discovery that 
structural studies provided molecular insights into its modes of action (Xue et al., 2011; 
Park et al., 2010; Koch et al., 2010; Neeper et al., 1992).  Due to its involvement in 
multiple chronic pathologies, it represents a significant therapeutic target for mitigating 
disease progression and the associated symptoms. 
4.3.1 Insect cell expression of RAGE constructs 
RAGE was almost exclusively expressed in insect cells for the first 10 years following its 
discovery.  Over the last 10 years, RAGE is increasingly expressed in prokaryotic hosts   
(Hofmann et al., 1999; de Arriba et al., 2003; Srikrishna et al., 2002; Xue et al., 2011; 
Park et al., 2010). 
As discussed in section 4.2.1, the disadvantages of baculoviral systems lie in the 
complexity of constructing and packaging the expression vector for delivery through a 
baculoviral particle.  This complexity in construct development hampers throughput in 
situations that require multi-parallel expression of many recombinant proteins such as 
RAGE isoforms.  A number of alternatives to homologous recombination baculoviral 
systems exist, including Bac-to-Bac (bacmid), BaculoDirect and a raft of others.  A non-
viral transfection system for Lepidoptera cell lines such as Spodoptera frugiperda 9 (Sf9), 
Sf21 and Trichoplusia ni (High Five™ or Tn5) was chosen for this project. 
The pIB/V5 TOPO plasmid (Invitrogen) used to construct the RAGE V, VC1 and VC1C2 
expression vectors in this study utilises a baculovirus immediate-early promoter OpIE2 
which removes the requirement of complementary viral activation factors.  Transient 
transfectants of all three RAGE constructs in Sf9, Sf21 and Tn5 cell lines were quick to 
generate using a lipid based transfection method (section 2.5.8).  Jarvis et al (1990)   
reported a direct correlation between transfected copy number and expression levels.  
Optimisation of our transfection protocol confirmed this observation. Four micrograms 
of high pure plasmid maintained culture viability and passage rates whilst optimising 
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levels of protein expression (Figure 25).  Transfection survival rates using 4 µg of plasmid 
were between 50-60% regardless of cell line, enabling the rapid expansion of transiently 
expressing cultures.  By utilising the native human RAGE signal peptide (a.a 1-22), 
recombinant RAGE was successfully secreted without the need to customise the pIB/V5 
vector itself.  The presence of recombinant human V, VC1 and VC1C2 was confirmed by 
Western blots of the P1 conditioned media of Sf9, Sf21 and Tn5 cultures only 48 hr post-
transfection (Figure 22 to Figure 24).   
Interestingly, there were two immunoreactive bands secreted by Sf9 and Sf21 for all 
three RAGE domain constructs, approximately 3 kDa apart (Figure 22, Figure 23).  
PNGaseF digestion of these proteins confirmed this variance was due to alternate forms 
of the N-linked glycans on the RAGE V domain (Figure 27).  Heterogeneity of 
glycosylation is not uncommon in insect cells, with oligomannosidic and 
paucimannosidic structures being attached somewhat interchangeably (Cao et al., 2005; 
de Arriba et al., 2003).    The V, VC1 and VC1C2 RAGE constructs were each expressed as 
single protein bands in Tn5 cells (Figure 24).  This is likely due to the higher metabolic 
potential of Tn5 cells and the significant down-regulation of paucimannosidic-type 
glycosylation of secreted proteins (only 5% of total glycospecies) compared to 
intracellular expressed proteins (56% of glycans attached) (Rendic et al., 2008)  .  A 
number of research groups have discussed the significant role of N-linked glycans on 
ligand binding within the RAGE V domain (Park et al., 2011; Srikrishna et al., 2002).  All 
of these studies utilise mammalian sources of RAGE due to the significantly more 
complex nature of glycosylation in mammalian cells (Srikrishna et al., 2002; Srikrishna et 
al., 2010).  Interestingly, Sf9, Sf21 and Tn5 are ovary-derived in their origin and do not 
possess the entire glycomic potential of other insect cell lines (Rendic et al., 2008; Kato 
et al., 2005; Usami et al., 2011).  Although here we report the expression of 
homogeneously N-linked glycosylation of three recombinant forms of RAGE using the 
Tn5 cell line (Figure 24), these glycans are not typical of those produced by mammalian 
cells; and as such, insect expressed RAGE is not a suitable source of protein for studying 
the role of these carbohydrate moieties.  We have demonstrated that by using a Tn5 
cells in place of the traditionally used Sf9 line in baculoviral production, alternate 
glycosylation can be minimised.  This ensures that insect expressed extracellular RAGE 
domains V, VC1 and VC1C2 are homogeneous in their composition and associated 
physical properties.   
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The initial transient expressing cultures were converted to stable cell lines in only two 
passages using Blasticidin, a potent peptidyl nucleoside antibiotic (Figure 26).  
Interestingly the levels of expression decreased dramatically across all cell lines with the 
removal of RAGE C-type domains (Figure 28).  A common rate-limiting factor in protein 
synthesis is poor translation initiation as a result of mRNA secondary structures that 
impede the ability of ribosomal initiation factors to recruit and position the AUG 
initiation codon (Jackson et al., 2010).  Thermodynamic ensemble prediction of RAGE V, 
VC1 and VC1C2 mRNA using the online tool RNAFold produced ensemble diversity 
estimates of 58 (ensemble ΔG -110 kcal/mol), 172.1 (ensemble ΔG -242 kcal/mol) and 
209 (ensemble ΔG -388 kcal/mol) respectively (Gruber et al., 2008).  This data suggests 
that the V-domain is more likely to have a ‘rigid’ structure than the VC1 and VC1C2 
domains, and may thereby promote the formation of matched pair stems that have the 
potential to lower translation rates and increase mRNA degradation (Bollenbach and 
Stern, 2003; Paddison et al., 2002).  Indeed, the minimum free energy structure for 
RAGE V mRNA predicts the presence of two matched stems with a very high probability 
of forming in the first 50 base pairstem loop (Figure 74).   No comparable matched pair 
stems were predicted with a high degree of likelihood in VC1 or VC1C2 mRNA (Figure 74).  
The preference of the V domain gene to insert in the reverse orientation (3’-5’ 
orientation) 95% of the time does suggest that the 5’ end of the gene may not be readily 
accessible or occluded by secondary structures such as those predicted (Figure 74).   
 
 
 
 
 
 
 
 
Figure 74.  Predicted mRNA secondary structures of RAGE domain constructs.  Putative 
minimum free energy structures of a) RAGE V mRNA b) RAGE VC1 mRNA and c) RAGE 
VC1C2 with a grey line indicating the first 50 base pairs of the mRNA from the AUG 
initiation codon.  Colour indicates the probability of the base pair being in that position 
(Lorenz et al., 2011). 
a) b) c) 
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The importance of native and synthetic transcript leaders in the 5‘-untranslated region 
(5’UTR) that modulate translation is discussed by Rojas-Duran and Gilbert (2012).  They 
conclude that the transcription start site is greatly underappreciated as a quantitatively 
significant mechanism for regulating protein production.  This is unlikely to be the cause 
of our observed decrease in translation as all constructs utilise the same 5’ vector 
promoter and transcription initiation elements.  Taken collectively, it is reasonable to 
speculate that the RAGE V domain mRNA may form secondary structures that are 
unfavourable to high rates of translation essential to overexpression of recombinant 
proteins. 
A number of groups have previously incorporated cleavable tags such as glutathione S-
transferase (GST) and maltose-binding protein (MBP) with the V-domain of RAGE 
expressed in prokaryote hosts that were used in purification (Ostendorp et al., 2007; 
Zong et al., 2010; Park et al., 2010).  Ling et al (2011)   amino-terminally fused expressed 
MBP with the RAGE V domain and reported that the presence of this tag reduced the 
ability of HMGB1 to bind the V domain by 3-fold.  Care must therefore be taken to 
ensure such fusion proteins do not alter the target proteins functional or structural 
characteristics. Whether these carrier proteins were incorporated solely for the purpose 
of purification, or to increase levels of expression, protein solubility or stabilisation of 
intermediate structures essential for correct folding was not reported.  NMR studies of 
RAGE suggest that the C1 domains play a key role in stabilising the structures of the V 
domain, with a loss of structure and increased random coils occurring in its absence 
(Dattilo et al., 2007; Xie et al., 2008).  Minimal recombinant RAGE was detected by 
Western blot within the insoluble fractions of Sf9, Sf21 or Tn5 across all three domain 
constructs, suggesting expressed protein was not aggregating due to mis-folding (data 
not included).  Whether the presence of a cleavable fusion protein is sufficient to disrupt 
the formation for mRNA secondary structures and increase translation of the V domain 
is sheer speculation.  Unfortunately, due to limitations in time and resources, the effect 
of fusion proteins on protein production was not investigated. 
There was no discernible difference in levels of expression of the V-domain between Sf9 
(20 µg/L) and Sf21 (19 µg/L) cells, however, Tn5 expression was 3-fold higher (62 µg/L of 
culture) (Table 8).  Collectively, Tn5 expressed all constructs at levels 4-10 fold greater 
than those seen in either Sf9 or Sf21 (Figure 28).  Wickham et al (1992)   similarly 
reported significant improvements in recombinant protein expression using Tn5 with a 
baculoviral system compared with Sf9.  Whilst the insect expression system in this study 
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offers advantages in speed, simplicity of construct production, cell maintenance and 
storage, yields were 10-100 fold less that that routinely reported for baculoviral 
expression (Figure 28) (Gomez-Sebastian et al., 2014; Berger et al., 2004; Kim et al., 
1993).  Significant work to evaluate adherent and suspension culture techniques, 
optimised culture conditions and media, with the aim of enhancing cell growth rates 
delivered improvements in yield of approximately 20% for the VC1C2 construct in Tn5 
(Figure 33).  Adapting all three cell lines to serum free suspension cultures provided 
higher cell densities and yields per litre of culture without compromising cell 
conditioning (3.3.5).  This approach simplified protein production as it dramatically 
reduced contamination by other host cell proteins normally released by lytic baculoviral 
systems and protein contained in serum.  However, despite optimisation, we were 
unable to produce the mg/L quantities, normally required for structural or in vivo 
studies, of any RAGE domain construct utilising the pIB/V5 expression vector in stably 
transfected Lepidoptera cells. 
Insect cells are often considered a happy median between prokaryotic and mammalian 
expression hosts due to their capacity for high yields, relatively simple culture 
requirements, and robust nature and, most importantly, their capacity for post-
translational modification.  Where there is no need for these modifications or they can 
be provided alternately, bacterial expression is often the system of choice for its 
unparalleled growth kinetics, low cost, high cell densities and associated high yields. 
4.3.2 Bacterial expression of RAGE constructs 
Almost all E. coli strains used for recombinant protein expression today are derived from 
the B and K12 lines (Rosano and Ceccarelli, 2014; Studier and Moffatt, 1986).  A number 
of significant modifications largely ubiquitous in expression strains today include the 
removal of various proteases (OmpT and Ion), improvements in plasmid retention and 
degradation, phage resistance, knockout of cytosolic reductases, and the addition of 
potent polymerases for high level mRNA transcription (Grodberg and Dunn, 1988; 
Rosano and Ceccarelli, 2014; de Marco, 2009; Brondyk, 2009). 
RAGE has largely been expressed in BL21 (DE3), with a small number of groups using 
alternative strains such as M15p (REP4) and JM83 (Kumano-Kuramochi et al., 2008; 
Srikrishna et al., 2002; Ostendorp et al., 2007; Park et al., 2004a; Wilton et al., 2006).  A 
handful of publications report the use of Origami strains to mitigate poor disulphide 
bond formation, with only two publications describing the use of a Rosetta-gami™ B 
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strain to address codon bias (Kumano-Kuramochi et al., 2008; Park et al., 2010; Dattilo et 
al., 2007; Xue et al., 2011). 
The correct formation of disulphide bonds has been identified as a significant limitation 
of E. coli expression systems since the late 1970’s along with a lack of post-translational 
modifications (de Marco, 2009; Brondyk, 2009).  In response to this and the ever-
increasing demand for recombinant proteins, an extensive catalogue of commercially 
available bacterial hosts has been developed to address the myriad of factors 
influencing the quantity, quality and scope of application of expressed proteins.  The 
scarcity of these strains within the field of RAGE research over the last 20 years, and the 
absence of a well-defined best practice for the bacterial expression of RAGE therefore 
warranted investigation. 
This study utilised five bacterial strains to overexpress synonymous V, VC1 and VC1C2 
RAGE domains constructs to those expressed in the three Lepidoptera cell lines (section 
4.2.1).  In the last 5-10 years, a number of methods for the systematic multi-factorial 
analysis of host conditions influencing expression have gained favour (Papaneophytou 
and Kontopidis, 2014; Noguere et al., 2012).  These approaches offer significant 
enhancements to the classic empirical ‘one-factor-at-a-time’.  There are many elements 
of prokaryotic expression that can be tuned to enhance quantity or quality of yields,  
such as media, temperature, timing of induction, strength of induction, length of 
induction, to name a few.  Although optimal recombinant protein expression is an 
exquisite entanglement of host, environmental conditions and the intrinsic nature of the 
recombinant protein, this project utilised conditions commonly reported for the 
prokaryotic expression of RAGE.  Some preliminary investigations of the temperature of 
expression, strength and timing of induction did confirm that these conditions as 
outlined in method 2.6.1 produced relatively good yields (data not included). If 
additional time and resources were available, refinement of the many environmental 
conditions associated with this RAGE expression would almost certainly yield improved 
levels of expression. 
In this study, BL21 (DE3), Rosetta-gami™ B and Origami™ B previously used for RAGE 
expression were evaluated alongside two strains optimised for enhanced disulphide 
bond formation – T7 Shuffle® B (rebranded as SHuffle® Express) (New England Biolabs), 
and T7 Shuffle® K12 (rebranded as SHuffle® T7) (New England Biolabs).    
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Expression in BL21 (DE3) of the optimised (synthetic) VC1C2 construct yielded 6.6 mg/L, 
however, less than 5% was present in the soluble fraction as determined by ELISA (Table 
7).  This is not surprising considering the presence of three cys-cys bridges (Figure 2) and 
the intrinsic reducing potential of the E. coli cytoplasm (de Marco, 2009; Brondyk, 2009).  
Wilton et al (2006) successfully expressed a similar VC1C2 form of RAGE into the 
periplasmic domain of E. coli utilising the native chaperones, foldases and isomerases 
that catalyse disulphide bond formation within this oxidising compartment (Kadokura et 
al., 2003; Messens and Collet, 2006).  Surprisingly, the yields reported were very good at 
7.7 mg/g wet weight of pellet which is equivalent to the native RAGE VC1C2 construct 
expressed by T7 Shuffle® K, but only one third of the optimised RAGE VC1C2 construct 
expression in T7 Shuffle® B (Table 7) (Wilton et al., 2006).  It is not uncommon for 
periplasmic expression to be relatively low yielding due to limited availability of enzymes 
required for trafficking and refolding, as well as leakage of protein from the periplasm 
into the outer membrane and culture media (Figure 75) (Rinas and Hoffmann, 2004; de 
Marco, 2009).  The additional complexity of tuning transcription, translation and 
translocation rates of periplasmic expression systems may also be required as trafficking 
machinery can become overwhelmed by recombinant protein at the expense of 
essential host periplasmic and outer membrane proteins (Wagner et al., 2007).   
 
Figure 75. Periplasmic expression pathway of recombinant protein in E. coli.  The 
pathway taken by recombinant protein expressed utilising the periplasmic 
compartment, demonstrating the complexity of E. coli periplasmic expression and tuning 
(adapted from de Marco, 2009). 
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As such, the exploration of hosts suitable for the cytoplasmic expression of soluble 
extracellular RAGE domains continued. 
Origami strains were the first to be used for cytosolic expression of recombinant RAGE 
where the application involved functional or structural applications of the protein 
(Dattilo et al., 2007; Xue et al., 2011; Allmen et al., 2008; Park et al., 2010).  Kumano-
Kuramochi et al (2008) reported the expression of functional recombinant soluble RAGE 
using Origami (DE3), with yields of 2.2 mg/L.  In this study, RAGE VC1C2, VC1 and V was 
expressed in an Origami™ B strain with yields of 3.72 mg/L, 0.86 mg/L and 0.09 mg/L 
respectively (Table 8).  It is interesting to note that our yields from Origami™ B were 
approximately half that reported by Wilton et al (2006).  A comparison of methods 
revealed similar media, expression temperature and inducer concentrations, however, 
we induced mid-log phase at an OD600 of 0.6-0.8 AU. Wilton et al (2006) reported the 
use of baffled flasks with higher revolutions per minute that likely improved oxygenation 
of their cultures, with induction occurring at 2-3 AU O.D600.  Induction often occurs mid-
log phase so as to maximise translation and associated yields (Rosano and Ceccarelli, 
2014).  It may be that by expressing in early stationary phase, Wilton et al (2008) 
reduced the rates of expression to prevent cytosolic accumulation of protein due to 
limitations in the number of gates available to transport recombinant protein into the 
periplasm (Galloway et al., 2003; Ou et al., 2004).  This ensures that although rates of 
expression and production are slower, the cell density is significantly higher and as such, 
the total protein produced is greater.   
In parallel with Origami™ B, this study expressed soluble forms of all three RAGE 
domains in Rosetta-gami™ B, T7 Shuffle® B and T7 Shuffle® K12.   The Rosetta strain 
expressed all optimised constructs at levels approximating those of Origami, which was 
not unexpected as the synthetic gene effaces the advantage provided by the pRARE 
tRNA encoding plasmid (Table 7).  Again, we observed the same decreasing levels of 
expression with the removal of the C domains as observed in the insect cell lines (Table 
9).  This phenomenon is clearly not confined to insect cell hosts, leading us to again 
speculate that it may be related to inefficient mRNA translation rather than the host 
organism inability to produce soluble, correctly folded recombinant RAGE. Investigation 
of mRNA transcription and accumulation within these various host cell lines by real-time 
PCR quantitative ananysis or mutagenic studies would have confirmed mRNA 
aggregation and supported the supposition that mRNA secondary structures impeded 
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translation; however, limitations in time and resources prevented these studies from 
being undertaken. 
General comparison of the Shuffle®, Rosetta and Origami strain genotypes immediately 
identifies a notable difference, with the presence of disulphide bond isomerase C (DsbC) 
in the Shuffle® strains cytoplasm (Table 9).  DsbC is a member of the thioredoxin 
superfamily which introduces disulphide bonds in target proteins through disulphide 
bond substitution from its active-site Cys30-Pro31-His32-Cys33; and generally assists in 
protein folding (Haebel et al., 2002; Segatori et al., 2004).  Although trxB/gor knockout 
minimises the reduction of cystidine amino acids in the first instance, it does not prevent 
it entirely, with reduced thiol groups unable to form functional cys-cys bridges.   
Table 9. The ratio of soluble recombinant RAGE V, VC1 and VC1C2 expressed by each 
host organism relative to the lowest expressing domain construct.  
 
 Yield (ratio) Yield (mg/L) 
Expression Host V  VC1  VC1C2 V VC1 VC1C2 
BL21 (DE3) 1 : 1 : 2 .08 .06 .18 
T7 Shuffle® B 1 : 7 : 142 .1 1.1 14.9 
T7 Shuffle® K12 1 : 7 : 47 .27 2.0 13.1 
Origami™ B 1 : 11 : 42 .09 .96 3.7 
Rosetta-gami™ B 1 : 17 : 103 .04 .71 4.4 
Sf9 1 : 1.5 : 3 .02 .03 .06 
Sf21 1 : 3.7 : 15 .02 .07 .3 
Tn5 1 : 1.6 : 6.8 .06 .1 .4 
 
In this study, the presence of DsbC and use of optimised gene sequences resulted in 
RAGE expression 7-fold greater than Origami (DE3) yields reported by Kumano-
Kuramochi et al (2008).  Although T7 Shuffle® K12 expression of RAGE VC1C2 was 12% 
lower than that of Shuffle® B, this strain produced approximately 2-3 fold more VC1 and 
V (Table 7).  A comparison of the B and K-12 genomes demonstrates a significant degree 
of similarity, with less than 2% nucleotide sequence divergence between B and K-12 
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adjacent to insertion sequence elements (Schneider et al., 2002).  This study found no 
difference in growth rates between B and K12 strains under inducing conditions (section 
2.6.1) (data not shown), to explain differences in yield as has been reported previously 
(Lobstein et al., 2012).  Lobstein et al. (2012), observed higher yields of recombinant 
protein expressed by Shuffle® B relative to the Shuffle® K12 strain and concluded this 
was due to subtle genetic difference between strains rather than engineered or 
environmental phenotypical factors.  Interestingly, the T7 Shuffle® K12 genome does not 
indicate the deletion of lon and OmpT proteases that are native to K12 strains, where as 
the T7 Shuffle® B genome is devoid of both.  It is therefore possible that the lower yields 
in T7 Shuffle® K12 may be a result of proteolytic degradation of recombinant protein, 
even in the presence of protease inhibitors.  Despite the slightly lower yields of the 
VC1C2 and VC1 constructs, the overall performance of T7 Shuffle® K12 led to its selection 
as our preferred prokaryotic host for heterologous expression of RAGE and its ligands. 
The suitability of T7 Shuffle® K12 and pGS-21a as a common ‘toolbox’ for the expression 
of various RAGE domain constructs, as well as its ligands, namely HMGB1, ΔHMGB1, 
S100B, S100P and S100A6 was subsequently investigated. 
High-Mobility Group 1 Box (HMGB1) has been heavily implicated in the progression of 
multiple pathologies through the binding and activation of RAGE (Sims et al., 2010).  It is 
an interesting molecule comprising an internal disulphide bond in Box A and a free thiol 
(Cys106) group in Box B, and is soluble in 6% perchloric acid with no subsequent loss of 
functionality.  Surprisingly, despite the presence of these three cys residues, the vast 
majority of recombinant HMGB1 used in RAGE binding studies have been expressed in 
Escherichia coli strains such as BL21 that don’t carry the trxB/gor reductase mutations 
(Rouhiainen et al., 2007; Venereau et al., 2012; Huttunen et al., 1999; Yang et al., 2010).  
Recently, the reversible redox potential of Cys106 was shown to modulate the ability of 
HMGB1 to bind and activate RAGE (Venereau et al., 2012).  Preliminary findings within 
our lab similarly identify a role for this free thiol group in HMGB1 self-association 
through the formation of a novel zinc clasp bridge (Figure 76). 
Human HMGB1 sub-cloned into pGS-21a and using the T7 Shuffle® K12 strain was 
successfully expressed at 1.8 mg/L, however, surprisingly it was observed that HMGB1 
was bactericidal, with cell death evident three hours post-induction (Figure 38).  By 
inducing late log phase (O.D600 ≈ 1), expression was optimised with an induction period 
of 2.5 hr.  Toxic protein expression commonly utilises hosts that have tight regulation 
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over the T7 RNA polymerase through the LacI repressor to suppress basal level 
expression pre-induction. 
 
 
 
 
 
 
 
 
 
Figure 76.  Modelling of HMGB1 self-association.  Modelling of HMGB1 homodimers 
formed by a novel ‘zinc clasp’ structure involving the free thiol group on Cys106 
(Anggayasti, Agostino, Mancera and Helmerhorst, Lorne Conference on Protein 
Structure and Function (2013)). 
No reduction in pre-induction culture growth rates of T7 Shuffle® K12 was observed in 
this study, almost certainly due to the presence of the laclq repressor (Figure 38).  A 
truncated form of HMGB1 (ΔHMGB1) was kindly provided by Dr Rouhiainen (University 
of Helsinki, Finland) and expressed as provided in T7 Shuffle® K12, largely for use in 
other projects within our group.  Delta HMGB1 was expressed at approximately 2.4 
mg/L under the same conditions as full length HMGB1 (Figure 58).  Whether the slightly 
higher level of ΔHMGB1 in comparison with HMGB1 expression is due to the presence of 
a carboxy-terminal fusion tag (GST) is difficult to determine in lieu of differences in both 
vector and gene insert.  Interestingly, it is reported that HMGB1 may undergo a number 
of post-translational modifications that include phosphorylation, methylation and ADP-
ribosylation (Bonaldi et al., 2003; Harris and Andersson, 2004). In addition, acetylation 
has been heavily implicated in its DNA binding avidity (Elenkov et al., 2011).  We discuss 
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the capacity of HMGB1 expressed in T7 Shuffle® K12 to bind DNA as an indication of 
functionality in section 4.4.2. 
S100B, S100P and S100A6 are members of the calgranulin subfamily of calcium binding 
proteins that progress a number of pathophysiologies through RAGE (Ostendorp et al., 
2007; Bianchi et al., 2007).  The heterologous expression of S100’s is well established in 
prokaryotic hosts, most notably BL21 strains, with some RAGE researchers using 
baculoviral systems as well (Hofmann et al., 2002; Huttunen et al., 2000; Srikrishna et 
al., 2010).  Human S100P, S100B and S100A6 were sub-cloned into pGS-21a and used to 
transform T7 Shuffle® K12.  Using this host, 10.6 mg/L, 14.4 mg/L and 6.9 mg/L of 
soluble S100B, S100A6 and S100P was produced, respectively (Figure 44).  The 
formation of inclusion bodies by recombinantly expressed S100s in E. coli is rare, most 
likely due to the structural simplicity of these proteins (Leclerc et al., 2007; Gribenko et 
al., 1998; Marlatt et al., 2010).  Interestingly, Western blot analysis of the soluble 
fractions from all three induced T7 Shuffle® K12 calgranulin cultures revealed a major 
band that correlated with the expected size of the recombinant proteins and a faint 
second immunoreactive band approximately twice the size of the majorative species 
(Figure 41-Figure 43).  It is speculated that the larger band represents homodimers 
formed in response to conformational changes associated with the binding of 
intracellular bacterial calcium and other divalent metal cations.  Despite these yields 
being less than the 20 mg/L reported for BL21 (DE3) strains by He et al. (2013), the levels 
of expression achieved with the pGS-21a vector and T7 Shuffle® K12 strain are certainly 
adequate for a wide range of applications, including structural studies (He et al., 2013). 
The T7 Shuffle® K12 recombinant soluble RAGE constructs and various S100 and HMGB1 
ligands were purified following optimisation of their expression.   As each protein is 
unique in the physical characteristics that can be exploited for the purpose of 
purification, different technologies and methodologies were utilised.   The objective in 
each case was to minimise the number of steps needed to achieve an appropriate level 
of purity whilst considering the speed, cost and yields of each method. The RAGE 
proteins were purified utilising their affinity for heparin, with approximately 80% of 
starting material recovered (Figure 45 to Figure 47 respectively).  All RAGE domain 
constructs were penta-his tagged at their C-terminus.  Polyhistidine tags are one of the 
most versatile and widely used strategies for purifying recombinant proteins largely due 
to their small size and ease of elution with imidazole, however, efficacy of purification is 
on a protein-by-protein basis (Cao and Lin, 2009).  All three recombinant RAGE domain 
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isoforms demonstrated excellent affinity for a nickel- nitrilotriacetic (Ni-NTA) acid resin, 
with approximately 65-70% of starting material recovered (Figure 48 to Figure 50).  
Interestingly, when the eluates were dialysed to remove the eluting imidazole, a white 
flocculate appeared that correlated with a significant loss in soluble RAGE.  The addition 
of EDTA to the dialysis buffer prevented the appearance of this particulate, confirming 
our suspicion that it was associated with leaching nickel coordinating the polyhistidine 
tags of RAGE to promote aggregation.  Full length HMGB1 was purified based on its 
remarkable solubility under acidic conditions and with the aid of a molecular sieve 
polishing step (Figure 52 and Figure 53 respectively).  Truncated HMGB1 was purified 
utilising a GST tag attached at the C-terminus (Figure 55).  A number of GST purification 
approaches were tried, with on-column cleavage delivering the highest degree of 
purification as determined by Coomassie staining (Figure 57).  The addition of a HisTrap 
column in series with the GST column ensured that the polyhistidine tagged PreScission 
Protease used to cleave the GST fusion protein was removed.  The intrinsic calcium 
binding characteristics of S100s is associated with a conformational shift that exposes a 
broad hydrophobic patch involved in S100 dimerization (Santamaria-Kisiel et al., 2006).  
This characteristic was exploited by passing bacterial cell lysates containing recombinant 
S100s across phenyl Sepharose® in the presence of 5 mM calcium.  Elution of bound 
protein was done using a wash buffer containing 2.5 mM EGTA, producing a single peak 
that was confirmed by Coomassie to consist of single S100B, S100P and S100A6 
molecules at >95% purity (Figure 59 to Figure 61).  Only S100A6 was detected in the 
column flow through by Coomassie, indicating that the column was overloaded, with an 
estimated capacity of approximately 14 mg/mL of S100 per millilitre of phenyl 
Sepharose® resin.   
Given the oligomeric propensity of many of these ligands and the likely multivalent 
nature of their interactions with RAGE, a molecular sieve step immediately prior to the 
use of any of the proteins expressed and purified in this study was used to ensure they 
were aggregate free prior to commencing functional studies. 
4.4 Functional Evaluation of Recombinant Proteins 
The ability of RAGE to bind a plethora of ligands has been investigated through the use 
of various techniques that include fluorescence, radiolabel based saturation assays, 
surface plasmon resonance and a handful of colorimetric assays (Hori et al., 1995; Xie et 
al., 2008; Kislinger et al., 1999; Schmidt et al., 1992).  It is difficult to interpret the many 
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affinities of interaction reported for RAGE due to the interchange of receptor sources, 
the varying methodologies applied and innate complexities of interaction.   
4.4.1 Binding of RAGE constructs to ribose AGEs 
This study developed a novel colorimetric binding assay (section 2.7.1), that enabled us 
to quickly evaluate the binding of RAGE to its ligands without the need to radiolabel 
RAGE, modify RAGE with fusion enzymes for use in measuring activity, or requiring 
expensive instrumentation.  Specificity of RAGE binding was demonstrated by two 
negative controls that included wells coated with unmodified BSA and a triplicate set of 
wells containing binding buffer without RAGE.  A very similar assay for the high 
throughput screening of compounds modulating RAGE binding, was patented in the US 
18 months post development of the method developed in this study, validating the 
suitability of this approach (US 2006/0078956 A1, Shahbaz (2006).  Both insect and 
prokaryote expressed VC1C2 and VC1 RAGE bound ribose-AGE with comparable affinities 
in the range of KD ≈ 58-79 nM and KD ≈ 71-89 nM, respectively (Figure 63, Figure 64).  
This correlates well with estimates of affinity published for insect expressed forms of 
VC1C2 (IC50 ≈ 73 nM) and endogenous bovine RAGE (KD ≈ 47 ± 23 nM) binding of AGEs 
(Valencia et al., 2004; Schmidt et al., 1992).  Srikrishna et al (2002) reported that N-
glycans present on endogenous RAGE influenced the affinity of interaction between 
RAGE and HMGB1.  Whether this is also the case for AGE-RAGE interactions requires 
further investigation, with current NMR explanations of AGE-RAGE mechanisms of 
binding not considering N-linked glycan involvement.   
The V domain expressed by insect cells bound ribose-AGE (KD ≈ 1600 ± 5 nM) with 
approximately 2-fold higher affinity than the prokaryote equivalent (KD ≈ 4300 ± 64 nM), 
yet 27 to 48-fold less than recombinant RAGE isoforms containing the C1 domain in 
prokaryote and insect cells, respectively (Figure 63 and Figure 64) (Valencia et al., 2004; 
Xie et al., 2008; Schmidt et al., 1992; Xue et al., 2011; Xue et al., 2014).  It is tempting to 
speculate that the dramatic difference in the strength of binding of AGEs to RAGE 
isoforms with, and without, C-type domains is related to mis-folding of the V domain, or 
a loss of oligomeric RAGE quarternary structure that is C1 domain dependent.  Xie et al 
(2008) were the first to propose that residues in the C-terminus of the C1 domain drive 
self-self association and the resultant multimeric forms of RAGE.  Sitkiewicz et al (2013)   
recently demonstrated the involvement of the interlinking loop between the C1 and C2 
domains in the formation of dimer-tetramers of extracellular RAGE, which is now know 
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to be its constitutive form (Xie et al., 2007; Koch et al., 2010).  However, the extent to 
which this loop affects oligomerisation and potentially ligand binding has not been 
demonstrated.  Closer inspection of both the prokaryote and insect VC1C2 and VC1 
estimates of affinity does show a consistently higher KD for the VC1C2 (bacterial KD ≈ 80 ± 
14 nM; insect KD ≈ 58 ± 12 nM), relative to VC1 (bacterial KD ≈ 89 ± 29 nM; insect KD ≈ 72 ± 
14 nM) in the order of 12% and 22%, respectively.  These differences, however, are not 
statistically significant (p= 0.9575) applying a two-tailed t-test.   
Surface plasmon resonance analysis of both insect and prokaryotic VC1 forms of RAGE 
demonstrated a many-to-one ratio of receptor to ribose-AGEs (Figure 70, Figure 71).  
The interaction of free ribose-AGE passed over RAGE VC1 captured on the surface of a 
CM5 chip was best described by a tetrameric model of binding with a KD ≈ 1.8 µM for the 
initial encounter complex (Figure 70, Figure 71).  Immobilising RAGE to the chip surface 
only enabled measurement of the initial encounter interaction between the first 
immobilised RAGE molecule to bind free ribose-AGE, with subsequent interactions not 
contributing additional response units (). If the arrangement of the SPR experimental 
conditions was reversed, so that ribose-AGE is immobilised and RAGE passed across the 
chip surface as analyte, the binding kinetics of all RAGE oligomer components with 
ribose-AGE could be described, along with the stoichiometry of multimeric RAGE.  It is 
enticing to speculate that the nanomolar affinity demonstrated in the plate based assay 
between VC1, VC1C2 and ribose-AGE is the high affinity multimeric RAGE-ribose AGE 
interaction as opposed to the low affinity monomeric VC1 binding demonstrated by SPR. 
The disparity in the binding affinities of RAGE constructs with and without a C1 domain 
expressed in both prokaryotic and eukaryotic hosts provides further support for the 
proposition that the dramatic differences in binding strength reported here are 
associated with a loss of oligomeric quarternary structure as opposed to mis-folding of 
the V domain. 
This study has demonstrated that the novel plate based assay developed within this 
laboratory is a simple, accurate, consistent and quick means of evaluating the binding of 
RAGE constructs with AGE molecules.  This is in stark contrast to the many assays 
previously reported that require either radiolabelling, enzymatic tagging of RAGE or 
complex instrumentation.  Collectively, the data produced using this assay in 
combination with SPR, support the likelihood that oligomerisation modulates the 
strength of binding between RAGE and AGE molecules as opposed to mis-folding of 
discrete V domain RAGE constructs by the heterologous host. The bacterial and insect 
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RAGE isoforms expressed in this study bound ribose-AGE with comparable affinities and 
approximated the micromolar affinities reported for V-domain binding and nanomolar 
affinities for VC1 and VC1C2 forms of the receptor. 
4.4.2 HMGB1 functionality 
In 1995, Hori et al demonstrated the specific binding of RAGE with HMGB1 using both 
recombinant baculoviral expressed HMGB1 and endogenous rat RAGE and HMGB1.  
They reported binding in the range of KD ≈ 6–10 nM dependent on the combination of 
receptor-ligand combination used (Hori et al., 1995).  In stark contrast, Liu et al (2009)   
reported affinities of KD ≈ 710 nM using recombinant human RAGE (equivalent to VC1C2) 
and HMGB1 expressed in BL21 (DE3) using a plate based assay similar to that described 
in section 2.7.1. Ling et al (2010)   were the first to publish the kinetics of interaction 
between human RAGE and HMGB1 (commercially purchased - bacterially expressed), 
using surface plasmon resonance, with an estimate of KD ≈ 98nM.  Interestingly, the 1:1 
Langmuir fit applied by Ling et al (2010) to their data does not appear to be a good fit 
(Chi2 values or residuals not reported), leading us to speculate whether a multimeric 
model would have been more appropriate. This broad set of binding affinity estimates 
for RAGE and HMGB1, spanning an order of magnitude is difficult to reconcile.  In part, 
the use of RAGE without N-linked glycans has been shown to reduce binding to HMGB1 
two-fold (Srikrishna et al., 2002).  Utilising a plate based assay, this study demonstrated 
no statistically significant difference (p=0.9425 two-tailed t-test) between estimates of 
binding between insect (KD ≈ 64 ± 14 nM) and bacterial (KD ≈ 58 ± 19 nM) expressed 
VC1C2 and HMGB1 (Figure 66).  The reported importance of post-translational 
modification of HMGB1 in relation to its ability to bind DNA and the sensitivity of these 
to purification strategies was investigated in this study (Bonaldi et al., 2003; Harris and 
Andersson, 2004)  . Circular dichroism analysis confirmed the presence of secondary 
structures in proportions commonly associated with functional HMGB1, suggesting the 
molecule is correctly folded (Figure 68) (Belgrano et al., 2013). Using SPR, this study 
found that prokaryote expressed HMGB1 purified through the use of a classical acid 
precipitation step, did not lose its ability to bind DNA, demonstrating a very high affinity 
interaction in the order of KD ≈ 0.3 pM with pBluescript II SK- cloning vector (Figure 72).  
Additionally, multicycle SPR analysis of the strength of binding between free VC1C2 RAGE 
and immobilised HMGB1 was KD ≈ 6 nM, strongly correlating with the plate based assay 
estimates of affinity (Figure 73).  Notably, our SPR estimate of affinity are 2-fold higher 
than that reported by Ling et al (2011), possibly due to differences in experimental 
 Page 183 
 
design such as the presence of a background reducing agent to preserve the integrity of 
the free Cys106 in Box B of HMGB1.  This study immobilised HMGB1 to the chip surface as 
opposed to RAGE, and subsequently passed RAGE across the surface to allow free 
oligomerisation of RAGE to occur.  This approach also avoided exposing RAGE to harsh 
regeneration conditions of 10 mM NaOH between cycles used by Ling et al (2010).  
Although speculative, it is possible that the lower strength of binding reported by Ling et 
al (2011) may possibly be due to reduced levels of functional RAGE following 
immobilisation and subsequent regeneration cycles, or limitations in the freedom of 
RAGE to oligomerise when immobilised on the chip surface.  Further studies are 
required to clarify this speculation. 
It is reasonable to assume that the large disparity in binding estimates of the RAGE-
HMGB1 interaction is in part a result of the myriad of receptor and HMGB1 sources 
utilised as well as variations in methodology.  Of significance was the recent findings 
that the redox state of the free thiol of HMGB1 (Cys106) modulates it ability to bind toll-
like receptor 4 (TLR4) (Yang et al., 2012; Venereau et al., 2012).  Tang et al (2010)   
reported that the pluripotent outcomes of RAGE-HMGB1 binding were in part regulated 
by the redox status of HMGB1.  Janko et al (2014)   postulated that this may be due to 
dimerization of HMGB1 mediated by the free Cys106 thiol.  Ongoing work within this 
laboratory using HMGB1 produced in this study has, in fact, demonstrated the role of 
this thiol in the formation of a novel ‘zinc clasp’ structure that drives self-self association 
(Figure 76).  This correlates with our observation that the V domain binds HMGB1 with 
an 8-fold lower affinity (KD ≈ 5 nM) than VC1C2 (KD ≈ 58 nM) (Figure 66). From these 
observations, it is reasonable to speculate that just as RAGE-AGE binding is influenced by 
the oligomeric state of the receptor, it is likely that RAGE-HMGB1 binding is even more 
complex, influenced by the multimeric form of HMGB1 driven by its redox state, the 
presence of zinc dications, as well as the quarternary structure of RAGE.  These early 
observations provide tantalising preliminary insights into the possible mechanism by 
which the pluripotent outcomes of RAGE-HMGB1 binding are progressed, demanding 
active ongoing investigation. 
4.4.3 Functionality of calgranulin (S100) molecules. 
As previously discussed in section 1.3.3, calgranulins are a sub-family of calcium binding 
proteins ubiquitously expressed in vertebrates.  They are associated with progression of 
a diverse array of pathophysiological outcomes in an autocrine or paracrine 
 Page 184 
 
manner through the activation of RAGE.  Hofmann et al (1999) were the first to describe 
RAGE as a cell surface receptor for S100A12 and S100B, with a number of subsequent 
studies identifying RAGE-S100B as an axis of inflammation in microglia, neuronal and 
neuroblastoma cell lines (Huttunen et al., 2000; Kogel et al., 2004; Leclerc et al., 2007; 
Adami et al., 2004).  Interestingly, a number of calgranulins elicit differential outcomes 
dependent of their physiological concentrations, with nanomolar concentrations 
promoting cell survival and micromolar triggering apoptosis (Schmidt et al., 2007; 
Vincent et al., 2007; Huttunen et al., 2000).  Datillo et al (2007) demonstrated by SPR 
that immobilised VC1 RAGE binding to free S100B was best described by a 
heterogeneous analyte model.  This implies that S100B was either not purely dimeric in 
form, or that immobilised RAGE consisted of various monomeric/multimeric forms that 
bound analyte with differing affinities estimated to be KD ≈ 289 nM and KD ≈ 11 nM.  The 
partial flexibility of the dextran matrix to which VC1 is coupled has been shown in some 
instances to allow receptor dimerization, however, this is highly dependent on the chip 
used, intrinsic characteristics of the receptor and the density of protein immobilised 
(Raghavan et al., 1995).  RAGE has been shown to form much more complex quarternary 
structures than homodimers, as described in this study by the tetrameric model of 
interaction between VC1 RAGE to ribose-AGE (Figure 70).  Datillo et al (2007) 
acknowledged that the heterogeneous model was not a particularly good fit to the 
experimental data, raising the possibility that a tetrameric model of binding may have 
better described their observed data.  Others have provided estimates of S100B that 
range from 2.2 nM to 3.6 µM, with this variation partly described by the oligomeric form 
of S100B and its multimeric arrangement with RAGE (Ostendorp et al., 2007; LeClerc et 
al., 2007; Datillo et al., 2007). 
In all published SPR studies of the interaction between RAGE and S100, RAGE was 
immobilised to the surface of a CM5 chip with the assumption that the partially flexible 
nature of the chip surface allows receptor oligomerisation.  By inverting the 
arrangement of molecules, not only could the immobilisation of dimer/tetramers of 
S100B be controlled and measured, but both the stoichiometry of the RAGE complexes 
and their associated kinetics of interaction with surface bound S100B could described in 
detail.  Utilising the plate based assay developed in this project, we confirmed that 
S100B and S100A6 bound prokaryotic VC1C2 RAGE with KD ≈ 36 ± 22 nM and KD ≈ 19 ± 6 
nM, respectively.  This is in in general agreement with the nanomolar affinities of 
interaction for these calgranulins reported by Ostendorp et al (2007) (KD ≈ 42 nM) and 
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S100A6 binding to the C2 domain reported by LeClerc et al (2007) (KD ≈ 28 nM).  RAGE-
S100P binding is poorly described in the literature, with estimates for V domain binding 
in the micromolar range (Penumutchu et al., 2014).  Penumutchu et al (2014) reported 
the binding of two V domains of RAGE to an S100P homodimer, which is not surprising 
considering the importance of oligomerisation in high affinity RAGE-ligand binding 
demonstrated in this and other studies. Here, we described for the first time the 
nanomolar binding of S100P to RAGE VC1C2 with a KD ≈ 154 ± 41 nM as determined by 
plate assay (section 2.7.1).  This almost certainly represents the interaction of 
multimeric RAGE with immobilised S100P in comparison to the interactions of 
monomeric V domains of RAGE reported by Penumutchu et al (2014).  A more detailed 
SPR analysis of the interaction of RAGE with S100P (and other molecules expressed and 
purified as part of this study) is needed to improve our understanding of the molecular 
mechanisms that potentiate the pathophysiological outcomes of S100P-RAGE ligation.   
In Addition to SPR and the plate based binding assay, functionality of the calgranulins 
expressed by T7 Shuffle® K12 was also confirmed by their ability to undergo 
conformational rearrangement in the presence of calcium and bind phenyl Sepharose® 
(Figure 59 to Figure 61).  
In summary, milligram quantities of functional calgranulins S100B, S100P and S100A6 
were expressed in a vector and host common to the expression of RAGE, with a one-
step purification strategy, and without the need for recombinant tags.  As with all RAGE 
ligands, published estimates of binding strength between calgranulins and RAGE are 
broad, ranging from 2-2000 nM (Ostendorp et al., 2007; Leclerc et al., 2007; Dattilo et 
al., 2007). It is reasonable to surmise that this variation is a reflection of the complexities 
of both RAGE and ligand oligomerisation, redox status, the RAGE source utilised and the 
method used to measure binding. There is a significant opportunity to use the molecules 
generated in this study to further investigate the precise nature of these interactions.  
By inverting the SPR experimental design of LeClerc et al (2007) so that calgranulins 
rather than RAGE are immobilised on the chip surface, greater detail surrounding the 
kinetics of interaction and stoichiometry of the associated RAGE complex could be 
described. 
4.4.4 Binding of RAGE to beta-amyloid. 
Beta amyloid (Aβ) is a potent progressor of pathophysiologies such as Alzheimer’s 
disease and its interaction with RAGE is implicated in the activation of apoptotic 
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pathways in microglia, endothelia and neurons (Lue et al., 2001a; Yan et al., 1996; 
Wilson et al., 2009; Sturchler et al., 2008; Origlia et al., 2008).  The precise means by 
which Aβ ligands bind RAGE to promote signal transduction is yet to be clearly 
delineated.  Complexities in intracellular signal crosstalk, activation of alternate Aβ 
receptors, the presence of differing RAGE isoforms, and the ability of Aβ to oligomerise 
are all complicating factors (section 1.3.2).  Yan et al (1998) have reported cell based 
affinities of interaction in the order of 25 ± 9 nM to 57 ± 14 nM between the more 
soluble form Aβ1-40 and RAGE.  Ding and Keller (2005)   postulated that RAGE primarily 
bound aggregated Aβ, implicating the V domain as the RAGE domain mediating ligation.  
The Aβ1-42 form is notoriously difficult to work with due to its propensity to form 
insoluble hydrophobic assemblies (Broersen et al., 2010; Mucke and Selkoe, 2012).  
Preliminary SPR analysis undertaken in this study of RAGE VC1 and anti-Aβ monoclonal 
antibody binding to largely monomeric Aβ1-42 produced estimates of affinity of KD ≈ 0.9 
nM (two-state reaction, Chi2 0.016) and KD ≈ 0.5 nM (1:1 Langmuir model, Chi
2= 0.016) 
respectively (Figure 69).  The propensity of Aβ1-42 to aggregate was minimised using a 
method that promotes the preparation of monomeric Aβ1-42 (section 2.7.3), and 
extremely diffuse (low) loading of amyloid on the chip surface at 10 pg/mm2.  Although 
only preliminary, it is exciting to demonstrate for the first time, bacterial expressed 
RAGE VC1 binding to monomeric Aβ1-42 by SPR with a high affinity.  The complexities of 
this interaction, as with all RAGE-ligand interactions discussed here, require significantly 
greater degrees of investigation than that undertaken in this study.  However, it is clear 
that these opportunities for investigating the interactions between RAGE and its ligands 
are possible through the use of the functional recombinant proteins produced in this 
study.  By using a common vector and host to express synthetic gene inserts, we have 
significantly simplified the process of production while providing the assurance that the 
recombinant proteins expressed are functional and a reflection of their endogenous 
forms. 
4.5 Conclusions and Future Direction 
This project set out to address fundamental questions surrounding the optimal method 
of producing functional RAGE and its ligands for use in a range of research contexts.  
Traditionally, eukaryotic expression of RAGE has been conducted using a baculoviral 
system and a Sf9 Lepidoptera host.  This project investigated the use of rapid 
recombinant technologies such as TOPO™, as a means of producing insect expression 
vectors quickly and simply.  Here it is reported that three RAGE extracellular domain 
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constructs using the pIB/V5 expression vector were produced in a matter of days.  The 
benefits of speed in construct development are clearly evident where a large number of 
alternate target isoforms is required, as is the case for the multiple alternate spliced 
variants of RAGE. Optimisation of culture and media conditions yielded a 20% increase 
in yields of sRAGE (VC1C2) through the use of the Lepidoptera cell line Tn5.  RAGE VC1C2 
was expressed in this cell line at levels 7-fold greater than Sf9.  In addition, sRAGE was 
homogeneously glycosylated by the Tn5 cells in contrast to the heterogeneous 
glycosylation observed in Sf9 and Sf21 cell cultures.  Whilst the use of a TOPO™ 
expression vector for stable expression of RAGE in a Lepidoptera host offers advantages 
of speed, simplicity of construct production and cell maintenance and storage, the 
relatively low yields made it unsuitable for our laboratory, where milligram quantities 
are required for functional and structural studies. 
Where there is no need for post-translational modifications, or this can be provided 
alternately, bacterial expression is often the system of choice for delivering a high yield 
of protein at a low cost.  In this project, five prokaryotic strains were successfully 
transformed with six RAGE constructs comprising synonymous canonical and optimised 
gene sequences.  Additionally, five archetypal RAGE ligands were expressed in milligram 
quantities using pGS-21a expression vector and T7 Shuffle® K12 host.  This combination 
of vector and host yielded optimal levels of expression across all three RAGE domain 
constructs and represents a common ‘toolbox’ that can be used to express both RAGE 
and its ligands in milligram quantities.  The success of this host appears to be associated 
with its ability to facilitate the correct formation of disulphide bonds through disulphide 
bond isomerase C (DsbC), resulting in a 3.5-fold increase in levels of expression relative 
to Origami B transformed with the same optimised synthetic construct. Optimisation of 
the native human gene sequence for prokaryotic expression resulted in a 4.6-fold 
increase in VC1C2 expression in T7 Shuffle® K12.  When both codon bias and disulphide 
bond formation are accounted for, this study demonstrated the ability of T7 Shuffle® 
K12 to express RAGE VC1C2 using the optimised gene sequence at levels 13-fold higher 
than Origami™ B transformed with canonical RAGE gene inserts.  This study, therefore, 
confirms that both disulphide bond formation and sequence heterology are significant 
rate limiters in the expression of RAGE that are mitigated through the use of optimised 
gene sequences and the prokaryote host T7 Shuffle® K12. 
It is speculated that the correlation between diminishing returns with the deletion of the 
C-type lectin domains in both eukaryotic and prokaryotic hosts, is a consequence of 
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mRNA secondary structures that are unfavourable to translation. It is tantalising to 
speculate that with the addition of a fusion protein, the predicted mRNA matched stem 
loops potentially impeding translation may be disrupted, particularly where those 
matched pairs occur in the first 50 base pair from the ribosomal binding site (RBS).  
Further investigation is required to determine if this is indeed the case. 
There was no significant difference in the ability of insect and bacterial forms of RAGE 
produced in this study, to preferentially bind ribose-AGEs, HMGB1, Aβ1-42, S100B, 
S100P or S100A6.  This suggests that the recombinant RAGE produced in either host 
system is functionally indistinguishable.   It is reported here that HMGB1 recombinantly 
expressed in T7 Shuffle® K12 binds RAGE domain constructs with sub-micromolar 
affinities.  Although it is difficult to compare the estimates of affinity from this study 
with those previously reported for RAGE-HMGB1 due to the variations in 
ligand/receptor source and methodologies, the majority of published data indicates 
nanomolar affinities. Similarly, the S100s expressed and purified in this study had 
comparable affinities to a number of published estimates as discussed in section 4.4.3.  
Collectively, we conclude that recombinant RAGE and its ligands expressed and purified 
here are functionally analogous to their endogenous counterparts.  This leads us to 
conclude that the glycosylation and post-translational capabilities of insect cells are not 
a compelling reason for their use over bacterial hosts for studies on RAGE.   
The novel plate based assay developed within this study produced comparable 
estimates of affinity between RAGE and its ligands, to those reported using a raft of 
complex, hazardous or bespoke methodologies.  The plate assay was of low cost, simple 
to perform and did not require a high level of expertise.  Notably, the results of the 
assay were in excellent agreement with surface plasmon resonance (SPR) studies which, 
whilst providing information in real time, were expensive and demanded considerable 
“built expertise”.  
Irrespective of the assay used, RAGE and ligand oligomerisation clearly complicates our 
understanding of the ligand-receptor interactions in question, which may explain why 
there is such diversity in reported affinities of interaction from nanomolar to 
micromolar.  The multivalent nature of the interactions may especially complicate the 
interpretation of assays where one partner is immobilised to a surface, as is indeed the 
case with both the plate binding and SPR approaches used in this study.  In such studies, 
care will need to be taken to characterise interactions in both orientations, with RAGE 
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treated as either the ligand or analyte.  For example, in all published SPR studies of 
S100-RAGE interaction (Leclerc et al., 2009; Ostendorp et al., 2007), RAGE was 
immobilised on the chip surface and S100 was passed over the sensor chip surface as 
the analyte.  Much greater detail surrounding the kinetics and stoichiometry of the 
interaction could be gained by comparing these results to those obtained with S100 
immobilised to the chip surface and with RAGE used as the analyte.  Alternatively, a 
microthermal isocolorimetry approach may be used, which does not rely on the 
immobilisation of one of the binding partners.  However, this method does have its own 
pitfalls; in particular, it requires significant quantities of protein for general functional 
studies.  
A significant body of work is now progressing in our laboratory as to the complex and 
intricate mechanisms of the oligomerisation of HMGB1 and its interaction with RAGE, 
leveraging the molecules and observations that have come from this study. It is 
apparent from these studies that HMGB1 specifically self associates in solution and that 
this affects the way it binds and bends DNA.  Future studies should now focus on the 
effect of HMGB1 self association on its binding to and activation of RAGE. In particular, 
attention should be focused on the role of the redox state of HMGB1 in these studies.  
Given the reported zinc clasp structure discussed within the body of this thesis (Figure 
76), the role of zinc and the redox state on HMGB1 and RAGE interactions, should also 
be investigated.  
In conclusion, this study has demonstrated that the bacterial expression of RAGE and its 
ligands using the T7 Shuffle® K12 is a superior platform to insect expression due to the 
speed, simplicity and low cost of construct development and culturing.  The system 
reported here represents a common ‘toolbox’ approach to the rapid production of 
milligram quantities of RAGE and its ligands.  This achievement is now enabling the 
progress of several functional and structural studies on RAGE and its plethora of ligands, 
which in future may lead to new opportunities for pharmaceutical interventions for 
diseases, such as diabetes, dementias, inflammatory diseases and cancer. 
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Appendix A. Genotypes of bacterial expression hosts used in this study. 
Table 10. List of bacterial expression hosts and their genotypes. 
Strain Name Genotype 
Origami B F– ompT hsdSB(rB
– mB
–) gal dcm lacY1 aphC gor522::Tn10 trxB 
(KanR, TetR) 
BL21 (DE3) F– ompT hsdSB(rB
– mB
–) gal dcm (DE3) 
Rosetta-gami™ 2 Δ(ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE 
galK rpsL F’*lac+ lacIq pro] gor522::Tn10 trxB pRARE23 (CamR, 
StrR, TetR)4 
Rosetta-gami™ 2(DE3) Δ(ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE 
galK rpsL (DE3) F’*lac+ lacIq pro] gor522::Tn10 trxB pRARE23 
(CamR, StrR, TetR)4 
T7 Shuffle® K12 F´ lac, pro, lacIQ / Δ(ara-leu)7697 araD139 fhuA2 lacZ::T7 
gene1 Δ(phoA) PvuII phoR ahpC* galE (or U) galK λatt::pNEB3-
r1-cDsbC (SpecR, lacIq) ΔtrxB rpsL150(StrR) Δgor Δ(malF)3 
T7 Shuffle® B fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal λatt::pNEB3-r1-
cDsbC (SpecR, lacIq) ΔtrxB sulA11 R(mcr-73::miniTn10--TetS)2 
[dcm] R(zgb-210::Tn10 --TetS) endA1 Δgor ∆(mcrC-
mrr)114::IS10 
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Appendix B. Expression vector maps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 77. Vector map of pGS-21a with the multiple cloning site sequence. (pGS-21a –
Genscript – Making Research Easy, vector sequence and map, 2015. Available from 
http://www.genscript.com/vector/SD0121-pGS_21a.html. [01 May 2015]). 
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Figure 78. Vector map of pIB/V5-His-TOPO with the multiple cloning site sequence. 
(pIB/V5-His TOPO® TA Expression Kit - Life Technologies, 2004. Available from 
http://tools.lifetechnologies.com/content/sfs/manuals/insectselectpibtopo_man.pdf. 
[01 May 2015]). 
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Figure 79. Vector map of pGEX-6P-1 with the multiple cloning site sequence and 
PreScission Protease cleavage site. (GE Healthcare Life Sciences “pGEX-6P-1”- , 2015. 
Available from https://www.gelifesciences.com/gehcls_images/GELS/Related% 
20Content/Files/1314774443672/litdoc28919162AC_20110831100927.pdf. [01 May 
2015]). 
 
